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Abstract
DNAmethylation is an important epigenetic modification that regulates gene expression,
thereby playing a crucial role in biological processes including cellular development
but also disease progression. Abnormal methylation patterns such as gene promoter
hypermethylation are the most common molecular lesions found in cancer. Since
DNA methylation is a reversible process, DNA methyltransferases (DNMTs) – the
enzymes responsible for the maintenance of methylation patterns - are regarded as
very attractive therapeutic targets.
To date, several DNMT inhibitors have been developed to reverse DNA hypermethyla-
tion. The clinically approved azanucleosides 5-azacytidine and 5-aza-2′-deoxycytidine
have high demethylating potency, but their use has remained limited due to their
nonspecific activity and cytotoxic side-effects. The lack of techniques for targeted
tissue-specific demethylation not only limits therapeutic potential but also restricts
our understanding of the functional significance of DNA methylation in a number of
biological processes, including cellular development and regeneration.
The aim of this thesis was to develop small molecule tools that could achieve spa-
tiotemporally targeted demethylation through light-based activation. We have used
a photocaging strategy to synthesise six novel photocaged azanucleoside analogues.
These analogues remained biologically inert until light illumination induced the release
of active azanucleosides with moderate-to-high rates and efficiencies. It was found that
the caging position strongly influenced the photochemical properties and aqueous sta-
bilities of the photocaged analogues. The analogue with the fastest uncaging rate and
best aqueous stability 3′-DEACMOC-dAC was evaluated for its biological performance
in a number of cancer cell lines. Global DNA methylation analysis showed that the
analogue achieved light-dependent demethylation at lower concentration treatments.
However, at higher concentrations unexpected activity was observed in the absence of
light, prompting further investigation using mass spectrometry analysis.

Impact statement
DNA methylation plays an essential part in maintaining and regulating key cellular
events. The ability to understand the functional changes in DNA methylation and
finely manipulate these changes (e.g. in order to prevent the development of cancer
and other diseases) can serve as a significant stepping stone in biomedical and cancer
research. Although a range of biological tools (e.g. CRISPR-Cas9,83 TALE-TET1
fusion proteins77) have been developed recently to study and induce DNA methylation,
there have been fewer chemical tools that could achieve similar effects.
This work presents the first example of a light-gated small molecule approach to
regulate DNA methylation within the cells. It was demonstrated that the activity
of decitabine, inhibitor of DNA methyltransferase and a key epigenetic drug, can be
masked by its synthetic modification (also known as “photocaging”) with a phototag,
a photochemically removable functional group.
The impact of this work can be beneficial primarily in academia, and if further improved,
potentially outside of academia too. The work provides novel insights on the chemistry
of azanucleosides (decitabine, azacytidine) and how the the photocaging and linker
strategy can affect photochemical performance and the compound’s aqueous stability
profile. The work also serves as a useful groundwork for the setup of photochemical,
biological and stability characterisation of current and future photocaged azanucleosides.
In their current form, photocaged azanucleosides require further improvement in their
stability profiles in order to be used as research tools to study epigenetic modifications.
For clinical applications and therapeutic impact, the photocaged compounds could
be further tailored to absorb at even higher wavelengths (λ > 500 nm) in order to be
biocompatible with thicker tissues and organs. Once it is achieved, this strategy can
potentially open up new avenues in basic and clinical research for the synthesis of other
photo-controlled epigenetic molecules or future improved versions of other epigenetic
drugs.
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Chapter 1
Introduction
1.1 Epigenetics
DNA is one of the most important biological molecules as it carries genetic information.
Nucleotides are the smallest building blocks of DNA, containing a phosphate linker,
deoxyribose sugar and one of four nitrogen-containing aromatic bases: guanine (G),
adenosine (A), thymine (T) and cytosine (C). The sequence of nucleotides encodes the
genetic information in coding regions of genes, which are transcribed into triplet codons
and further translated into corresponding amino acid sequences.1 The latter carry vital
instructions on how proteins are synthesised and function in living organisms.2 The
haploid human genome contains around 3 billion nucleotides and around 20 000 - 25
000 protein-coding genes, but these genes are utilized differently across various cells
and developmental stages. The genetic code is essentially a script of all the information
a cell could use to function, but its use depends on how the cell reads this script.3
Epigenetics determines how the genetic code is read by the cell. The word epigenetics
is of Greek origin, meaning ’above’ or ’on top’ of genetics.4 It refers to the mitotically
heritable changes on top of the DNA that do not alter the nucleotide sequence, but
highly influence gene expression.5
A classic example in which epigenetics plays an essential role is in developmental
biology.6 Waddington’s illustration of the epigenetic landscape (Figure 1.1) serves as a
metaphor of how gene regulation modulates development.7 In a multicellular organism,
all cells are ’born’ with the same genetic material. The marble on the top of the hill
represents a pluripotent cell that has the potential to differentiate into any cell type.8
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During cell development, different sets of genes are switched on as a result of epigenetic
reprogramming and this triggers differentiation. As the cell moves towards its final
differentiated state, represented by the movement down the hill along a restricted path,
its potential to become a different cell type diminishes.
Fig. 1.1 The epigenetic landscape by Conrad Waddington8
The expression of a gene is determined by the accessibility of the DNA to the tran-
scriptional machinery.9 DNA is packaged and wrapped around an octamer of histone
proteins to form a nucleosome unit, which is further organised into higher organisational
units of chromatin.10 Chromatin can either exist in relatively open, accessible and
transcriptionally active domains (euchromatin) or more compact and inactive forms
(heterochromatin).11 Epigenetic modifications maintain a balance between these two
states by either remodeling or directly altering the chromatin structure in a covalent
or non-covalent fashion. The three main modifications include: histone modifications,
non-coding RNAs and DNA Methylation (Figure 1.2).12
The post-translational modifications of histone proteins (such as acetylation, methy-
lation, phosphorylation, ubiquitination and sumoylation) can greatly influence the
biophysical properties of histones, which have downstream effects on the chromatin
structure.13 For example acetylation of lysine residues removes the positive charge on
histones, which decreases interaction with the negatively charged DNA. This loosens
the structure of the condensed chromatin and as a result, DNA becomes more accessible
to transcription. Nevertheless, following successful transcription, gene expression can
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still be blocked. MicroRNAs selectively bind to target messenger RNAs (mRNAs)
with a complementary sequence to induce cleavage or degradation and subsequently
block translation and gene expression.14 These epigenetic modifications have been well
reviewed in literature. However, DNA methylation is probably the most extensively
studied epigenetic mark.15,16
Fig. 1.2 Structure of the chromosome and summary of epigenetic modifications17
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1.2 DNA methylation
1.2.1 DNA methylation in mammals
In mammalian DNA, methylation occurs predominantly on Cytosine-phosphate-Guanine
(CpG) dinucleotides, where the cytosine residue is followed by a guanine nucleotide.18
If located within a promoter sequence, the presence of a methyl group is associated
with transcriptional silencing.19 The methyl group can physically block the binding
of transcription factors. In addition, it can also recruit methyl-CpG-binding proteins
(MBPs), which can further recruit transcriptional co-repressor molecules to induce
downstream gene repression.20
Within the genome, CpG dinucleotides are not distributed evenly. They are con-
centrated in short CG rich stretches of DNA (‘CpG islands’) and regions of long
repetitive sequences such as centromeric repeats.21 CpG islands are found in proximal
promoter regions of at least 60% of mammalian genes. Within these regions, CpGs are
unmethylated in order to be recognised by transcription factors and associated DNA-
binding proteins. Methylated CpGs within promoter regions can also occur naturally,
for example during X-chromosome inactivation22 and genomic imprinting.23 On the
contrary, CpGs found within the rest of the genome tend to be heavily methylated in
order to prevent chromosomal instability. Methylation in these regions prevents the
expression of unwanted repetitive sequences and transposable DNA elements.24
1.2.2 DNA methyltransferases
DNA methylation patterns are established and maintained by the family of DNA
methyltransferase (DNMT) enzymes.25 While five different DNMT isoforms exist, only
three are active in mammalian cells: DNMT1, DNMT3A and DNMT3B. DNMT3A
and DNMT3B are essential for the establishment of new methylation patterns (de novo
methylation).26 Targeted disruption of these enzymes resulted in lethality in mice.27
Maintenance of global methylation patterns is achieved by DNMT1 enzyme and its
binding partner Ubiquitin-like Homeodomain and RING Finger domain 1 (UHRF1).28,29
These enzymes are ubiquitously expressed in proliferating cells. They are localized in
the replication foci during S-phase and preferentially bind to hemimethylated CpGs,
where only one of the two strands in the parent duplex is methylated.30 For each
hemimethylated CpG site, the target recognition domain of DNMT1 first recognizes
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and binds to the parent strand and the catalytic domain then binds to the corresponding
cytosine on the growing daughter strand.28 This is followed by the covalent transfer of
a methyl group onto the cytosine of the newly replicating strand.
The catalytic mechanism of DNMT is illustrated in Figure 1.3. The DNMT enzymes
catalyse the covalent transfer of a methyl group from S-adenosyl-L-methionine (SAM)
cofactor molecule onto position 5 of the cytosine base (a to e).31 This transfer consists
of several steps. Firstly, a covalent complex is formed between the DNMT1 catalytic
pocket and the cytosine residue (b). This is initiated by the nucleophilic attack of
the highly conserved cysteine C1229 on position 6 of the cytosine base. The adjacent
glutamic acid residue (Glu1266) can simultaneously stabilize the increased electron
density of the aromatic ring by proton donation to the nitrogen atom at position 3
(c). In the presence of the positively charged SAM cofactor, the electron-rich cytosine
base attacks the methyl group, which is subsequently released from the cofactor (c).
As a result, neutral S-adenosyl-homocysteine (SAH) is formed and the methyl group
becomes covalently bound to the C5 of the cytosine base. The final step of the transfer
is the β-elimination of the proton and cysteine residue at position 5 and 6 respectively
(d). This step enables the regeneration of the cytosine aromatic system and the release
of the DNMT1 enzyme along with the 5-methylcytosine (5mC) product.
Fig. 1.3 Catalytic mechanism of cytosine methylation by DNMT1
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While the mechanism of DNA methylation is well understood, considerably less was
known about DNA demethylation. Passive DNA demethylation occurs, when mainte-
nance methyltransferases are inactivated during the replication cycle.32 As a result,
the unmethylated state is retained in the newly synthesised daughter strands. This
process depends on DNA replication and thus takes time to occur. Conversely, active
demethylation is more rapid; it involves one or more ‘demethylase’ enzymes that
operate independently of DNA replication.
1.2.3 TET enzymes
The recent discovery of the ten-eleven translocation (TET) enzymes has provided major
insight into the mechanism of active DNA demethylation.33,34 It has been found that
TET enzymes can oxidise 5mC to 5hmC in the presence of Fe(II) and α-ketoglutarate
(α-KG).35 The proposed catalytic pathway is shown in Figure 1.4. At the active site of
TET, Fe(II) is bound by highly conserved His-His-Asp residues, water and α-KG. In
the presence of oxygen, the α-KG is oxidised into enzyme-bound succinate and the
Fe(II) complex results in a high-valent Fe(IV)-oxo intermediate. The intermediate
reacts with 5mC to yield 5hmC via a net oxidative transfer of single oxygen. As a
result, the Fe(II) species is regenerated at the end of the reaction.35
Fig. 1.4 Catalytic mechanism of Fe and α-KG dependent oxidation of 5mC to 5hmC
by TET35
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The 5hmC can be further oxidised to 5-formylcytosine (5fC), 5-carboxylcytosine (5caC)
which are then excised by thymine-DNA glycosylase (TDG) enzymes to generate an
abasic site.36 These sites are targeted by the base excision repair process to regenerate
cytosine at the site of interest.37 The dynamic modification cycle of cytosine analogues
by DNMT, TET and TDG enzymes is summarised in Figure 1.5.35 The molecular
details of these conversion processes and the regulatory roles of these analogues are
currently being investigated.38–41
Fig. 1.5 Dynamic modifications of cytosine analogues35
Three different TET isoforms have been discovered to date: TET1, TET2 and TET3.
Despite their similar catalytic activity, each isoform has a distinctive function in
development. TET1 plays an important role in maintaining pluripotency in embryonic
stem (ES) cells.42 It has been shown that active demethylation is important for resetting
the epigenetic state of the parental genome.43 For example in early embryos, parental-
origin-specific imprints are erased in order to set up pluripotent states.44 TET2 on the
other hand functions as a physiological regulator of haematopoiesis,45 whereas TET3
acts as a critical factor for zygotic epigenetic reprogramming.46
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1.2.4 Disruption of methylation pattern in disease
DNA methylation and demethylation play a crucial role in cell development,47 regulation
of key cellular processes48 and maintaining chromosome stability.49,50 Consistent with
these vital roles, perturbations of DNA methylation patterns are frequently observed
in a growing number of diseases. The diseases affected by aberrant DNA methylation
include imprinting disorders, chromosomal instabilities and cancer.51
Imprinting disorders arise when genomic imprinting is lost during development. Ge-
nomic imprinting is a phenomenon whereby certain genes are expressed in a parent-of-
origin-specific manner.23 This is due to epigenetic modifications that lead to silencing
of a specific parental allele in the gamete or zygote. As a result, only the other parental
allele is expressed in the somatic cells of the offspring. Although genomic imprinting
only affects around 100 genes in mammals, there are a number of human diseases that
are associated with disruptions of imprinted epigenetic marks through gain or loss of
DNA methylation. Examples include Angelman’s Syndrome, Prader-Willi syndrome52
and Beckwith-Wiedemann syndrome.53 In these conditions an abnormal phenotype
is established as a result of missing parental copies or the deregulation of imprinted
genes.54
Chromosomal instabilities can emerge from global changes in DNA methylation levels.55
Such alterations are the direct results of mutational changes in the genomic regions
of regulatory enzymes. For example, ICF syndrome (Immunodeficiency, Centromeric
region instability and Facial anomalies) is caused by mutations in the DNMT3B gene
that are linked to abnormal global DNA hypomethylation.56,57 Furthermore, Rett
Syndrome - a severe neurological disorder characterised be developmental regression
and seizures - is a result of germline mutations of MeCP2 methyl binding protein.58
The role of MeCP2 protein is to bind to methylated DNA and initiate gene silencing.
In Rett Syndrome, the protein is unable to bind to DNA and silence genes. As a result,
genes that are normally repressed by MeCP2 remain active when their products are
not needed. This ultimately leads to the disruption of the normal functioning of nerve
cells.58
Cancer is one of the most significant diseases in which the disruption of DNA methyla-
tion patterns can have a crucial role. The link between aberrant DNA methylation
and cancer has been established several decades ago,59–61 but the underlying cause
of methylation defects in cancer is still unknown. It is now widely recognised that
aberrant DNA methylation is perhaps the most common molecular lesion found in
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cancer cells.55 These lesions are generally the result of two aberrant methylation events:
hypomethylation within the genome and hypermethylation at gene promoter regions
as shown in Figure 1.6.62
Fig. 1.6 DNA methylation patterns in normal and cancer cells62
Loss of DNA methylation at CpG dinucleotides was the first epigenetic abnormality
identified in cancer cells.63,64 These events occur within the genome and result in
illegitimate recombination events and expression of potentially damaging and viral
elements.65 While loss of DNA methylation generally has global consequences via
predisposing cells to genetic instability, gene-specific effects of hypomethylation may
also occur. For example, the melanoma antigen (MAGE) family of genes are normally
silenced in healthy cells. They encode tumour antigens and are frequently demethylated
and re-expressed in cancer.
Hypermethylation of gene-promoter regions is the other aberrant methylation event that
is frequently observed in cancer. The resulting changes effectively silence the expression
of key tumour suppressor genes (TSG) involved in cell-cycle regulation, cell signalling,
DNA repair and tumour suppression.66,67 Examples of frequently hypermethylated
genes are summarised in Table 1.1.68 In addition, apoptotic genes are also known to
become silenced in nearly every tumour type.69 Such changes provide tumour cells
great advantage in survival, facilitating uncontrolled growth and proliferation.
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Gene Function Tumour type
Rb Cell-cycle regulation Retinoblastoma
APC Wnt signal transduction Colorectal cancer
p14/ARF Cell-cycle regulation Colorectal cancer
p15/CKDN2B Cell-cycle regulation Leukemias
p16/CDKN2A Cell-cycle regulation Various cancers
BRCA1 DNA repair Breast, ovarian cancer
VHL Tumour suppressor Renal cell cancer
hMLH1 DNA mismatch repair Gastric, endometrial cancers
ER-α Estrogen receptor-α Breast, colorectal cancers
Table 1.1 Frequently hypermethylated genes in sporadic cancers
1.3 Strategies to target DNA methylation
Given that aberrant DNA methylation is associated with a great number of diseases, the
regulatory enzymes of this machinery such as DNMTs are seen as attractive therapeutic
targets.70 In contrast to most genetic mutations, epigenetic alterations are reversible
and it is possible to reprogram them.71 Reversing methylation is not only of therapeutic
interest, but it could also serve as a research tool. The ability to experimentally
lower methylation levels could provide useful insights on the cellular processes that are
normally regulated via DNA methylation patterns.
Currently there are two main strategies to reverse methylation levels in biological
organisms. Methylation can be targeted in a locus-specific manner using biological
editing tools or it can be targeted in a nonsequence-specific (global) manner using
small molecule chemical tools. For the latter strategy, only lowering of methylation
levels have been achieved to date, whereas biological tools have been successfully used
to add or remove methylation marks.
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1.3.1 Biological editing tools
Several biological tools have been developed to date that can achieve locus-specific
epigenome editing (Summarised in Figure 1.7).72,73 Together these tools enable the
selective activation or repression of specific genes. These techniques in combination with
comparative phenotypic analyses can further aid our understanding of how individual
epigenetic modifications can exert control on processes in the cellular machinery.
Fig. 1.7 Models of biological editing tools74
The classical epigenome editing technology relies on custom-engineered proteins that are
composed of two modules: a DNA binding domain, which can target specific sequences
of the genome, and an effector domain that modifies epigenomic features (Figure 1.7).
The Transcription Activator-Like Effector (TALE) and Zinc Finger (ZFN) proteins are
often chosen as DNA binding domains due to the relative ease to engineer them to
target different genomic regions of interest.75,76 DNA binding domains have been fused
to a variety of chromatin modifiers to carry out epigenome editing (Figure 1.7, pink
circles). Examples include the TALE-TET1 fusion system that successfully removed
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methylation at target sites although with moderate efficiency.77 Another example was
TALE fused to Lysine Specific Demethylase 1 (LSD1) that removed methylation from
histone proteins (H3K4me1 and H3K4me2).78 Furthermore, it was also demonstrated
that the effector proteins can be recruited with a light-sensitive cryptochrome protein,
which introduced an additional spatiotemporal control to the approach.79
Despite the promising results, the design of TALEs and ZFNs is still cumbersome
and labour intensive. The recent development of the CRIPSR/Cas9 genome editing
technology initiated a new wave of excitement within the scientific community because it
offered a faster, cheaper and more accurate approach to edit DNA.80,81 CRISPR stands
for Clustered Regularly Interspaced Short Palindromic Repeats. The CRISPR/Cas9
system is composed of 3 distinct modules: A guide RNA, a modified bacterial Cas9
nuclease and an effector chromatin modifier of choice. The guide RNA sequence
determines the binding position of the complex within the genome and it can be
custom-designed at a low cost.82 The catalytically dead dCas9 nuclease is fused to a
chromatin modifier and the complex together with the guide RNA are used to add
or remove epigenetic marks, depending on the chromatin modifier. Several groups
have successfully fused the CRISPR/Cas9 system with DNMT3A or TET1 enzymes to
add or remove DNA methylation marks at specific loci in the genome with improved
efficiencies compared to TALE systems.83–85
The TALE and CRISPR/Cas9 systems enable the interrogation of individual sites in
the genome with precision at the nucleotide level. While these tools are invaluable for
our understanding of epigenetic modifications, the field is still in its infancy - there
is still room for optimisation of modification efficiencies. In spite of this, the results
of the first trials on human embyronic cells have recently been reported by Ma and
coworkers.86
While biological tools enable the targeting of individual methylation marks, small
molecules provide a genome-wide approach to induce methylation changes. Small
molecules are easier to prepare and modify compared to biological tools. To date,
several agents have been developed in order to reverse DNA methylation through direct
or indirect interference with DNMT enzymes.87 Inhibition of DNMTs result in the
blocking of maintenance methylation of newly replicating DNA strands, leading to
genome-wide lowering of methylation levels in daughter strands (global demethylation).
A number of analogues have high ’demethylating’ efficacy and long-established clinical
profiles. Chemical tools can be classified into non-nucleoside inhibitors and nucleoside
inhibitors.
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1.3.2 Chemical tools I: non-nucleoside inhibitors
Non-nucleoside DNMT inhibitors can directly interfere with the enzyme activity.
Although in most cases the mechanism of inhibition is unknown, a number of small
molecules have been reported to date that showed moderate inhibitory effect against
DNMT1 (Scheme 1.1). Among drugs known for different applications, hydralazine 1
and procainamide 2 – known cardiovascular drugs – have been reported to inhibit DNA
demethylation in cells.88 (-)-Epigallocatechin3-gallate 3 a major component of green
tea extracts has also been shown to inhibit DNA methylation presumably through
binding to DNMT1.89
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Scheme 1.1 Structures of non-nucleoside DNMT inhibitors
RG108 4 is a small-molecule inhibitor of DNMT1 that was developed using a computa-
tional screening approach based on the three-dimensional structure of DNMT1.90 This
analogue has shown promising activity in vitro by inhibiting methylation of tumour
suppressor genes at gene promoter regions. In addition, it does not demonstrate cyto-
toxic effects even at high concentrations.91 Various derivatives of RG108 are currently
being investigated to identify more potent inhibitors.92
The final and possibly most promising non-nucleoside DNMT inhibitor is MG98. It
is a second-generation 20mer antisense oligonucleotide designed to hybridize with
DNMT1 mRNA and prevent further processing of the mRNA and eventually reduce
cellular levels of DNMT1.93 There are two particular chemical traits that enhance
the plasma life of MG98. First of all, the conventional phosphodiester linkages are
replaced by phosphorothioate linkages which improve its stability in plasma. Secondly,
specific 2′-O-methyl modifications are included on the strands in order to increase the
molecule’s affinity for mRNA targets and reduce off-target binding and toxicity. MG98
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has been extensively investigated clinically in advanced solid tumours and renal cell
carcinomas.94
Non-nucleoside inhibitors offer a strategy to selectively target DNMT1 enzymes, however
the potency of these analogues need further improvement. Conversely, nucleoside
inhibitors are historically the most popular strategies to target and reverse DNA
methylation in organisms.
1.3.3 Chemical tools IIa: nucleoside inhibitors
Introduction: Azanucleosides
The two most widely used nucleoside DNMT inhibitors to date are the azanucle-
osides 5′-azacytidine (AC) (VidazaTM , Azacitidine) 5 and 5-aza-2′-deoxycytidine
(dAC) (DacogenTM , Decitabine) 6 (Scheme 1.2).95 They are structural analogues
of 2′-deoxycytidine 7 that contain a nitrogen in place of the 5-carbon of the pyrimidine
ring.
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Scheme 1.2 Structures of first generation azanucleosides and cytidiney
The history of azanucleosides dates back to the 1960s. They were first synthesised
by Pískala and Šorm.96 Originally intended to be used as cytotoxic agents, they were
tested in leukaemia therapies,97,98 until their demethylating effect was reported in
1980.99,100 AC and dAC were clinically approved in 2004 and 2006 respectively for the
treatment of myeloid dysplastic syndromes (MDS).101,102 In addition, AC is also used
in the treatment of acute myeloid leukaemia (AML).
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The molecular pharmacology of azanucleosides
The mechanisms of uptake and activation of azanucleosides are shown in Figure 1.8.103
Azanucleosides enter the cells via nucleoside transporters that normally allow the
uptake of cytidine and uridine.104 Nucleoside transporters are classified into two main
families, the Na+-dependent human concentrative nucleoside transporter (hCNT) and
the Na+-independent human equilibrative nucleoside transporter (hENT) proteins.
Among the hCNT family isoforms, isoform 1 (hCNT1) has been shown to have the
highest affinity to AC (Km= 63 µM), but isoform 3 (hCNT3) showed the highest rate of
transport.104,105 Other transporters in the hENT family also showed modest transport
capacities for AC.
Fig. 1.8 Uptake and incorporation of azanucleosides103
Conversely, dAC is mainly transported by hENTs (isoform 1 and 2). The transport of
dAC - similar to uridine - is concentration and time-dependent and Na+-independent.104
This suggests facilitated-diffusion uptake and is a characteristic of hENT transport.
The Km value for dAC uptake by hENT1 is 1.09 µM, which is 900 times lower than
that of uridine to hENTs and 60 times lower than the affinity of AC to hCNT1.106 The
transport rate of dAC by hENTs is also substantially lower compared to the transport
of AC by hCNTs.
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In both cases, AC and dAC transport can be mitigated by the presence of the nucleoside
transport inhibitor S -(4-nitrobenzyl)-6-thioinosine (NBMPR).104,106 In summary, the
presence, absence and types of nucleoside transporters (for example hCNT1 in kidney
cells or hENT1 in colon carcinoma (HCT116) cells) are key determinants of the activity
of azanucleosides in the cellular environment.
Once inside the cell, azanucleosides are converted into their active form to become
substrates for the DNA replication machinery. This is achieved via three consecutive
steps of phosphorylation by kinases (Figure 1.8). In the case of dAC, the first step
is catalysed by deoxycytidine kinase (dCK) to produce the monophosphorylated
form of dAC, or 5-aza-2′-deoxycytidine-5′-monophosphate (5-aza-dCMP).107 This is
the rate-limiting step of the activation. The two subsequent steps are catalysed by
deoxycytidine monophosphate kinase (dCMPK) and the nucleoside diphosphokinase
(DPK) to produce the di- and triphosphorylated version of the drug respectively.108
The activated drug then gets incorporated into replicating DNA with the aid of DNA
polymerases.109
In a similar fashion, AC is phosphorylated by three different kinases, and in addition
10% of it is converted into dAC analogues via a reductase enzyme.110 However, the
majority of activated AC (80-90%) is incorporated into RNA in order to interfere with
protein synthesis.111 Azanucleosides belong to the family of S-phase specific drugs,
suggesting that they are only active once incorporated in the DNA/RNA of cells.112
This enables them to selectively get incorporated into the DNA/RNA of rapidly dividing
cells, which gives them a preference towards cancer cells.113
Azanucleosides, once incorporated into the DNA, are recognised by DNMTs, similarly
to cytidines. However, the 5-nitrogen has a key role in the mechanism of inhibition as
illustrated in Figure 1.9.
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Fig. 1.9 Mechanism of DNMT1 inhibition by azanucleosides
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The nitrogen essentially blocks the final β-elimination step due to the absence of a
proton in position 5. As a result, the enzyme remains covalently bound to the DNA
and its demethylating function is blocked. The resulting covalent complex not only
prevents DNMTs from methylating further DNA strands in replicating DNA, but it
is also targeted by ubiquitin-E3 ligase for proteosomal degradation.114 This leads to
depletion of DNMT1 levels and the subsequent reduction in DNA methylation levels
(global genome-wide demethylation) in daughter strands.111 This is the commonly
accepted mechanism of azanucleosides, which is based on the initial report by Santi
and coworkers.115 It states that the activity of dAC is replication dependent, suggesting
that dAC is required to be incorporated in order to exert DNMT1 depletion.116
However, a study by Ghoshal and coworkers suggested that there may be an additional
pathway towards DNMT depletion by dAC that is replication-independent.117 Their
study suggests that dAC is able to inhibit free DNMT1 through interaction with Protein
kinase C δ (PKCδ) which then hyperphosphorylates DNMT and induces proteosomal
degradation.118 The exact mechanism of this phenomenon remains elusive.
Effect of azanucleosides on RNA metabolism
Numerous studies have indicated that the mode of action of azanucleosides are not
limited to DNA methylation inhibition. It has been shown that incorporation of
triphosphorylated azacytidine into RNA inhibits tRNA methylation and processing by
reducing tRNA methyltransferase levels..119 This can subsequently give rise to defective
messenger and transfer RNA. The disrupted tRNA processing can ultimately lead to
inhibition of mRNA and protein synthesis and thus inducing apoptosis.120
It has also been shown that azacytidine incorporation into RNA is able to repress the ex-
pression of the M2 subunit of ribonucleotide reductase ribonucleotide reductase (RRM2)
and therefore interfere with the conversion of ribonucleotides to deoxyribonucleotides,
ultimately leading to inhibition of DNA synthesis and repair.120
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Mechanisms of resistance to azanucleosides
The activity of azanucleosides greatly depends on each of these systems described above
(uptake, phosphorylation, incorporation and inhibition of DNMT1). When one of these
components is altered, resistance against dAC can develop.121 There are three main
pathways that are closely correlated with dAC resistance that have been identified and
characterised to date:
1. Low hENT expression by the cell leads to reduced uptake of dAC122
2. Low dCK expression or deficiency leaves the cell unable to activate dAC121
3. Enzymatic degradation by cytidine deaminase (CDA) renders dAC inactive by
converting it into 5-azauridine compounds.123 Efforts were made to circumvent this
by using CDA inhibitors such as tetrahydrouridine, however the concentration of
these compounds need careful consideration as they can cause toxicity at elevated
levels.124,125
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In addition, the chemical configuration of azanucleosides is essential to their activities.
Two structural isomers of dAC have been characterised to date: α- and β - dAC (Scheme
1.3). The isomers differ based on the relative configuration and stereochemistry of the
triazine ring to the deoxyribose sugar.
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Scheme 1.3 Structures of dAC anomers
The α anomer is more stable compared to the β anomer, however it has a less
pronounced bioactivity. This is because the α anomer itself is not incorporated into
DNA and is not recognized and degraded by cytidine deaminase.126 However, its
biological activity is based on its spontaneous conversion into the β isomer which
then enters the DNA synthesis pathway.127 It has been shown that the α isomer has
hypomethylating capacity128 and it can also downregulate hTERT mRNA expression
in human leukemia cell lines.126 Davies et al. investigated the crystal structure of
dAC and have established that dAC as we know today is mostly composed of the β
isomer.129
dAC as a demethylating tool
dAC is a powerful demethylating tool.130 It is able to reverse hypermethylated states
in the genome (regions with high density of methylation) by targeting and inhibiting
the methylating enzyme DNMT during replication, which leads to the lowering of
methylation levels in the resulting daughter strands. The demethylating function of
azanucleosides is most evident at lower drug concentrations (sub 1 µM) because at
higher concentrations these drugs exhibit greater cytotoxicity by interfering with DNA
synthesis and causing DNA damage.131
Ever since the hypomethylating effect of dAC was established, there has been a growing
interest in the use of dAC not only as a therapeutic agent, but also as a research tool.
The ability to modify methylation levels of cells and analyse the resulting cellular and
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phenotypic changes has greatly aided our understanding of the functional significance
of DNA methylation in different biological processes.132 There are many studies that
try to correlate the changes in methylation profiles in response to dAC treatment and
resulting changes in gene expression profiles and cellular pathways in different cancer
cell lines.133–140
Most of our current knowledge of genetic alterations present in human cancers is derived
from in vitro established human cancer cell lines.141 The advantages of biological studies
in cancer cell lines is that there are a wide spectrum of tumour types available and
they are easy to culture in vitro. It is relatively easy to get significant amounts of DNA
and they are usually free of contamination. However, it is known that different cell
lines (even tumour types) have varying baseline methylation levels and gene expression
profiles and varying sensitivity to dAC treatment.142,143
To create a normalized database, a systematic profiling study was carried out by
Paz and coworkers, whereby the baseline methylation levels of 70 tumour cell lines
were measured and their response against dAC treatment was assessed.141 There was
considerable variation in percentage CpG island hypermethylation between cell lines
(7-73%), with haematological cell lines having the highest and renal/thyroid cells having
the lowest methylation. It was also found that dAC treatment left the cells with a
narrow range of 5mC content. The more hypermethylated CpG sites a cell line has,
the more sensitive it is to dAC treatment.
In addition, dAC was also used for a ’chemogenomic’ screening in gastric cancer
cell lines.144 Genes that were silenced in gastric cancer cells were identified and were
successfully re-expressed following dAC treatment. Although it is often stated that
dAC is a genome-wide hypomethylator, several studies suggested that the functional
effects of dAC treatments are limited to a small subset of protein-coding genes and are
associated with specific CpG sites in CpG islands.145,146
The role of dAC is rapidly emerging in other fields such as regenerative medicine,147
developmental biology148 and cellular reprogramming.149 Given that dAC is able to
’reset’ the epigenetic patterns of cells by erasing methylation, it has been successfully
used to chemically induce reprogramming of somatic cells to pluripotent stem cells
and neural cells (enhancing and in some cases replacing reprogramming transcription
factors).150
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Azanucleosides as therapeutic agents
As previously mentioned, dAC has been clinically approved for the treatment of
MDSs.120 This is a group of diseases that affects normal blood cell production in the
bone marrow. As a result, in MDS, the bone marrow produces abnormal, immature
blood cells that fail to mature and work properly. At low concentration dose schedules,
dAC has been reported to have significant activity against MDS.151 It has also shown
activity against AML and Chronic Myeloid Leukaemia (CML). Several trials suggested
that the effect of dAC could be further enhanced with combination treatments with
growth factors, HDAC inhibitors and other chemotherapeutic agents such as cytarabine
or gentuzumab.120 Although azanucleosides are only used for treatment of myeloid
disorders, a number of recent clinical trials indicate that dAC has potential against other
cancer types such as ovarian, colorectal, cervical cancer and other solid tumours.152
It has also been indicated that dAC could enhance the sensitivity of tumour cells to
treatments against which they previously acquired resistance.153
Limitations of azanucleosides
Despite the promising efficacies and potential applications of azanucleosides, their use
have several limitations. One of the main challenges of AC and dAC is their chemical
instability in aqueous solutions due to the opening of the triazine nucleobase.154,155 A
simple model of dAC’s decomposition is shown in Figure 1.4. The triazine ring is prone
to nucleophilic attack by water at position 6 (I), which could then undergo subsequent
ring opening (II) and deformylation (III). The rate of degradation greatly depends
on the pH and temperature of the solution.155 Higher pH and higher temperatures
increase the rate of degradation. The measured half-life of the drug is 10 hours at 37
0C in potassium phosphate buffer pH 7.4.155
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The clinical use of azanucleosides is also limited due to its cytotoxic side-effects. Due
to the chemical instability and cytotoxicity of azanucleosides,prolonged administration
at lower doses are preferable in the clinic. In addition, azanucleosides are rapidly
metabolized by CDA following administration.156
1.3.4 Chemical tools IIb: nucleoside inhibitor analogues
Alternative cytidine nucleoside analogues
To improve the stability and efficacy of azanucleosides, several alternative cytidine
analogues have been developed in recent years (Scheme 1.5).103,157
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Scheme 1.5 Structures of second generation nucleoside DNMT inhibitors
5,6-dihydro-azacytidine (8) and 2′-deoxy-5,6-dihydro-azacytidine (9) are hydrolytically
stable analogues of AC and dAC.158,159 The saturation of the 5,6-double bond in the
triazine ring abrogates nucleophilic attack of position 6 by water. Unfortunately DHAC
has exhibited cardiac toxicity in clinical studies,158 but DHDAC is well tolerated and
has been shown to have promising activity as an anti-HIV agent.160 Its prodrug KP1461,
is currently under clinical investigation.161 Crystallographic studies have also indicated
that 9 is able to inhibit DNMT1 by occupying the active site of the enzyme as a
transition state mimic rather than forming a covalent bond like dAC.160 Although 9 is
efficient as a free nucleoside analogue to inhibit DNMT, its hypomethylating potency
is much lower than that of dAC.159
Zebularine (10) is a cytidine analogue that lacks an amino group at position 4 of the
pyrimidine ring. Its greatest advantage is its stability against cytidine deaminase,
which enabled this drug to be taken orally.162 However, inefficient metabolic activation
and unexpected fatal toxicity found in monkeys hampered further clinical development
of this agent.91
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The next cytidine analogue, 5-fluoro-2′-deoxycytidine (11) has also shown promising
hypomethylating activity in human breast and lung carcinoma cells.163 Compound
11 is stable in aqueous solution, however its rapid metabolism by cytidine deaminase
remained an issue. In addition, its metabolic side-product, 5-fluoro-2′-deoxyuridylate
turned out to be an inhibitor of thymidilate synthase which limited its further clinical
development.164
Prodrugs of azanucleosides
In addition to exploring alternative cytidine analogues, a number of groups have focused
on the development of prodrugs for AC and dAC in order to improve their stabilities
and cellular delivery (Scheme 1.6).
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Güimil and co-workers synthesised 4-NPEOC-dAC (12), which contains a 4-nitrophenethyl
carboxy (4-NPEOC) group at position 4 of the triazine ring.165 This group protects
dAC from degradation by CDA enzyme and could therefore prolong the lifetime of dAC.
Preclinical studies have shown that the 4-NPEOC group could be selectively removed
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by human carboxylesterase 1 in liver cancer cell lines. However, 4-NPEOC-dAC 12
is less potent than dAC and its dependence on the carboxylesterases would limit its
potential activity to organ with high concentration of this enzyme, such as the liver.166
Astex Pharmaceuticals have recently developed SGI-110 (13), a dinucleotide prodrug of
dAC. In SGI-110, the active dAC is linked to deoxyguanosine (dG) via a phosphodiester
bond. This linkage results in reduced susceptibility to degradation by CDA and provides
prolonged plasma stability and high tolerance in humans.167 Since 2010, a number
of clinical studies began to evaluate the safety and efficacy of SGI-110 in various
haematological and ovarian cancers.168
Efforts were made not only to improve the stability of azanucleosides, but also to
improve their delivery within the cell and the entire body. CP-4200 (15) is an elaidic
ester analogue of AC developed in order to render AC less dependent on conventional
nucleoside transport systems.169 This analogue has shown superior efficacy to 5 in
mouse tumour models. In addition, to improve oral bioavailability, 2′,3′,5′-triacetyl-
5-azacytidine (14) was developed as a potential prodrug for AC.170 The prodrug
demonstrated significant pharmacokinetic improvements in bioavailability, solubility
and stability over AC. Although this analogue was not investigated further, different
oral formulations of AC (CC-486) have also been developed and are currently under
clinical investigations.171 An orally administrable version of dAC involving its mesylate
salt was also reported in a preclinical study.172
1.3.5 Need for controlled DNA methylation
In addition to the ever growing interest in its therapeutic effects in clinical settings,
dAC continues to serve as an immensely valuable research tool in the field of epigenetics
and developmental biology. It remains the most efficacious demethylator despite the
numerous attempts to develop alternative nucleosides with improved stability profiles.
Due to its challenging chemistry, only a few dAC prodrugs were successfully made
with reported improvements in their pharmacological properties such as their uptake173
and reduced toxicity.166,174 In most cases, intracellular enzymes (such as esterases
and phosphatases) serve as ’activators’ of these prodrugs. It remains a challenge to
control the intracellular levels of these enzymes and thereby the activity of these dAC
analogues.
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Currently there is no small molecule with a tuneable bioactivity that can modulate
DNA methylation. A molecule with a tuneable bioactivity would enable the study
of methylation changes in the same biological environment, thereby further aiding
our understanding of the functional significance of DNA methylation as part of many
biological processes. The therapeutic advantages of tuneable DNA demethylators would
be the potential targeted approach of treatments with reduced cytotoxic side effects.
Since azanucleosides have high demethylating efficacy and potential to reactivate
tumour suppressor genes, the possibility to develop analogues with tuneable bioactivity
would be very desirable.
Light is an excellent tool that could provide control over the bioactivity of small
molecules in a spatiotemporal confinement.175 Optical control of histone acetylation
via small molecules equipped with photoswitches has been recently reported.176 In
addition, light-tuneable versions of the TALE and CRISPR-Cas systems have also been
explored to edit the epigenome with moderate to good efficiencies.177–180 However, no
chemical tools have been developed to date that could target DNA methylation in a
light-dependent manner. A light-tunable methylation tool would enable researchers to
direct methylation changes to specific areas in the cell or tissues. In order to make
light-tuneable small molecules, one could pursue a photocaging strategy.181 Photocaged
compounds are light-sensitive probes that functionally encapsulate biomolecules in an
inactive form.182
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1.4 Tuning bioactivity using light: Photocaging
1.4.1 Principles of photocaging
The principal idea behind photocaging is that a biologically active molecule of interest
can be rendered temporarily inactive by chemical modification or ’caging’ with a
photolabile protecting group (also termed as phototag or photocage).181 The ’caged’
compound can enter the cell via similar transport systems as their active equivalent.
(Figure 1.7) Restoration of biological activity can be achieved by irradiation of the caged
compound at a particular wavelength.175 This results in a photochemical cleavage of
the phototag and simultaneous concentration spike of the unmodified active substance,
which can then exert its biological effect.182 This process is also termed as ’uncaging’,
’photouncaging’ or ’deprotection’.
Scheme 1.7 Light activation of a photocaged-compound
Light is an ideal and orthogonal signal.175 It easily penetrates cell membrane, and
provided the wavelengths used are not too short, cells are not harmed by light. Fur-
thermore, light can achieve both global and focused illumination on cells, depending on
the light source and techniques used.182 Light cannot only be directed, but it can also
be modulated in time and amplitude. Thus, uncaging can be used to produce rapid,
repetitive release of biomolecules and it can also be finely tuned for gradual uncaging
of the compound. Overall, these properties of light triggered uncaging would enable
one to control the location, time and dosage of a drug once it has entered the cell.
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1.4.2 Phototags
The choice of the phototag plays a crucial role in the behaviour of the caged compound
and the properties of its uncaging. In the first part of this section, a number of
important characteristics of phototags will be discussed, followed by a brief review of
the two most popular phototag families used in literature.
Important characteristics of phototags
The criteria and design of a good phototag depends on its application. For cell biological
applications, the phototag should have strong absorption (ϵ) at wavelengths that are
less damaging to the biological environment (λmax > 300 nm).181 A good phototag
should also have high aqueous solubility and be able to pass through biological barriers
such as cell membranes. Furthermore, the photochemical deprotection (’uncaging’) of
the caged compound should be complete: it should only release the ’uncaged’ product
and the phototag. The efficiency of release is another important factor. The quantum
yield of uncaging (Φ) is the measure of the efficiency with which the light absorbed
converts the caged compound to its uncaged derivative.181 It is the number of molecules
converted per number of photons absorbed. The closer this value is to 1, the more
efficient is the uncaging process. And finally, when the photouncaging is complete,
the remaining byproducts should be transparent and non-toxic to the cells. Several
phototags meet many of the criteria above.
Nitroaryl-based (o-NB and o-NPE) phototags
The ortho-nitrobenzyl (NB) and ortho-nitrophenethyl (NPE) compounds are the
most commonly used phototags to date. Their popularity can be attributed to their
commercial availability and the ease by which they can be conjugated to bioactive
molecules. Structures of the frequently used derivatives are shown in Scheme 1.8.
The first o-nitrobenzyl- (NB) analogue 16 was reported as a general photolabile
protecting group in 1970.183 Its derivatives carry a leaving group at the benzylic
position to release the protected substrate upon irradiation. Substrates can include
alcohols, amines, but carbonic acid derivatives such as carbonates and carbamates are
the most convenient choices to synthesise due to the ease of chemical conjugation.184
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Scheme 1.8 Popular NB and NPE phototags in literature
Modifications in the aromatic ring can greatly affect absorbance and solubility of
NB phototags. For example, the addition of two methoxy groups in 4,5-dimethoxy-2-
nitrobenzyl (DMNB) 17 resulted in a 95 nm increase in λmax. Furthermore, substituents
in the benzylic position (such as a methyl group in methyl-2-nitrobenzyl 18 can also
positively affect the quantum yield of uncaging (from Φ = 0.13 to Φ = 0.64).185 Other
groups such as the -cyano, -carboxylic acid and other NB rings were also explored, but
their effect on quantum yield was not as great as for the methyl group.181
While the photochemical properties of NB analogues were extensively studied, the
main drawback of these phototags remained the toxic nitrosoaldehyde side-products
that were formed upon photolysis.186 This issue was overcome by the NPE phototags,
which release a more biocompatible nitrostyrene byproduct. These compounds were
discovered in the late 1990s by Hasan and coworkers.187 In addition to the improved
biocompatibility, the first NPE phototag 19 had a greater quantum yield of uncaging
(Φ = 0.042) compared to its NB equivalent 16 (Φ=0.033).181 Similarly to the NB
phototags, the addition of two methoxy groups in 4,5-dimethoxy-2-nitrophenethyl
phototags 20 improved the absorption maximum by nearly 100 nm. Analogue 21 had
eight times higher quantum yield (Φ = 0.35) compared to the parent NPE phototag
19.188
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Despite the similarity in their structures, the NB and NPE phototags undergo markedly
different uncaging mechanisms.181 The mechanism of uncaging of a NPE-protected
carbamate 22 is shown in Scheme 1.9. Firstly, light irradiation induces radical formation
within the nitro group. These radicals proceed with an intramolecular hydrogen
abstraction at the α-position, which is followed by β-elimination of the protected
substrate. This gives the nitrostyrene byproduct 23 with concomitant liberation of
CO2 and the unprotected amine 24.
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Scheme 1.9 Photodeprotection of an NPE-derived carbamates181
In summary, NPE compounds are easily accessible phototags with excellent photochem-
ical characteristics. They also serve as good reference compounds for photouncaging.
However, their use is more suitable with chemical applications due to their limited
aqueous solubilities. Notable applications of NPE phototags include light-automated
DNA oligonucleotide synthesis188 and transient disruption of DNA hybridization.189
Coumarin-based phototags
The coumarin compounds are attractive phototags for cellular applications not only
because they have improved aqueous solubility profiles, but they exhibit better pho-
touncaging properties at longer wavelengths (up to λ = 450 nm).181 They have very
high molar absorption coefficients and high quantum yields and as a result, faster release
rates at longer wavelengths compared to their equivalent NB/NPE caged compounds.186
The first analogue of the coumarin-based phototags, 7-methoxycoumarin 25 (λmax =
320 nm) was used to cage diethyl phosphate derivatives and was reported by Givens et
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al.190 Modifications in the C6 and C7 position enabled further improvement in water
solubility profiles and increase in absorption maxima. Most notably in the 6-bromo-
7-hydroxycoumarin phototag 26 (BHC), the bromine substitution was designed to
lower the pH of the OH group at position 7 by two units to achieve its complete
deprotonation at physiological pH.191 This enhanced the aqueous solubility and in
addition increased maximum wavelength of absorption by 50 nm (λmax = 370 nm).
But so far, the most successful modification to date is the introduction of a 7-amino
substituent in 7-diethylaminomethylcoumarin (DEACM) 27. With the highest quantum
yield among all the coumarin analogues, DEACM has recorded quantum yields between
Φ = 0.21 and Φ = 0.28 and it also has the higher absorption maxima (λmax = 390
nm).192
Further efforts were made to push the (λmax) to even higher wavelengths, towards
λmax = 500 nm. Bao et al. introduced an additional styryl group at position 7
giving styrylcoumarin 28 to increase the absorption wavelength to λmax = 407 nm.193
Substitution of the carbonyl group of the coumarin ring to a thionyl group in analogue
29 also resulted in a further bathochromic shift of 100 nm, reaching a final λmax = 487
nm.194 Although these agents have compromised quantum yields at high wavelengths
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(Φ(420nm) = 0.00079 and Φ(470nm) = 0.005), the prospect of long wavelength phototags
are promising as they allow deeper penetration and reduced toxicity by UV light.
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The synthetic strategies towards coumarin-caged compounds are summarised in Scheme
1.11. Substrates are generally attached to the 4-methyl position of the coumarin
scaffold. The desired methylcoumarin derivatives 30 can be commercially purchased
or synthesised via Pechmann condensation.195,196 The methylcoumarin can either be
converted into a halide derivative such as 4-bromo-coumarin 31 via treatment with
N -bromosuccinimide (NBS) or a hydroxy derivative (coumarinyl-4-methanol, 33) via
oxidation with selenium dioxide SeO2.181 The bromide handle can provide access to
thiols, alcohols, amines via direct alkylation to give 32 or carboxylic acids and amino
acids via SN2 substitution. Conversely, the hydroxycoumarin 33 derivative is a common
precursor to carbonates, carbamates, esters, phosphates and sulphonates 34.181
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Scheme 1.11 Synthetic strategies towards coumarin-caged compounds
The suggested uncaging mechanism of coumarin-caged compounds containing a carboxy
linkage is shown in Scheme 1.12. The first step upon light irradiation is the heterolytic
(C O) bond cleavage within the coumarin-caged compound 35. This is followed by
a formation of a tight ion pair 36, which then reacts with water to form a stable
coumarinmethyl alcohol 37 and the unstable liberated carboxylate residue 38 undergoes
decarboxylation to give the uncaged product 39 as a free alcohol or amine. The
heterolytic bond cleavage is thought to proceed rapidly, whereas ion recombination
is slower and decarboxylation is the slowest, rate-limiting step. Alcohols, phenols,
thiols and amines are poor leaving groups, while carbamates and carbonates tend to
be released faster and more efficiently. In the case of a coumarin-caged compound
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with no carboxyl linkage, the mechanism is identical with the omission of the final
decarboxylation stage and the direct release of the uncaged substrate.
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Scheme 1.12 Suggested deprotection mechanism of coumarin-caged molecules
DEACM 27 is one of the most commonly used coumarin phototags in literature.
This is indicated from a number of studies where DEACM phototag was used to
cage a variety of biomolecules, for example Hagen and co-workers photocaged cyclic
nucleotide analogues to selectively activate cyclic nucleotide-gated ion channels in
human embryonic kidney (HEK293T) cells.192 In addition, DEACM was also used to
cage adenosine triphosphate (ATP) to control transcription in vitro using light in a
study by Pinheiro et al.197 Furthermore, DEACM-caged cholesterol was also synthesised
for the purpose of studying sterol pathways.198
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1.4.3 Photocaging nucleosides
In this project, we are interested in photocaging azanucleosides. Given that they are
nucleoside analogues, the past caging strategies for nucleosides will be reviewed in this
section. Nucleosides can be caged at three different positions: 5′-position, 3′-position
and the nucleobase (Figure 1.10). For each position, the general synthetic strategies
and applications of the resulting caged-nucleosides will be discussed.
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Fig. 1.10 Summary of nucleoside caging strategies
Caging the 5′-position
Caged-ATP was the first protected nucleoside reported by Kaplan and coworkers.199 In
their study, the NB phototag was linked to the γ-phosphate group on ATP. Caged-ATP
enabled researchers to analyse fast, energy-requiring biological events such as ion
transport and signal transduction. Both NB and coumarin photocages have been used
to cage ATP, GTP and other cyclic nucleotides.197,200,201
The majority of the studies focused on the photocaging 5′-phosphorylated nucleosides.
Historically, there are two main methods by which the phototag could be linked to this
position (Scheme 1.13). Method A involves the direct coupling of the diazo derivative
of the phototag to the nucleoside mono-, di- or triphosphate 40. Geissler and et al.
explored this method with coumarin phototags, but their reported yields to obtain 41
were very low (1.7%) due to the low reactivity of 4-(diazomethyl)coumarins.201
Conversely, method B is significantly higher yielding despite requiring multiple synthetic
steps. The phototag phosphate is prepared from the phototag alcohol in 3 steps (not
shown) via treatment with a phosphoramidite, oxidation with tert-butyl hydroperoxide
and subsequent hydrolysis with trifluoroacetic acid.201 The phototag phosphate is then
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Scheme 1.13 Nucleoside photocaging strategies at 5′-position I.
coupled with carbonyldiimidazole-activated nucleoside monophosphate or diphosphate
to give analogue 42.202 In addition to photocaging of the phosphate group, direct
caging of the 5′-OH of nucleoside 43 via phototag-chloroformate has also been reported
by Bühler et al (Scheme 1.14).203 In the resulting photocaged-nucleoside 44, 5′-OH
and the phototag was linked via a carbonate bond.
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Scheme 1.14 Nucleoside photocaging strategies at 5′-position II.
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Caging the 3′- and 2′-position
The 2′- and 3′-OH groups are important positions for biomolecular recognition.204
The 3′-OH is essential for chain elongation during DNA synthesis. Thus, temporarily
blocking this position terminates the polymerase chain reaction and prevents further
incorporation of nucleotides into DNA. Photocaging the 3′-OH creates reversible chain
terminators, which were particularly useful for improving pyrosequencing techniques.205
Photocaging of the 2′-OH ribonucleotides enabled researchers to study the mechanism
of RNAzyme in detail.206
Synthetic strategies for photocaging these positions are summarised in Scheme 1.15.
3′-caging so far has only been reported via direct alkylation of the 3′-OH by reacting
starting nucleoside 45 with the phototag-bromide in the presence of NaOH to give
photocaged analogue.207 It is essential that the 5′-OH and the nucleobase are protected
prior to the photocaging.
In this example, the 5′-OH is protected with a tert-butyldimethylsilyl (TBDMS)
group and the exocyclic amine of adenine nucleobase is replaced with a Cl group.
Direct coupling to the photocage-bromide gives an ether-linked photocage at the
3′-position. The removal of the protecting groups is achieved by treatment with
tetrabutylammonium fluoride (TBAF) followed by methanolic ammonia (NH3/MeOH)
to give the desired 3′-protected nucleoside analogue 46.
The functionalisation of 2′-OH like in analogue 47 is similarly carried out in the
presence of base (NaH), and it requires previous protection of 3′- and 5′-OH groups.208
The final photocaged analogue 48 is linked via an ether linkage in position 2. Simul-
taneous protection of 2′- and 3′-OH groups is also possible. Deiters et al. reported
the photocaged version of an adenosine analogue Toyocamycin 49. This analogue can
efficiently inhibit ribozyme function. The photocaging of Toyocamycin was achieved
in the presence of photocage-aldehyde derivative and ZnBr2 and heat to give caged
analogue 50.209
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Caging the nucleobase
Placing the phototag on the nucleobase transiently blocks base-pairing properties
and enzymatic recognition.204 Due to these properties, nucleobase caging has been
extensively used in molecular biology - to control the formation of DNA structures
upon light exposure.210 Other applications include light regulation of transcriptional
activity,211 secondary and tertiary structure formation,212 DNAzyme activity213 and
even DNA replication.214
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Scheme 1.16 Nucleoside photocaging strategies at the nucleobase
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Photocages are generally linked to the exoxyclic amine (cytidine, adenine) or the
carbonyl moiety (thymidine and guanosine) of nucleobases. For simplicity, only caging
of cytidine and thymidine nucleobases will be presented here. Caging strategies
are summarised in Scheme 1.16. Starting from the thymidine/carbonylated dC 51,
one can couple the phototag-OH via a Mitsunobu-like reaction in the presence of
triphenylphosphine (PPh3) and diisopropyl azodicarboxylate (DIAD). In the resulting
photocaged analogue 52, the phototag is linked via an ether bond.
In order to photocage cytosine nucleobases via an amine linker, one would also start from
the carbonylated version of the nucleobase 51. But in this case, activation of the C-O
position is necessary with a 2-mesitylenesulfonyl-group. Addition of mesitylsulphonyl-
chloride (MTS-Cl) to 51 gives the activated 52. This activating group can be easily
replaced when the amine-photocage derivative is added. As a result, the phototag is
successfully installed on the nucleobase via an amine linker (54).
Furuta and coworkers reported a milder caging strategy that involves the direct coupling
of the photocage-chloroformate to cytidine 55.215 In this case, it is essential that the 3′-
and 5′-OH groups are transiently protected to selectively target the nucleobase. In the
resulting photocaged-analogue 56, the phototag is linked to cytidine via a carbamate
bond.
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1.5 Aims of the project
In this project, we aimed to pursue the photocaging strategy by designing and synthesis-
ing photo-responsive ‘caged’ derivatives of azanucleosides that can achieve tissue-specific
hypomethylation under spatiotemporal control. (Figure 1.11)
Fig. 1.11 Aims of the project
There were three main aims for this project:
(1) Chemical design and synthesis of caged-azanucleoside analogues
(2) Photochemical characterisation and stability analysis of these analogues
(3) Cell biological studies to inspect light-induced demethylating activity in vitro
It is envisaged that photocaged azanucleosides would be able to enter the cell through
the same nucleoside transport system utilized by azanucleosides. Depending on where
the phototag is placed, it is assumed that the phototag would prevent the formation of
key interactions (dCK, polymerization or phosphorylation). Restoration of biological
activity can be achieved by irradiation of the caged compound (uncaging), resulting
in bioactivity only at the site of illumination, which would greatly reduce unwanted
cytotoxicity of healthy cells. If successful, the photocaged azanucleosides would have
the same clinical benefits as the original azanucleosides but the cytotoxic side-effects
would be greatly mitigated.
Photocaged azanucleosides may also hold great promises as research tools. As light
tuneable demethylators, they would be able to induce methylation changes in a tissue-
specific manner. This would be invaluable in the field of developmental biology and
regenerative medicine where the differential effects of methylation changes could be
compared in the same environment.
Chapter 2
Synthesis of Photocaged
Azanucleosides
2.1 Introduction
Photocaging azanucleosides offers light-tuneable, spatiotemporal control over their
bioactivity. Similarly to conventional nucleosides, the activity of azanucleosides can
be blocked by modification at the nucleobase, 3′- or 5′-OH groups. A phototag on
the exocyclic amine of the nucleobase or the 5′-OH prevents the phosphorylation of
azanucleosides by dCK, while placing the phototag on the 3′-terminal blocks chain
elongation.
In this chapter, the design and synthesis of caged azanucleoside analogues will be dis-
cussed. NPE and coumarin-derived phototags were attached to all three possible caging
positions of azanucleosides. The photocaged analogues were tested to examine the
influence of the phototag and the caging-position on the stabilities and photochemical
properties of the compounds.
2.2 First generation photocaged azanucleosides
Given the abundant literature on nucleobase modifications, the exocyclic amine was
chosen as the first site for photocaging. It was also hypothesised that a phototag on the
exocyclic amine could protect azanucleosides from degradation by cytidine deaminase.
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Previous work in the Howorka group attempted to photocage 5′-azacytidine with
NB-derived phototags, but unsuccessfully. Coupling of NPE-phototags were successful,
but only when added in great excess. Here, we describe the preparation of NPE-derived
phototags followed by the successful coupling strategy that was adapted from a protocol
by Güimil et al.165
2.2.1 Design and synthesis
Synthesis of NPE-caged azanucleosides
NPE-derived phototags are popular due to their easily accessible structures and
good photouncaging properties.181 Our aim was to attach the NPE phototags to
azanucleosides via carbonate or carbamate linkers as these derivatives have reportedly
better uncaging properties compared to their ether or amine linked counterparts.
The first step was to convert phototags bearing hydroxyl groups into reactive chlo-
roformates. The commercially available 2-nitrophenethyl alcohol 57 was mixed with
phosgene overnight to afford the corresponding chloroformate 58 in 94% yield (Scheme
2.1).
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94%
O
NO2
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Scheme 2.1 Synthesis of NPE-chloroformate 58. Reagents and Conditions: (i) COCl2 ,
THF, 0 ◦C, 1 h then rt, 16 h
The resulting chloroformate 58 was then coupled to 5-azacytidine (AC) 5 via a
one-pot transient protection strategy (Scheme 2.2).165 AC was first treated with
hexamethyldisilazane (HMDS) in order to protect the 3′- and 5′- hydroxyls groups
from unwanted side reactions. This was followed by the addition of 11 equivalents of
chloroformate 58 in situ, and the subsequent removal of hydroxyl protecting groups
using tris(dimethylamino) sulfonium difluorotrimethylsilicate (TAS-F), an anhydrous
source of fluoride ions.216
Due to the instability of the triazine nucleobase, maintenance of anhydrous conditions
was essential.154 As a result, the first photocaged azanucleoside analogue 59 was
resynthesised in 14.8% yield. However, this analogue had very poor aqueous solubility.
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Scheme 2.2 Synthesis of bis-NPEOC-AC 59. Reagents and Conditions: (i) HMDS,
pyridine, DMF, rt, 2h; (ii) 11 eq chloroformate 58, CH2Cl2/DMF, rt, 16 h; (iii) TAS-F,
DMF, rt, 2 h
To address the solubility issue, the next aim was to attach a single phototag on the
exocyclic amine using dAC 6 instead of AC as our substrate of interest. Attaching a
single phototag would potentially improve the solubility due to the additional proton on
the carbamate linker that could form hydrogen bonds with water molecules. Following
the established protocol, two equivalents of chloroformate 58 were introduced to the
silyl-protected dAC, affording mono-NPEOC-dAC 60 in 53% yield (Scheme 2.3). This
analogue had slightly improved, but still modest aqueous solubility.
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Scheme 2.3 Synthesis of mono-NPEOC-dAC 60. Reagents and Conditions: (i) HMDS,
pyridine, DMF, rt, 2h; (ii) 2 eq chloroformate 58, CH2Cl2/DMF, rt, 16 h; (iii) TAS-F,
DMF, rt, 2 h
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Synthesis of DMNPE-caged azanucleoside
The 4,5-dimethoxy-2-nitrophenethyl (DMNPE) phototags were also used to photocage
azanucleosides. These phototags have higher wavelength of maximum absorbance
(λmax) than their NPE equivalents due to the additional methoxy groups on their
aromatic ring.
The synthesis of DMNPE phototags was achieved in two steps. Reduction of commer-
cially available 4,5-dimethoxy-nitrophenylacetic acid 61 via BH3 gave the corresponding
alcohol 62 in 98% yield. This analogue was further subjected to overnight phosgenation
to afford chloroformate 63 in 96% yield (Scheme 2.4).
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Scheme 2.4 Synthesis of DMNPE-chloroformate 63. Reagents and Conditions: (i) BH3,
THF, rt, 2 h; (ii) COCl2, THF, 0 ◦C, 1 h then rt, 16 h
Mono-DMNPE-dAC 64 was prepared at 28% yield via the established transient
protection protocol and the addition of two equivalents of chloroformate 63 phototag
(Scheme 2.5). In general, the synthesis of mono-tagged derivatives was achieved at
significantly higher yields and this could be attributed to the greater hydrolytic stability
of dAC compared to AC.
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Scheme 2.5 Synthesis of mono-DMNPEOC-dAC 65. Reagents and Conditions: (i)
HMDS, pyridine, DMF rt, 2h; (ii) 2 eq chloroformate 63, CH2Cl2/DMF, rt, 16 h; (iii)
TAS-F, DMF, rt, 2 h
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2.2.2 Photochemical characterisation
UV-Vis absorption
The UV-Vis absorption spectra of caged analogues and their components are depicted
in Figure 2.1. The corresponding λmax and ϵ values are summarised in Table 2.1.
Fig. 2.1 UV-Vis absorption profiles of first generation photocaged azanucleosides
In general, all three analogues had strong absorptions in the lower UV regions. The
molar absorbance of bis-NPEOC-AC 59 was ϵ = 14800 M−1cm−1 at λ = 260 nm and
that of mono-NPEOC-dAC 66 was ϵ = 16400 M−1.cm−1 at λ = 233 nm. The strong
absorption in the lower UV region is due to the the triazine nucleobase. The NPE
phototag absorbs modestly at λ = 260 nm (Figure 2.1B). However in bis-NPEOC-AC
59, the presence of two NPE phototags significantly intensified absorption at λ = 260
nm, represented by the additional "shoulder" in the absorption profile of 59 (Figure
2.1A). Figure 2.1C shows that the presence of two methoxy groups in DMNPE phototags
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and mono-DMNPEOC-dAC 67 shifted the λmax to longer wavelengths (λ=365 nm) as
expected, however the absorption remained modest (ϵ = 4000 M−1cm−1).
Photocaged analogue λmax Absorption ϵ, [M−1.cm−1]
bis-NPEOC-AC, 59 260 0.74 14800
mono-NPEOC-dAC, 60 233 0.82 16400
mono-DMNPEOC-dAC, 64 365 0.20 4000
Table 2.1 UV-Vis absorption properties of first generation photocaged azanucleosides
Photouncaging properties
Subsequently, the photouncaging properties of the caged analogues in water were
assessed. Bis-NPEOC-AC 59 was subjected to irradiation at λ = 254 nm using a
benchtop UV lamp, given its strong UV absorption in this region. The uncaging
reaction was monitored via analytical HPLC every 30 minutes over 2 hours. Analysis of
the HPLC traces was challenging due to the extreme instability of triazine nucleobase
in water. The caged nucleoside peak rapidly disappeared after 30 minutes, mainly
giving hydrolytic and other unknown breakdown products. The addition of 1% acetic
acid significantly slowed down triazine hydrolysis and enabled the analysis of two
"uncaged" product peaks that were appearing over time.
The proposed uncaging mechanism is depicted in Scheme 2.6. Irradiation of 59 first
gives mono-NPE-tagged 68, which is then uncaged into AC 5. In each step, nitrostyrene
byproduct is released.
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Scheme 2.6 Uncaging mechanism of bis-NPEOC-AC 59
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In Figure 2.2, the molar ratio of each species was plotted against time. After 2 hours,
80% of bis-NPEOC-AC disappeared as it deprotected into the mono-caged analogue or
hydrolysed via the opening of the triazine ring. The amount of mono-caged analogue
initially increased in response to bis-NPEOC-AC uncaging, but after 1 hour it remained
unchanged.
Fig. 2.2 Photouncaging profile of bis-NPEOC-AC 59 at λ = 254 nm
Although it was successfully shown that under certain conditions photoactivation
occured, the photocaged AC had several limitations. First of all, AC analogues are
not viable options for uncaging as the triazine rapidly decomposed before sufficient
amounts of compound could be uncaged. Furthermore, the presence of two phototags
introduced an additional intermediate (mono-NPEOC-AC) that required additional
uncaging into AC. This further elongated the uncaging process.
These limitations were overcome by the mono-tagged dAC analogues as the presence
of a single phototag enabled direct uncaging. dAC has significantly improved aqueous
stability compared to AC. The uncaging rates of mono-NPEOC-dAC 60 and mono-
DMNPEOC-dAC 64 at λ = 254 and λ = 365 nm were investigated next. The results
are summarised in Figure 2.3.
Monitoring the photolysis of caged dAC analogues was significantly simpler compared
to caged AC analogues as triazine hydrolysis was less prevalent. At λ = 254 nm, mono-
NPEOC-dAC 60 showed a much faster uncaging profile than its DMNPE analogue
64 (Figures 2.3A and C). At the end of the 90 mins irradiation, 48% of uncaged dAC
was released from 60, while 64 only released 4%. Of the initial caged compound, 18%
remained in solution for analogue 60 and 58% for analogue 64. It is likely that the
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(A) mono-NPEOC-dAC 60, λ = 254 nm (B) mono-NPEOC-dAC 60, λ = 365 nm
(C) mono-DMNPEOC-dAC 64, λ = 254 nm (D) mono-DMNPEOC-dAC 64, λ = 365 nm
Fig. 2.3 Photouncaging profiles of first generation photocaged dAC analogues 60 and
64
conversions into dAC at this wavelength were not quantitative, possibly due to minor
hydrolysis or decomposition effects, which could be characteristics of this wavelength.
On the contrary, irradiation at λ = 365 nm avoided the decomposition effects. Conver-
sion into dAC also seemed to be more quantitative, though photolysis occurred at a
significantly slower rate. After 90 mins of irradiation, 37% of dAC was released from
mono-NPEOC-dAC 60 and only 7% dAC from mono-DMNPEOC-dAC. In summary,
DMNPE-caged dAC had significantly poorer uncaging rates at all wavelengths tested.
Table 2.2 summarises the measured and calculated photouncaging properties of the
photocaged analogues. Details of the calculations can be found in the Experimental
Section (page 153).
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Photocaged analogue ϵ365nm, [M−1.cm−1] k, [s−1] Φ365nm Φϵ365nm
bis-NPEOC-AC, 59 460 N/A N/A N/A
mono-NPEOC-dAC, 60 200 8,33E-05 4.93E-03 0.986
mono-DMNPEOC-dAC, 64 4000 6.67E-05 3.94E-03 15.76
Table 2.2 Photochemical properties of first generation photocaged azanucleosides
2.3 Second generation photocaged azanucleosides
While the NPE-derived phototags provided a good starting point for the caging strategy,
the photochemical measurements confirmed their modest uncaging rates at λ = 365
nm. Coumarin photocages could potentially address these limitations as they have
strong absorption between λ = 350 and 400 nm and reportedly higher quantum yields.
2.3.1 Design and synthesis
Two coumarin phototags were chosen for our next photocaging strategy. The 6-bromo-
7-hydroxymethylcoumarin (BHC) phototag has excellent water solubility and a strong
absorption at λ = 370 nm. The 7-diethylaminomethylcoumarin (DEACM) phototag
has even higher λmax (387 nm) and reportedly the highest quantum yields among all
of the coumarin analogues,181 though not higher than BHC phototags’ according to
others.191
We decided to synthesise and assess both phototags before coupling them to dAC.
The synthesis of the BHC phototag was carried out in two steps following literature
procedures (Scheme 2.7).215
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Scheme 2.7 Synthesis of BHC phototag 71. Reagents and Conditions: (i) methyl
4-chloroacetoacetate, CH3SO3H, rt, 2 h; (ii) H2O, reflux, 5 d
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Commercially available 4-bromoresorcinol 69 was treated with methyl 4-chloroacetoacetate
in the presence of methanesulfonic acid to generate 4-chloro-BHC 70 in 63% yield via
Pechmann condensation. The resulting coumarin 70 was refluxed in water over 5 days
to afford hydroxylated BHC 71 in 85% yield.
The resulting BHC phototag contained two OH groups. The aim was to convert the
aliphatic OH to chloroformate to serve as a point of conjugation to azanucleosides.
Protection of the aromatic OH prior to chloroformate formation was necessary to
avoid any side reactions. The methoxymethyl (MOM) protecting group has been pre-
viously used to protect BHC phototags.215 However, its harsh removal conditions using
trifluoroacetic acid (TFA) can potentially interfere with the stability of azanucleosides.
As an alternative option, the 2-(trimethylsilyl)ethoxymethyl (SEM) group was used to
protect the aromatic OH. SEM protecting groups are structurally similar to MOM
protecting groups, but their removal requires fluoride ions - a condition we know
to be compatible with azanucleoside stability. BHC coumarin 71 was mixed with
one equivalent of 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) in the presence of
N,N -diisopropylethylamine (DIPEA) base.
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Scheme 2.8 Hydroxyl-protection of BHC phototag 71. Reagents and Conditions: (i)
SEM-Cl, DIPEA, CH2Cl2, 0 ◦C; (ii) MOM-Cl, DIPEA, CH2Cl2, 0 ◦C
Instead of the expected analogue 72 carrying a SEM protecting group at the aromatic
OH, we obtained the aliphatic OH-protected version 73 in 54% yield (Scheme 2.8).
Unfortunately this derivative could not be used for further coupling. MOM-protection
using methoxymethyl chloride (MOM-Cl) on the other hand gave the desired MOM-
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protected analogue at the aromatic OH 74 in 57% yield (Scheme 2.8). The selectivity
of the MOM-protecting groups towards aromatic and secondary alcohols could have
been controlled by steric factors.
The use of BHC as a phototag for azanucleosides faced several limitations. Firstly, the
BHC phototag requires the MOM protection to sufficiently couple to azanucleosides
without unwanted side reactions. The removal of the MOM-protecting group after
the coupling step using highly acidic conditions (as suggested in literature) may be
problematic.217 Secondly, the synthesis of phototag-chloroformate requires 4 steps
including a 5-day long reaction. Furthermore the overall yield of BHC preparation was
very low, suggesting that a lot of starting material would be required at the start of
the synthesis to prepare sufficient amounts of phototag-chloroformate for coupling to
azanucleosides.
By contrast, the preparation of the DEACM phototag-chloroformate only requires 3
steps with a total duration of 4 days. Furthermore, the phototag requires no protection
and the reported synthetic yields are also higher. The synthesis of DEACM phototag
is summarised in Scheme 2.9.218,219
Commercially available 4-diethylaminocoumarin 75 was converted into hydroxylated
DEACM-OH 76 in two consecutive steps. Compound 75 was first refluxed with
selenium dioxide (SeO2) over 24 hours, followed by a 4 hour reduction with sodium
borohydride(NaBH4) to obtain 76 in 53% yield. This analogue was converted into
the corresponding chloroformate 77 via treatment with phosgene in the presence of
DIPEA over 3 hours.
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Scheme 2.9 Synthesis of DEACM-chloroformate 77. Reagents and Conditions: (i) SeO2,
p-xylene, reflux, 24 h; (ii) NaBH4, EtOH/THF, rt, 4 h; (iii) COCl2, DIPEA, THF,
0 ◦C, 3 h
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The resulting DEACM-chloroformate 77 was subsequently coupled to dAC 6 via the
transient protection strategy to obtain N-DEACMOC-dAC 78 in 16% yield (Scheme
2.10).
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Scheme 2.10 Synthesis of N-DEACMOC-dAC 78. Reagents and Conditions: (i) HMDS,
pyridine, DMF rt, 2h; (ii) 2 eq chloroformate 77, CH2Cl2/DMF, rt, 16 h; (iii) TAS-F,
DMF, rt, 2 h
2.3.2 Photochemical characterisation
N-DEACMOC-dAC 78 exhibited strong absorption between λ = 350 and 450 nm, with
λmax = 387 nm (Figure 2.4A). Its molar absorbance at λ = 395 nm was ϵ = 10000
M−1cm−1 and at λ=365 nm it is ϵ = 7000 M−1cm−1, almost twice the absorbance of
mono-DMNPEOC-dAC 64 (ϵ = 4000 M−1cm−1). Figure 2.4B shows the photouncaging
profile of 78.
Fig. 2.4 (A) UV-Vis absorption and (B) photouncaging profile of N-DEACMOC-dAC
78
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The strong absorption at λ = 365 nm is reflected in the rate and efficiency of the
photolysis. After 1 hour of irradiation at λ = 365 nm, almost all of the caged
compound (98%) has disappeared, and ’uncaged’ dAC appeared in almost quantitative
amounts (92%). This uncaging profile is significantly faster compared to the NPE- and
DMNPE-tagged azanucleosides that were examined previously.
The HPLC traces for the photolysis of analogue 78 at λ = 365 nm are shown in
Figure 2.5. The traces show that the single peak (Rt = 14 min) representing the
caged analogue 78 at t = 0 min rapidly disappeared after 30 and 60 min. This was
accompanied by the quantitative appearance of two additional peaks that corresponded
to dAC (Rt = 4.5 min) and DEACM-OH (Rt = 15 min). The traces show that the
uncaging proceeded without any unwanted side products. The calculated quantum
yield of uncaging (Φ365nm = 0.028) was lower than reported values in literature.191
Fig. 2.5 HPLC traces for photouncaging of N-DEACMOC-dAC 78 at λ = 365 nm
2.3.3 Stability studies
In summary, N-DEACMOC-dAC 78 had the best photochemical characteristics among
all the photocaged azanucleoside analogues. Since this analogue was prepared for the
purpose of cell biological applications, it was essential that it possessed good stability
under such conditions.
The stability of 78 was assessed by incubation in water at 37 ◦C in the dark and
aliquots were analysed via HPLC. The results indicated that compound 78 had very
poor stability (Figure 2.6). After 2 hours of incubation, nearly all of the caged
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compound 78 had decomposed followed by complete degradation after 5 hours. It was
also observed that the main peak was degrading into two unknown peaks.
To confirm the identity of the peaks, the decomposed solution was spiked with dAC
and re-analysed by HPLC. dAC eluted after peak 1, suggesting that peak 1 may be
a more polar, closely related analogue of dAC. The solution was further spiked with
DEACM-OH to determine the identity of peak 2. HPLC analysis of the re-spiked
mixture showed that DEACM-OH and peak 2 identical retention times, indicating that
peak 2 corresponds to DEACM-OH.
Fig. 2.6 HPLC stabiltiy studies of N-DEACMOC-dAC 78 at 37 ◦C. In order to
determine the identity of the degradation peaks, the stability mixture was spiked with
dAC, followed by DEACM-OH.
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Together these findings suggested that the dark instability was due to the carbamate
bond hydrolysis that resulted in the dissociation of the phototag. One possible
mechanism for the process is outlined in Scheme 2.11. The carbamate linker between
the phototag and the azanucleoside can dissociate in the presence of water, leading to
the release of the DEACM-OH phototag and potentially a carbamic acid intermediate
that could eventually decarboxylate into dAC. The rate of decarboxylation is dependent
on a range of factors, such as temperature and pH of the solution and the characteristics
of the carboxylated compound itself.
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Scheme 2.11 Proposed mechanism for dark instability of N-DEACMOC-dAC 78
The carboxylated dAC is a viable intermediate for this breakdown process as the HPLC
analysis suggests the presence of the dissociated DEACM-OH phototag (corresponding
to peak 2 in Figure 2.6) and a more polar dAC analogue (corresponding to peak 1
in the same Figure). In order to test this hypothesis, further characterisation of the
degradation products was attempted by mass spectrometry.
In the mass spectormetry analysis, the stability mixture was re-created (1 mM of
N-DEACMOC-dAC, 78 was incubated in water overnight) and peak 1 of the stability
mixture was isolated via semi-preparative HPLC. The solvent was removed and the
mixture was submitted for mass spectrometry analysis. The mass spectrometry analysis
was carried out by Dr Kersti Karu.
The calculated exact mass of the carbamic acid intermediate is 272.08 and of the dAC
is 228.09. The negative mode electrospray ionisation analysis (TOF MS ES-) detected
a base peak value at 226.4376 as shown in Figure 2.7, which is likely corresponding to
dAC (that has lost two protons of 3′and 5′-OH during the negative mode ionisation).
This suggests that the analysed mixture predominantly contained dAC.
Another significantly smaller peak at 270.4261 m/z could potentially correspond to the
carbamic acid intermediate. However, it is likely that the carbamic acid intermediate
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would lose 3 protons (given the low pKa of carbamic acid derivatives) during the
electrospray ionisation process, giving an expected mass of 269 after ionisation, which
is one less than the value detected during the analysis. Given this, the presence of the
carbamic acid intermediate cannot be confirmed from these measurements.
Fig. 2.7 Mass spectrometry profile of N-DEACMOC-dAC 78 degradation product
The HPLC and mass spectrometry analyses gave significantly different observations,
suggesting different mechanisms of the carbamate instability. The HPLC measurements
suggested that when the carbamate bond was hydrolysed by water, a more polar, (likely
carbamic acid intermediate) of dAC was formed, which can potentially convert into
dAC by decarboxylation. The kinetics of the latter process was not measured by HPLC.
On the other hand, mass spectrometric analysis of the isolated intermediate suggested
that it mainly composed of dAC and the presence of carbamic acid dAC could not be
confirmed.
There could be several reasons for this discrepancy between the HPLC and Mass
Spectrometry analyses. While the HPLC analysis gave a direct measurement of the
stability mixture that only had to pass through a C18 column until detection of the
individual compound peaks, the sample for the mass spectrometry analysis had to go
several steps of preparation. Starting from the same stability mixture, the carbamic acid
intermediate was first isolated by semi-preparative HPLC, followed by solvent removal
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using a rotary evaporator. The dried sample was then resolubilised and subjected to
mass spectrometry analysis. During the mass spectrometry analysis, the compound
underwent electrospray ionisation, that typically results in the deprotonation of the
sample in order to enhance their detection. Given the greater number of preparative
steps for the mass spectrometry analysis, it is possible that the compound (that is
already supposedly unstable, based on its structure), underwent decarboxylation during
one of these processes which then resulted in the dominating presence of dAC in the
final sample mixture.
Both the photouncaging and stability experiments conducted on N-DEACMOC-dAC,
79 resulted in the release of the photocage (and eventually dAC), via decarboxylation.
However, HPLC analyses indicated that the mechanism of these two processes are
different, given the different products observed:
During the photouncaging, light irradiation targets the C-O bond of the photocage,
leading to heterolytic bond cleavage (as shown and explained in Scheme 1.12). This is
followed by the formation of a tight ion pair, the positively charged photocage and the
negatively charged carbamate dAC intermediate. Once water attacks the positively
charged photocage, the negatively charged dAC carbamate undergoes decarboxylation
to give the final dAC product that is detected by HPLC.
During the hydrolytic instability, the presence of water molecules trigger the process
by first attacking the carbamate bond, which then releases the photocage (confirmed
by HPLC). The remaining carbamic acid intermediate is still likely protonated and
this could be a reason why decarboxylation does not happen perhaps instantly. Due to
that, the carbamic acid analogue can still be detected via HPLC, even after 3 hours
of incubation. On the contrary, the series of preparative steps in mass spectrometry
analysis may have contributed to the deprotonation and therefore accelerated decar-
boxylation of the carbamic acid analogue which may have lead to the major presence
of dAC in the isolated mixture.
In the future, further work is prompted to better understand the main factors (e.g.
sample preparation process, stability solution environment) on the deprotonation and
decarboxylation properties and kinetics of the carbamic acid intermediate to better
predict the stability profile of caged-dAC compounds.
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Further analysis of the dark instability of 79 revealed that the rate of degradation
decreased when other solvents such as acetonitrile (ACN) were present in the stability
solution (Table 2.3). Furthermore, when biological buffers were used instead of water,
the rate of degradation increased.
Time
(min)
0.1%
ACN/Water
27 ◦C
0.1%
ACN/ Water
37 ◦C
15%
ACN/ Water
37 ◦C
MOPS-KOH
pH 7.2
37 ◦C
HEPES
pH 7.5
37 ◦C
0 100 100 100 100 100
30 81 62 77 52 31
60 78 45 62 28 15
Table 2.3 Stability of N-DEACMOC-dAC 78 under alternative solvents and buffers
To investigate the cause of the dark instability, the stabilities of alternative analogues
were explored. The aim was to establish whether the cause of the instability was dAC,
the carbamide bond or the phototag itself. To test the latter, the stability of another
photocaged dAC analogue, mono-NPEOC-dAC 60 was measured. In addition, the
stabilities of other nucleosides were assessed. We chose dC as our reference compound
due to its closely related structure dAC. The nucleobase of dC contains a carbon
instead of a nitrogen in position 5, which makes it non-susceptible to ring opening.
dC reference compound was caged with NPE and DEACM phototags to yield the two
photocaged dC analogues mono-NPEOC-dC 80 and mono-DEACMOC-dC 81 (Their
syntheses are described in the Experimental Section) (Scheme 2.12).
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Scheme 2.12 Structures of photocaged dC reference compounds 80 and 81
The stability studies suggested that the phototag had a moderate effect on compound
stability (Table 2.4). Mono-NPEOC-dAC 60 was more stable than DEACM-caged
dAC 78 (after 60 mins of incubation, 85% of 60 remained intact compared to 45% of
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78). However, both caged dAC compounds showed considerable dark instability. By
contrast, it was also observed that dC analogues had excellent stability at 37 ◦C even
after 7 hours of incubation.
Time
(min)
% DEACMOC-
dAC, 78
% DEACMOC-
dC, 81
% NPEOC-
dAC, 60
% NPEOC-
dC, 80
0 100 100 100 100
30 62 100 91 100
60 45 100 84 100
Table 2.4 Stability results of photocaged dAC analogues and dC reference compounds
The results indicate that the carbamate bond alone is stable to hydrolysis. It was
confirmed that the replacement of a C to a N atom in the triazine ring had a dramatic
effect on the stability of photocaged dAC analogues. The possible explanation for this
phenomenon is summarised in Scheme 2.13. The nitrogen atom in position 5 may have
an inductive effect on the triazine ring. As a result, the triazine ring could become
electron poor, making the neighbouring carbamate bond more susceptible to hydrolytic
attack. In addition, the nitrogen atom in position 5 may coordinate to water molecules
via its lone pairs. The presence of water molecules in such close proximity to the
carbamate bond may also increase the chance of hydrolytic attack.
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Scheme 2.13 Proposed mechanism of instability in N-DEACMOC-dAC 78
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In summary, we successfully photocaged azanucleosides at the nucleobase position.
Unfortunately the incubation of these analogues at 37 ◦C led to rapid dissociation of
the phototag due to the electronic properties of the triazine ring. We proposed that
placing the phototag on alternative positions would overcome these limitations.
2.4 Third generation photocaged azanucleosides
Given the the strong influence of the triazine ring on compound stability, we envisaged
that placing the photocage away from the triazine ring could improve compound
stability. Therefore the aim was to place the phototag on the 5′-OH and 3′-OH of dAC
to avoid the direct link between the phototag and the triazine ring. In this section, we
will describe the preparation and characterisation of 5′- and 3′-caged dAC analogues.
2.4.1 Pre-assessment of carbonate linker stability
The proposed strategy had the consequence of replacing the carbamate linker with a
carbonate linker as the photocage would be linked to an OH instead of a NH2 group.
Carbonate linkers have reportedly poorer hydrolytic stabilities,220 though some studies
claimed otherwise in the context of 5′-caged nucleosides.221 With regard to DEACM
phototags, no stability data of 5′-DEACM-caged nucleosides have been reported to date.
The aim was to assess the stabilities of other 5′-DEACM-caged nucleosides (attached
via a carbonate linker) to determine if these linkers have stability issues.
DEACM phototag was first coupled to thymidine nucleoside to assess the carbonate
link stability. Thymidine is a good starting point as it does not require any nucleobase
protection prior to coupling. 5′-caging of thymidine was achieved in one step, via
direct coupling of DEACM chloroformate 77 to thymidine 82 following a protocol
described by Bühler et al. (Scheme 2.14).203 The resulting 5′-DEACMOC-thymidine
83 was isolated in 31% yield. Stability analysis of the compound indicated that it is
stable even after 7 hours of incubation at 37 ◦C (98% of the caged-compound remained
intact). This finding confirms that the carbonate linker and the DEACM-phototag do
not cause inherent stability issues.
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Scheme 2.14 Synthesis of 5′-DEACMOC-Thymidine 83. Reagents and Conditions: (i)
1.3 eq chloroformate 77, CH2Cl2/pyridine, rt, 16 h
2.4.2 Synthesis of 5′-caged analogue
Direct coupling of DEACM-chloroformate to dAC
For the synthesis of 5′-caged dAC, direct coupling of dAC to the DEACM-phototag
was first attempted. Due to the low reactivity of the exoxyclic amine, it was assumed
that its separate protection was not necessary, given that the 5′ OH is the most
reactive among the three functional groups of dAC. Unfortunately direct coupling of
DEACM-chloroformate 77 to unprotected dAC 6 did not yield any product even in
the presence of excess (5 equivalents) phototag.
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Scheme 2.15 Reagents and Conditions: (i) 5 eq chloroformate 77, CH2Cl2/pyridine, rt,
16 h, (ii) 1.5 eq chloroformate 77, DBU, DMF, rt, 16 h
An alternative strategy was pursued. A recent study be Weiss et al. described the
5′-functionalisation of gemcitabine without the protection of the exocyclic amine.222
Gemcitabine is a closely related structural analogue of dC with a fluorine group attached
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to the C2 position of the ribose ring. Direct coupling to the 5′-OH of gemcitabine
was achieved in the presence of a bulky base 1,8-diazabycycloundec-7-ene (DBU). The
method was trialled on DEACM-chloroformate 77 and dAC but unfortunately no
product was detected. Due to the unsuccessful attempts to directly couple photocage
chloroformate to dAC, the protection of the exocyclic amine was explored next.
5′-coupling via protection of the exocyclic amine
In order to develop an optimised protocol for the synthesis, commercially available
dC 7 was used as a model compound. The synthetic strategy is outlined in Scheme
2.16. The first step of the synthesis was the protection of the amine nucleobase with
carboxybenzyl (CBz) protecting group. This was achieved in three steps, following the
transient protection strategy to obtain N-Cbz-dC 85 in 79% yield. The CBz group
was chosen as the protecting group because its removal conditions are mild enough
to leave dAC and the triazine ring intact. Although the optimisation of the synthetic
protocol was carried out using dC 7, all of the reagents and reaction conditions were
chosen with careful consideration to ensure their compatibility with dAC stability.
The next step was to conjugate a phototag on the 5′-position. Analogue 85 was first
coupled to NPE-chloroformate 58 to obtain N-CBz-5′-NPEOC-dC 86 in 55% yield. In
the final step, the CBz protecting group was rapidly removed via palladium-assisted
hydrogenation to give 5′-caged compound in 94% yield (although the nitro group of
the phototag was also reduced to an amine group, in line with expectations). This
confirmed that the strategy is feasible, so the coupling of the DEACM-phototag was
trialled next.
Coupling of Cbz-dC 85 to DEACM-chloroformate 77 to obtain N-Cbz-5′-DEACMOC-
dAC 88 was successful, but with significantly lower yield (4%). The final hydrogenation
of analogue 88 was unsuccessful, due to the nitrogen lone pair of NEt2 that may have
coordinated to and intefered with the palladium catalyst.
In summary, the synthesis of 5′-caged analogue was not possible via CBz protection
of the nucleobase. The removal of the CBz group was deemed challenging in the
presence of DEACM-phototag. Alternative nucleobase protecting groups in literature
(benzoyl, isobutyryl and dimethylformamidyl) are generally removed under very harsh
conditions (conc. NH4OH, 55 ◦C). And even the recent, ultramild protecting groups
(phenoxyacetyl-, acetyl- groups) are removed under basic conditions (MeOH/K2CO3),
which would be detrimental to dAC stability. Given the absence of any alternative,
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Scheme 2.16 Synthesis of 5′-caged dC via protection of exocyclic amine. Reagents and
Conditions: (i) HMDS, pyridine/DMF, rt, 2 h; (ii) Cbz-Cl, CH2Cl2/pyridine, rt, 16 h;
(iii) TAS-F, DMF, rt, 2 h; (iv) NPE-choroformate 58, CH2Cl2/pyridine, rt, 16 h; (v)
H2/Pd, MeOH; (vi) DEACM-chloroformate 77, CH2Cl2/pyridine, rt, 16 h
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viable protecting groups that could be tested, an alternative strategy was pursued to
synthesise 5′-caged dAC analogues.
PFP-activated and DMAP-catalysed direct coupling
The next strategy relied on the coupling of DEACM phototag to 5′-OH of dAC without
any protecting groups. Since the chloroformate on its own had limited reactivity towards
5′-OH, an alternative activation and coupling strategy was required. In a recent study
by Zhang et al., the synthesis of 5′-dAC esters were described.173 The authors coupled
activated amino acid moieties to dAC in the presence of 4-(dimethylamino)pyridine
(DMAP) catalyst to form the desired dAC ester. It was envisaged that DEACM-
phototag could be similarly activated and coupled to dAC via a carbonate bond instead
of an ester bond.
The pentafluorophenyl (PFP) group was chosen as the activating group for DEACM
phototag. PFP groups have been previously used to activate and couple amino acids
in peptide synthesis, but they can also be used to activate alcohols. PFP-esters
are sufficiently stable to isolate and they generally undergo couplings with high effi-
ciencies.223,224 DEACM-OH alcohol was treated with bis(pentafluorophenyl)carbonate
(BPFPC) in the presence of DIPEA to obtain PFP-activated DEACM in 94% yield
(Scheme 2.17).
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Scheme 2.17 Synthesis of DEACMOC-PFP 90. Reagents and Conditions: (i) BPFPC,
DIPEA, THF, rt, 16 h
The PFP-activated DEACM-carbonate 90 was coupled to dAC 6 in the presence of
DMAP coupling agent (Scheme 2.18). After overnight stirring, the formation of a new
compound was detected by thin layer chromatography (TLC) and was successfully
isolated at 27% as a yellow solid. Mass spectrometry analysis indicated that this
analogue had the desired mass, identical to the target compound 5′-DEACMOC-dAC
84.
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Scheme 2.18 Synthesis of 5′-DEACMOC-dAC 84 via DMAP coupling and PFP activa-
tion. Reagents and Conditions: (i) DMAP, DMF, rt, 16 h
NMR analysis in DMSO confirmed the presence of DEACM peaks in addition to the
dAC peaks. It was also observed that the 5′-OH peak that is normally present in
dAC had disappeared, indicating that the 5′-OH group has been successfully modified.
However, there were additional peaks present that were yet to be identified. HPLC
analysis of the solid revealed the presence of two main peaks in the mixture despite
appearing as a single spot on TLC (Figure 2.8). The different batches correspond to
different fractions purified by flash chromatography.
Fig. 2.8 HPLC traces of purified 5′-DEACMOC-dAC ’crude’
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Further NMR analysis of the mixture indicated that the additional peaks belonged to
the 3′-modified dAC analogue (Figure 2.9A). Most notably, the 3′-OH peak was absent
and the proton peaks from the deoxyribose ring had shifted δ values: the value for
H-3′was higher and H-5′was lower. Other peaks (H-1′, triazine and DEACM peaks)
remained unchanged. This suggests that during the coupling, modification at the 5′-OH
and 3′-OH occurred simultaneously despite the lower reactivity of 3′-OH.
(A) Partial NMR spectrum of the crude mixture with annotated H environments
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(B) Structures of 5′- and 3′-modified dAC analogues with highlighted H environments corre-
sponding to annotated NMR peaks in (A)
Fig. 2.9 NMR analysis of ’crude’ mixture from the synthesis of 5′-DEACMOC dAC 84
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Optimisation of synthesis and purification of 5′-caged analogue
Isolation of pure 5′-caged analogue from the 5′- and 3′-caged dAC mixture was next
attempted. The first issue was that the two compounds had identical Rf values on
TLC and were eluted as one single spot. However, it was possible to analytically
separate 3′- and 5′-caged dAC via HPLC, though the two peaks eluted soon after
each other (Rf = 13.6 and 13.8 min). HPLC was essential to differentiate between
the two analogues. Therefore the purification of these mixtures involved flash column
chromatography coupled to HPLC analysis to assess the purity of the collected fractions.
In order to optimise the synthesis of 5′-caged analogue, the reaction conditions were
modified to rely on the higher reactivity of 5′-OH compared to 3′-OH. The synthesis
was repeated at −20 ◦C to slow down the reaction and enhance the equilibrium towards
the formation of the kinetic product, the 5′-caged analogue. In addition, only 0.8
equivalent of the phototag was used and the reaction time was reduced to 5 h. When
isolating the products of these reactions, it was found that the ratio between 5′- and
3′-caged analogues was improved (5:1). Careful column purification with slow MeOH
gradient allowed the collection of 5 mg (7% yield) of pure product which was only
enough for NMR and MS analyses.
Since selective synthesis of 5′-caged dAC was unsuccessful and there were no alternative
3′-OH specific protecting groups, the next aim was to optimise the purification of the
5′- and 3′-caged dAC mixture. Conventional flash column purification did not yield
sufficient amounts of pure 5′-caged analogue, semi-preparative HPLC was explored as
a purification method. Yet it did not yield the desired outcome as peak separation was
limited. The amount that could be purified from this method was also low.
Recrystallisation was the final purification method that was attempted. The synthesis
was repeated at a larger scale to obtain sufficient amounts of crude mixture for
recrystallisation trials 5′-DEACMOC-dAC 84 was successfully recrystallised from
methanol, collected in sufficient amounts (>25 mg) and had its purity confirmed by
HPLC.
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2.4.3 Synthesis of 3′-caged analogue
Following the conjugation of DEACM phototag to the 5′-position, photocaging strate-
gies at the 3′-position were also explored. The synthesis of the 3′-caged analogue was
achieved in three steps (Scheme 2.19).
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Scheme 2.19 Synthesis of 3′-DEACMOC-dAC 93. Reagents and Conditions: (i) TIPS-
Cl, imidazole, DMF, rt, 16 h; (ii) DEACMOC-PFP 90, DMF, 0 ◦C; (iii) AcCl, MeOH,
rt, 3 h
In order to selectively synthesise 3′-modified analogue, the 5′-OH was first protected
with the triisopropylsilyl (TIPS) protecting group. TIPS is one of the most stable silyl
protecting groups in literature. Apart from its great stability, it was chosen due to its
mild, fluoride-based removal protocol that has previously shown compatibility with
dAC stability.
dAC 6 was treated with triisopropylsilyl chloride (TIPS-Cl) in the presence of imidazole
base to afford 5′-TIPS-dAC 91 in 52% yield. The TIPS-protected dAC was treated
with PFP-activated DEACM phototag 90 in the presence of DMAP catalyst. These
are the same conditions used for the 5′-caged analogue.
The final step was deemed to be more challenging than initially expected. Several
unsuccessful attempts were made to remove the TIPS-protecting group using TAS-F
and TBAF. An alternative protocol reported by Khanet al. was utilized.225 Analogue
92 was treated with acetyl chloride in anhydrous methanol (to generate anhydrous
hydrogen chloride in situ) in the presence of molecular sieves for 3 hours. The desired
product 3′-DEACMOC-dAC 93 was successfully isolated in 56% yield.
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2.4.4 Photochemical characterisation
UV-Vis absorption
The UV-Vis absorption properties of the 3′- and 5′-caged analogues were comparable
to that of the N-caged mono-DEACMOC-dAC’s (summarised in Figure 2.10).
Fig. 2.10 UV-Vis absorption profiles of DEACM-caged analogues 78, 84 and 93
Absorption at λ = 250 nm for all three compounds were almost identical, with N-caged
analogue having slightly higher absorption compared to the other two. All compounds
had strong absorption around λ = 400 nm, but the exctinction coefficients varied
between the analogues. N-caged analogue had the lowest absorption (ϵ = 10000
M−1.cm−1), whereas 3′-DEACMOC-dAC had the highest (ϵ = 12000 M−1.cm−1).
The slight variation in absorption could be accounted for by the positioning of the
phototag on the dAC nucleoside. The absorption coefficients of the caged analogues
increased as the phototag was placed further from the triazine ring. It is possible that
the triazine ring affects the absorption of the DEACM-ring via electronic effects.
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Photouncaging properties
The uncaging profiles of the 5′- and 3′-caged analogues at λ = 365 nm are summarised
in Figure 2.12.
Fig. 2.11 Photouncaging profiles of third generation photocaged azanucleosides 84 and
93
It was observed that the 5′-caged analogue 84 had a notably slower deprotection rate
compared to the 3′-caged analogue 93. Illumination of 84 resulted in 38 and 18% of
the caged analogue remaining after 30 and 60 min, respectively. Uncaging of analogue
93 resulted in 8% and 2% of the intact analogue after 30 and 60 min of irradiation.
The conversion to dAC was quantitative.
The reason for the slower deprotection rate of 5′-caged dAC is still elusive. The ability
to fit a biphasic exponential curve (as opposed to a monophasic exponential curve)
suggested that there is an additional mechanism going on during the course of the
uncaging. However, there were no other peaks observed in HPLC apart from the
uncaged dAC and the phototag, indicating that there are no other side visible reactions
taking place.
Figure 2.12 shows an additional observation that confirms the unusual behaviour
of 5′-caged analogue. When a 1:1 mixture of 3′- and 5′-DEACMOC-caged dAC was
irradiated at λ = 365 nm, the corresponding HPLC traces showed that after 30 mins,the
3′-caged dAC peak decreased more significantly compared to the 5′-caged dAC peak.
This suggests that 3′-caged dAC uncaged more rapidly than the 5′-caged dAC. These
findings confirm that an additional mechanism occurs in 5′-caged analogue that slows
down its deprotection rate.
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Fig. 2.12 HPLC analysis of photodeprotection of 1:1 5′- and 5′caged dAC mixture
A possible explanation for the slower uncaging rate of 5′-DEACMOC-dAC is proposed
in Figure 2.20. In this, possible conformational isomers of 5′-DEACMOC-dAC are
shown. The bond between C5 and O5 can freely rotate and as a result, higher energy
isomers of the 5′-caged-dAC could form (B and C). Within these higher energy isomers,
the phototag and the triazine ring come in close contact and stabilising interactions
(such as hydrogen bonding, represented by the blue bond) could form between them.
This stabilisation may interfere with the cleavage of the C O bond (shown in red) and
thus reduce photouncaging rate.
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Scheme 2.20 Proposed stabilising interactions within 5′-DEACMOC-dAC 84
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2.4.5 Stability studies
The motivation for synthesising the 3′- and 5′-caged dAC was to attain a higher
hydrolytic stability compared to the NH2 modified dAC. The compounds were analysed
to test whether their stabilities were superior. The caged analogues were incubated in
water at 37 ◦C and their stabilities were monitored via HPLC over 24 hours (Figure
2.13). Stability studies for dAC and DEACM-OH were also conducted.
3′-DEACMOC-dAC 93 had significantly improved stability compared to the N-DEACMOC-
dAC 78 (Figure 2.13A). After 3 hours of incubation, 50% of the initial 3′-caged dAC
peak was still intact as opposed to the completely degraded N-caged dAC 78 under
the same conditions (Figure 2.6). In addition, no dAC was released as suggested by
the lack of degradation peaks at Rt = 5 mins, indicating that the dark stability was
markedly improved. However, the triazine ring of the 3′-caged dAC analogue likely
underwent ring opening, as implied by the appearance of smaller degradation peaks
between Rt = 12 and 15 mins.
The stability profile of 5′-DEACMOC-dAC 84 also suggested improved stability as
no dAC was being released (Figure 2.13B). No alternative degradation peaks were
observed, however the main caged-dAC peak significantly reduced in intensity after 24
hours of incubation.
Figure 2.13C showed that dAC 6 also underwent moderate degradation. The initial
dAC peak at Rt = 5 mins reduced in intensity and gave rise to neighbouring degradation
peaks, which is due to the triazine ring opening.155 This is potentially the same process
that leads to the moderate degradations of 84 and 93. By contrast, the stability of
DEACM-OH was unaffected after 24 hours of incubation (Figure 2.13D).
In summary, the HPLC stability studies indicated that the 3′- and 5′-caged analogues
93 and 84 had improved stabilities compared to N-caged dAC 78. No release of dAC
was observed during the incubation of these analogues at 37 ◦C in the dark, suggesting
that the carbonate link between dAC and the phototag remained intact. However, the
photocaged analogues did undergo moderate degradation during these incubations that
could be attributed to the triazine ring-opening that is also observed in the parent
dAC compound.
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(A) 3′-DEACMOC-dAC, 93 (B) 5′-DEACMOC-dAC, 84
(C) dAC, 6 (D) DEACM-OH, 76
Fig. 2.13 Stability profiles of dAC, DEACM and analogues 93 and 84 at 37 ◦C
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2.5 Summary
In this chapter, the design and synthesis of six novel photocaged azanucleoside analogues
have been presented and discussed (Figure 2.21). In general, dAC analogues had better
stability compared to the AC analogue 59. Furthermore, the coumarin-caged dACs
showed superior photochemical characteristics compared to the NPE-caged analogues.
It was also established that the positioning of the phototag had a strong effect on
compound stability and photouncaging kinetics:
• Placing the phototag on the nucleobase (78) was not suitable due to the hydrolytic
instability of the carbamate, likely caused by the triazine ring.
• Conjugation to the 5′-OH group (84) seemed to significantly improve dark stability
of the caged compound, but the kinetic uncaging rate reduced possibly due to
the stabilising interactions between the phototag and nucleobase.
• Photocaging on the 3′-OH gave 93 with fast uncaging kinetics and improved
stability. In summary, this caging position was found to be the most suitable.
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Scheme 2.21 Structures of novel photocaged azanucleoside analogues
For subsequent biological studies, we selected compound 93, given its equivalent stability
to dAC and fast deprotection rate under moderate, cell-compatible illumination.
Chapter 3
Bioactivity of Photocaged
Azanucleosides
3.1 Introduction
Abnormal methylation such as gene promoter hypermethylation is a commonly observed
molecular lesion in cancer cells (Figure 3.1A). DNMT enzymes are responsible for
maintenance of methylation patterns in dividing cells. In order to lower methylation
levels, DNMTs can be blocked with azanucleosides to achieve global demethylation
(Figure 3.1B).111,141 The aim of the project was to achieve light-targeted demethylation
using photocaged azanucleosides (Figure 3.1C). The objective was to test whether
placing a phototag on an azanucleoside would block its bioactivity and result in
unchanged methylation levels. It was also investigated whether light illumination can
lead to the removal of the phototag and the release of the active azanucleoside, resulting
in lowered methylation levels at targeted locations.
As described in the previous chapter, photocaged azanucleoside analogues have been
successfully synthesised and characterised. In this chapter, the biological evaluation of
the most promising caged analogue - 3′-DEACMOC-caged dAC 93 - is discussed in
more detail. In the cell biological experiments, the effect of 3′-caged dAC (3′-CD) on
DNA methylation levels, DNMT1 levels and cell viability were assessed. The human
osteosarcoma (Saos-2) cell line was chosen as model system due to its high baseline
methylation levels. First, currently used DNA Methylation assays in literature will be
reviewed.
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Fig. 3.1 Light tunable bioactivity of photocaged azanucleosides
3.2 DNA methylation assays in literature
3.2.1 Importance of DNA methylation analysis techniques
Natural changes in methylation levels can occur throughout cellular differentiation
and organismal development.226 By contrast, abnormal methylation changes are highly
associated with tumorigenesis and a number of other diseases. The analysis and profiling
of DNA methylation are thus vital to our understanding of the role of epigenetic changes
on cell cycle regulation and disease progression.227,228 DNA methylation profiling
techniques have been extensively reviewed in literature.229 They can be classified into
two main categories: locus-specific and global methylation analysis approaches.
3.2.2 Locus-specific DNA methylation analysis techniques
Locus-specific approaches are used to detect single methylation changes in the genome.
Historically, these were one of the earliest methods used and typically involved the use of
restriction endonucleases coupled to read-out with gel electrophoresis and hybridization
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on southern blot.230 They were prone to false-positive results caused by incomplete
digestion.
A further development of locus-specific approaches are the genome-wide methylation
analysis techniques, where multiple methylation sites can be interrogated in parallel.
These techniques are less labour intensive and have recently been coupled to high-
throughput platforms such as microarrays or next generation sequencing (NGS). A
summary of locus-specific and genome-wide methylation analysis techniques is shown
in Table 3.1.231
Pretreatment
Analytical step
Locus-specific
analysis
Gel-based
analysis
Array-based
analysis
NGS-based
analysis
Enzyme
digestion
HpaII-PCR Southern blot DMH Methyl-Seq
RLGS MCAM MCA-seq
MS-AP-PCR HELP HELP-seq
MethylScope MSCC
CHARM
MMASS
Affinity
enrichment
MeDIP-PCR MeDIP MeDip-seq
mDIP MIRA-seq
mCIP
MIRA
Sodium
bisulphite
MethyLight Sanger BS BiMP RBBS
EpiTYPER MSP GoldenGate BS-Seq
Pyrosequencing MS-SNuPe Infinium BSPP
COBRA WGSBS
Table 3.1 Summary of locus-specific and genome-wide methylation analysis techniques231
In general, the DNA sample requires pretreatment in order to differentiate methylated
cytosines from their unmethylated counterparts. The pretreatments include enzyme
digestion, affinity enrichment or sodium bisulfite treatment. The pretreated DNA can
then be ’read’ using a range of analytical techniques such as gel-, array- and next
generation sequencing (NGS)-based analyses. The latter technique is more flexible and
powerful as it allows for allele-specific DNA methylation analysis and can cover more
of the genome with less input DNA. The disadvantage of these technologies is the high
cost and thus the limited number of samples that can be analysed. In addition, these
technologies require specialised equipment.
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3.2.3 Global methylation analysis techniques
Global methylation analysis is the other category of DNA methylation profiling tech-
niques. Using these techniques, the overall methylation levels of cells can be measured
without focusing on the individual methylation sites. Measurements from global
DNA methylation profiling can be used for classifying and characterising cancers and
other diseases.232 In addition, global methylation profiling can aid the identification of
biomarkers and can be useful for drug screening.229
HPLC
For many years, the method of choice for quantitative determination of the global
DNA methylation levels has been high performance liquid chromatography (HPLC).233
Similar to the locus-specific and genome-wide techniques, the DNA is subjected to
pretreatment whereby the total genomic DNA is hydrolysed to deoxyribonucleotides
using a combination of nuclease enzymes (deoxyribonuclease I and nuclease P1) followed
by further treatment with alkaline phosphatase to produce deoxyribonucleosides.234
The products are then separated by standard reverse-phase HPLC and quantified via
monitoring the UV absorbance at λ = 254 nm. The limitation of this technique is that
it requires relatively large amounts of DNA (3-10 µg).
HPCE
High performance capillary electrophoresis (HPCE) is a more simple, rapid and cost-
effective alternative of HPLC.235 In this technique, the digested DNA sample mixture
is separated in an open-tube capillary system upon application of electric current.236
Generally, the sensitivity of detection is high, but not enough for routine processing of
tissue specimens.
LC-MS/MS
In order to improve the detection sensitivity of HPLC techniques, new methods have
been developed by combining HPLC separation with mass spectrometry analysis.
Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) requires
smaller quantities of hydrolysed DNA (50-100 ng). In mammalian DNA 2-5% of
cytosines are methylated. LC-MS/MS is able to detect ranges between 0.05 and 10%
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and it can also confidently detect 0.25% differences between samples. This method has
many advantages, however it also requires specialist equipment that is less abundant
than HPLC.
ELISA-based assays
Global methylation can also be measured by immunofluorescence using antibodies.
Antibody-based assays are more affordable alternatives to the previously mentioned
techniques. These methods rely on anti-5mC antibodies to selectively detect methylated
cytosines by quantitative fluorescence in an ELISA-like reaction. The final readout in
fluorescence or colorimetric change is proportional to the %5mC present in the sample
DNA. The advantages of this technique is that they are quick to perform (several
commercial kits are available) and they serve well to detect large changes in global
methylation. The limitation is that these are only suitable for rough estimation of
DNA methylation and are also prone to high variability.
LINE-1 Pyrosequencing
Another global methylation technique involves the determination of the methylation
states of certain repetitive regions such as Arthrobacter luteus (ALU) or long interspersed
nuclear elements 1 (LINE-1).229 Repetitive element methylation is directly proportional
to global methylation content. The genomic DNA is subjected to bisulphite treatment
followed by PCR amplification of ALU or LINE-1 consensus sequences. The methylation
of the amplified fragments is then quantified by pyrosequencing. This method is suitable
for medium high throughput analysis of samples.
LUMA Assays
The most recently developed technique is the luminometric methylation assay (LUMA),
first reported by Karimi et al. in 2006.237 This technique enables researchers to
study global methylation by using methylation-sensitive restriction enzymes followed
by pyrosequencing. The specificity of the method is high and the variability is low.
These are essential for the precise measurement of changes in global methylation. The
advantage is that only small amounts of DNA are needed (250-500 ng), however high
quality DNA is essential to ensure that complete enzymatic digestion occurs.
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3.3 Selecting a suitable DNA methylation assay
The method of choice should deliver an unbiased answer to the biological question
being asked.238 Some of the key considerations are listed below:
• Amount and quality of DNA samples
• Sensitivity and specificity requirements of the study
• Robustness and simplicity of the method
• Availability of bioinformatics software (for selected techniques)
• Availability of specialized equipment and reagents
• Cost
In this project, DNA methylation assays will be used to determine the effect of dAC
analogues on baseline methylation levels. dAC is a global demethylator. By inhibiting
DNMT enzymes, it can indirectly remove methylation marks across the genome in a
non-specific manner. Methylation changes induced by dAC are generally quantified
by global DNA methylation profiling techniques such as HPCE,111,113 LINE-1166 or
LUMA.146 Locus-specific and genome-wide analysis of methylation changes are also
used to assess gene-specific responses to azanucleoside treatments.239
The question of this thesis is whether photocaged versions of dAC can achieve light-
dependent demethylation in cancer cells. Despite the detailed information that could
be extracted from genome-wide sequencing studies, our primary goal was to measure
the global methylation changes in response to photocaged dAC treatment to assess
whether the phototag can successfully block the biological effects of dAC.
The optimal DNA methylation assay for our study would allow the simultaneous
and high-throughput analysis of multiple samples (>100) to enable the testing of
different treatment conditions (concentrations, light, in triplicate). A sensitive yet
simple method was required due to the limited availability of specialized equipment.
Consequently, two methylation assays (ELISA-based assays and LC-MS/MS methods)
were trialled to assess their suitability for our study purposes.
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3.3.1 Trial: ELISA assays
ELISA-based assays were initially chosen due to their simplicity, high speed and low
cost. Prior to conducting trial runs, the shortcomings and limitations of ELISA-based
assays for measuring DNA methylation changes were carefully considered.
As mentioned before, ELISA-based assays are suitable for a rough estimation of DNA
methylation, however its ability to be able to detect small changes in methylation
levels has been questioned by others.238 It has been suggested that ELISA can only
detect relatively large changes in methylation levels (e.g. 1.5-2x fold) due to the high
level of inter and intra-assay variabilities.240 These variabilities can arise due to a
number of factors such as human technical errors (e.g. pipetting inaccuracies, splashing
of reagents between wells, variability due to freeze-thaw cycles), machine errors (e.g.
uncalibrated pipettes, plate readers and softwares etc.) and contaminations of plates,
samples and reagents. For a reliable reading, it is important that the % coefficient of
variability is less than 15% for inter-assay (between independent assays) and less than
10% for intra-assay (variability of sample readings within the same assay). The other
limiting factor of ELISA-based assays is their high signal-to-noise ratio. The average
methylation level of human DNA ranges between 2-6%.32 This measurement represents
the % of 5-methylcytosine in the DNA present compared to total methylated and
unmethylated cytosines. Therefore, it is crucial for the ELISA-based assay to be able
to detect slight changes within this range in order to be suitable for our applications.
In 2012, Kremer and colleagues described a novel methDNA-ELISA system that was
able to accurately quantify global DNA methylation levels in the regions between 1-10%
making it highly suitable for the typical ranges from 2-6% in mammalian genomes.241
In another work by So and colleagues, the changes in methylation levels of BEAS-
2B (human lung) cells were successfully shown in response to 24 hour azacytidine
treatment using Epigentek’s 5mC ELISA-based assay.240 Given the high frequency of
publications that mentioned the use of Epigentek’s ELISA assay (258 as of Aug 2017),
the MethylFlash Methylated DNA 5mC Colorimetric Quantification Kit (Epigentek)
was chosen as our initial tool for trial methylation measurements.
The assay comprised a 48-well plate allowing the measurement of 12 control and 36
test samples. The 12 control samples included 2 negative (unmethylated DNA) and
10 positive controls (DNA with increasing amounts of 5mC) in order to establish a
calibration curve and validate the assay. The details of the protocol are discussed
in the Experimental Section. In addition to the control samples, 36 test genomic
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DNA samples were included. These were extracted from Saos-2 cells that were treated
with increasing concentrations of dAC (0-365 µM) in duplicate. Figure 3.2 shows the
measured average absorption values at λ = 450 nm (OD450 nm) that are proportional
to the amount of 5mC detected in the DNA samples.
Fig. 3.2 Results of ELISA-based assay trials for assessing methylation
changes in SaOS-2 cells. The graph depicts optical density measurements at
λ = 450 nm from two independently conducted assays, Trial 1 (red) and Trial 2 (in
blue). The optical density measurements are proportional to the amount of 5 mC
detected in the DNA samples. For each trial, 6 control and 10 test samples were tested
in duplicates. The control samples included negative and positive samples containing
0.5, 1, 2, 5, 10 ng methylated DNA (included in the test kit). The test samples were
extracts of SaOS-2 cells that were previously treated with increasing concentrations of
dAC (0-365 µM) for 24 hours. The results show that ELISA-based assays would not
be suitable for future methylation measurements due to lack of sensitivity and high
level of variability in the results obtained.
The first limitation of the assay was the measurement of samples in duplicates instead
of triplicates. Ideally, samples should have been done in triplicates, but for the interest
of screening more dAC treatment concentrations, we decided to lower the power of
the samples for an initial screen, after which a more thorough screen could have been
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conducted with triplicate samples and narrower treatment concentrations. However,
the initial results themselves seemed problematic.
The results highlighted two problems with this technique. Firstly, the measured
absorption values for positive control samples were not reproducible between different
trial runs or even between replicates of the same run (represented by the large error
bars). Secondly, the measured values for the genomic DNA samples were extremely
low, equivalent to the negative control. This suggests that either the concentrations of
DNA samples were not sufficient or the DNA samples had very low methylation levels.
The insufficient DNA concentration was likely an explanation in this case. However,
the reproducibility issue remained a more significant concern. Various changes were
made in the protocol to improve the reproducibility such as increasing DNA binding
time, development time or keeping the reagents at room temperature. Unfortunately,
none of these attempts were successful. Due to the unsuitability of this approach to our
studies, with high variability of the results both within an assay and between assays,
the ELISA-based assays were not pursued further.
3.3.2 Trial: LC-MS/MS analysis
LC-MS/MS was used as an alternative method to determine methylation levels. LC-
MS/MS analysis has reportedly high sensitivity and accuracy rates in determining %
5mC values in genomic DNA samples.242
For the LC-MS/MS equipment and technical expertise, a collaboration with Professor
Shankar Balasubramanian’s group from Cambridge (UK) was set up. The LC-MS/MS
analyses of genomic DNA samples were performed by Dr Shiqing Mao (Department of
Chemistry, University of Cambridge).
Briefly, Saos-2 cells were treated with dAC every 24 h for 4 days at three different
concentrations (0.5, 1 and 1.5 µM). Each treatment was carried out in triplicate. 24 h
after the last treatment, cells were collected and the genomic DNA was extracted and
submitted to Cambridge for LC-MS/MS analysis.
The preliminary results indicated that the measurements were highly reproducible.
Figure 3.3 shows the measured % 5mC values in response to different concentrations
of dAC treatments. The untreated cells had on average 2.4% 5mC. Upon treatment
with 0.5 µM dAC, the methylation dropped to 1.3% (53% of baseline methylation) and
further decreased to 0.74% and 0.75% in response to 1 and 1.5 µM dAC respectively.
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Fig. 3.3 Results of LC-MS/MS methylation assay trial (n=3). The graph
depicts the measured % 5-mC content of DNA samples extracted from SaOS-2 cells
that were treated with 4 different concentrations of dAC: 0, 0.5, 1 and 1.5 µM. The
cells were treated with dAC every 24 h for 4 days and each treatment was carried out
in triplicates. The results represent the mean ± standard error of three independent
samples per treatment. Asterisks above SD bars show the statistical significance of the
difference with respect to control treatment (0 µM) after 4 days. *p<0.05 (Student
t-test). The corresponding p-values for the 0.5, 1 and 1.5 µM dAC treatments were
0.0017, 0.0004 and 0.0007 respectively.
The demethylating effect of dAC reached a plateau at 1 µM, potentially due to the
passive demethylating nature of dAC that is limited by the cell replication cycle.
Given the promising and reproducible results from the LC-MS/MS analysis, we selected
this approach as our main analytical technique to determine DNA methylation changes.
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3.4 DNA methylation analysis via LC-MS/MS
3.4.1 Optimisation of treatment conditions
Treatment concentration, duration and frequency
For the following treatments with 3′-caged dAC (3′-CD), we aimed to establish an
optimised treatment schedule that would minimise toxicity to the cells and maximise
the amount of DNA that could be extracted. In the trial experiments, it was observed
that daily treatment of the cells with the highest concentration of dAC (1.5 µM) had a
significant effect on cell growth. Hence, the treatment duration was reduced to 24 h
as it is known that dAC can induce effective demethylation after 24 h.243 In addition,
lower treatment concentrations (0.1 and 0.3 µM) were also included.
Cell line screening
Our initial cell experiments were carried out on Saos-2 cells. Although these cells
showed concentration-dependent decrease in methylation for the 4-day treatment
schedule (Figure 3.3), when switching to the 24-h treatment schedule, the concentration-
dependency was no longer visible.
In order to determine if this is a cell-line dependent phenomenon, additional cell lines
were screened in order to evaluate their sensitivity to dAC. For the cell-line screening,
human bladder (T24), human lung carcinoma (A549) and human embryonic kidney
(HEK293T) cells were treated with increasing concentrations of dAC for 24 h and the
genomic DNA was extracted and submitted for LC-MS/MS analysis in Cambridge.
The results show that among the cell lines, Saos-2 cells had the highest baseline
methylation (3%), whereas the remaining cell lines had on average 2.5% 5mC (Figure
3.4). As discussed before, Saos-2 cells did not show a concentration dependent response
to dAC treatment. At the lowest dAC concentration (0.1µM), the methylation levels
dropped to 2.2%, which remain largely unchanged for higher concentration treatments.
This pattern was also the case for A549 cells. In contrast, T24 and HEK293T cells
showed promising concentration dependent trends, and hence were chosen as additional
control cell lines for further cell biological studies.
Note about the number of samples: One limitation of this assay is that the samples
were not run in triplicates. Given the number of cell lines and treatment concentrations
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Fig. 3.4 Cell line screening in response to dAC treatment (n=1). LC-MS/MS
analysis of methylation changes in four different cell lines were conducted to measure
their sensitivity to dAC treatment. A549, HEK293T, SaOS-2 and T24 cells were treated
with 5 different concentrations of dAC (0, 0.1, 0.3, 0.5 and 1.5 µM) for 24 h. Among the
cell lines tested, HEK293T and T24 cells showed the strongest concentration-dependent
methylation changes in response to dAC treatments.
that were considered for this initial screen (20 conditions), the samples were run in
singlicate to enable faster turnaround of results. Each time a treatment was conducted,
the samples were sent to a different laboratory (in Cambridge), where the main
limiting factor was the availability of the LC-MS/MS machine. Since the treatments
of the chosen cell lines were repeated several times (and in triplicates) in subsequent
experiments, it felt was justified to conduct the initial cell screening in singlicate.
3.4.2 Measurement of DNA methylation changes
After demonstrating that LC-MS/MS can accurately determine methylation levels of
our DNA samples, Saos-2, T24 and HEK293T cells were treated with 3′-CD 93 for
24 h at different concentrations (0.1-1.5 µM). After treatment, the cells were either
illuminated for 1 h at λ = 365 nm or were kept in the dark. dAC treatments were also
included as controls. 24 h after treatment, the cells were collected and the isolated
genomic DNA was submitted for LC-MS/MS analysis (carried out by Dr Shiqing Mao).
All cells were treated with the 3′-CD 93, but in the case of T24 cell lines, a treatment
set with 5′-caged dAC (5′-CD) 84 was also included.
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DNA methylation changes in Saos-2 Cells
Figure 3.5 presents the DNA methylation change (expressed as % of baseline methyla-
tion) in Saos-2 cells in response to 3′-CD and dAC treatments. Six different concen-
trations were administered, including the media only treatment at 0 µM. Three main
observations were drawn from this dataset.
Fig. 3.5 LC-MS methylation analysis of SaOS-2 cells (n=3). In order to de-
termine the light-dependent effect of 3′-CD on methylation levels, SaOS-2 cells were
treated with 6 different concentrations of dAC and 3′-CD (0, 0.1, 0.3, 0.5, 1 and 1.5
µM) with and without UV irradiation. The light-dependent demethylating effect of
3′-CD was most significant at 0.1 µM. At 0.1 µM, 3’-CD maintained 95% ± 4.3 %
of the baseline methylation, whereas the same treatment followed by UV treatment
resulted in a 23% drop in methylation (p=0.0065) to 72 ± 0.5%, due to the uncaging
and release of active dAC. This treatment achieved comparable methylation levels to
0.1 µM control dAC treatment (64 ± 7%, p=0.09). The light dependent effect was
also significant at 0.3 µM and 0.5 µM (p=0.010 and p=0.0167 respectively), however
little differentiation was observed at 1 and 1.5 µM treatments (p=0.524 and p=0.132).
This trend is due to the concentration dependent demethylating effect of 3′-CD in the
absence of UV light. Treatments were carried out in triplicates. Key for symbols of
statistical significance: ns: p > 0.05, *: p < 0.05, **: p < 0.01. Statistical significance
was determined using a two-tailed Student’s t-test and standard deviations. For all
analyses, p < 0.05 was considered significant
Firstly, the Saos-2 cell line is highly sensitive to dAC as mentioned before. The lowest
concentration treatment (0.1 µM) induced a 35% drop in the baseline methylation
levels. This effect remained constant with increasing dAC concentrations.
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Secondly, the UV illumination resulted in the successful activation and release of dAC.
This is confirmed by the equivalent methylation levels of dAC treated and 3′-CD treated
and illuminated (CD UV) cells.
The final point is that the non-illuminated, 3′-CD treated cells also resulted in decreased
methylation levels especially at higher treatment concentrations. Methylation dropped
to 78%, 77%, 68% and 66% in response to 0.3, 0.5, 1 and 1.5 µM 3′-CD respectively.
However at 0.1 µM 3′-CD, the methylation levels of the cells remained unchanged.
These results suggest that the light-dependent demethylating effect of 3′-CD was most
notable at lower concentration treatments (0.1 µM). The phototag sufficiently masked
the bioactivity of dAC, resulting in an unchanged methylation level. Upon irradiation,
the active dAC was successfully released and achieved equivalent methylation drop
compared to the non-caged dAC control treatment. Unfortunately at increasing
treatment concentrations, significantly increasing activity was also observed even in
the absence of light.
DNA methylation changes in T24 Cells
Figure 3.6A shows the DNA methylation changes of T24 cells in response to 3′-CD
93 and dAC. The number of treatment concentrations were reduced to four (0, 0.1,
0.5 and 1.5 µM). In addition, T24 cells were also treated with 5′-CD 84 in a separate
set of experiments to investigate whether different analogues of photocaged dAC exert
different biological effects (Figure 3.6B).
T24 cells exhibited a concentration-dependent response to dAC treatment. Similarly
to Saos-2 cells, 0.1 µM dAC treatment resulted in a 35% drop in baseline methylation.
Increasing the concentration to 0.5 µM led to a further drop of 17%, which remained
unchanged at 1.5 µM. For the non-illuminated 3′-CD treatments, a concentration-
dependent reduction in methylation levels was also detected, with the strongest effect
observed at 1.5 µM (34% drop). As 3′-CD is expected to stay inactive in the dark and
maintain methylation levels, this pattern indicates unexpected and unwanted activity.
This trend of ’dark activity’ was also observed in Saos-2 cells.
Upon light exposure, the baseline methylation dropped to 81%, 57% and 51% in
response to increasing 3′-CD concentrations. This confirmed that light-dependent
release of dAC was successful. However, it was noted that light-activation was less
efficient at lower treatment concentrations. 0.1 µM of the illuminated 3′-CD lowered
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Fig. 3.6 LC-MS methylation analysis of T24 cells in response to (A) 3′-
CD treatment and (B) 5′-CD treatment (n=3). In two separate experiments,
T24 cells were treated with dAC and either 3′-CD or 5′-CD with or without UV
illumination (for 1 hour) at 4 different concentrations (0, 0.1, 0.5 and 1.5 µM). (A)
3′-CD treatment set. The light-dependent demethylating effect of 3′-CD has been
demonstrated across all concentrations with varying extent. In response to 0.1 µM
3′-CD in the dark, methylation was maintained at 95% ± 0.1% of the baseline. The
same treatment followed by irradiation resulted in a significant drop to 81% ± 0.1%
(p=0.0304). In comparison, the control 0.1 µM dAC achieved a methylation drop to
65% of the baseline. This suggested that the light activation of 0.1 µM 3′-CD may
not have released equivalent amounts of uncaged dAC compared to control dAC. On
the other hand, it was shown that at 0.5 µM and 1.5 µM, the light-activated 3′-CD
achieved significant drop in methylation levels (p=0.0017 and p=0.0219 respectively)
and they were also comparable to the dAC controls of the same concentration (p=0.091
and 0.6766). (B) 5′-CD treatment set. Addition of 0.1 µM 5′-CD did not result in
statistically significant changes in methylation compared to baseline (96.7% ± 4.5%),
and although irradiation after the same treatment did lower methylation to 83% ±
4.6%, this was not deemed statistically significant (p=0.0994). At 0.5 µM and 1.5 µM,
light activation resulted in significant reduction of methylation. At 0.5 µM, methylation
dropped from 77.4 ± 6.8 % to 58.4 ± 3 % (p=0.0418) and at 1.5 µM methylation
reduced from 63.4 ± 3.5% to 53.5 ± 5.2% (p=0.0245). Methylation levels equivalent to
control dAC were only achieved at 1.5 µM treatment (p=0.121 suggesting that the two
values are not significantly different). In conclusion, the light activating effects of 5′-CD
were moderate considering the week light activating effects at lower concentration.
Treatments were carried out in triplicates. Key for symbols of statistical significance:
ns: p > 0.05, *: p < 0.05, **: p < 0.01. Statistical significance was determined using
a two-tailed Student’s t-test and standard deviations. For all analyses, p < 0.05 was
considered significant
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methlylation levels to 81%, as opposed to the 65% achieved by 0.1 µM dAC. For the
5′-CD treated cells, the pattern was almost identical to its 3′-caged counterpart (Figure
3.6B).
DNA methylation changes in HEK293T Cells
Figure 3.7 shows the LC-MS methylation analysis results for HEK293T cells. In general,
the methlyation levels of HEK293T cells were less sensitive treatments with dAC and
3′-CD. At 0.1 µM, HEK293T cells showed almost no response, with nearly unchanged
DNA methylation levels. At 0.5 and 1.5 µM treatment concentrations, dAC decreased
methylation levels to 72% and 63% of baseline methylation, respectively.
By contrast, 3′-CD did not induce any response at 0.5 µM, and only a moderate
decrease at 1.5 µM treatments (75% for irradiated 3′-CD and 85% for control 3′-CD
treatments). The limited activity of irradiated 3′-CD treatments could be due to
their reduced transport into HEK293T cells, interference with light-activation or other
sources of compound inactivation within the cells.
The growth rate of HEK293T cells is significantly lower than that of Saos-2 and T24
cells. Their doubling time is 24 h, whereas for Saos-2 and T24 cells, the doubling times
are 19 and 17 h respectively. Although the cells could only complete one replication
cycle, considerable demethylation occured at 0.5 and 1 µM dAC treatments. This
could be due to the additional replication-independent effects of dAC, described by
Ghoshal and colleagues.117,118
3.4.3 Summary of LC-MS/MS methylation results
The LC-MS/MS analysis provided valuable insights into the effect of dAC and 3′-CD
on the methylation levels of three different cell lines (Saos-2, T24 and HEK293T). In
general, all cell lines responded to dAC treatments, though with varying sensitivities
in the following order: Saos-2>T24>HEK293T.
The low sensitivity of HEK293T cells could be due to their lower growth rates, which
limit the amount of dAC that could be incorporated into the replicating DNA. HEK293T
was also the only non-cancerous cell line in our studies. The origin of this cell line
(human embyronic kidney cells) may also be accountable for the sensitivity differences
observed.
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Fig. 3.7 LC-MS methylation analysis of HEK293T cells (n=3). In order to
determine the light-dependent effect of 3′-CD on methylation levels on HEK293T cells,
dAC and 3′-CD at 4 different concentrations (0, 0.1, 0.5 and 1.5 µM) were administered
with or without UV light. In general, HEK293T cells were less sensitive to both dAC and
3′-CD. At 0.1 µM, none of the treatments resulted in statistically significant methylation
changes compared to baseline. At 0.5 µM, dAC reduced baseline methylation to 72 ±
3%, however 3′-CD treatment resulted in almost unchanged methylation levels with
or without illumination. HEK293T cells responded to the 1.5µM treatment series
with the greatest extent. Control dAC achieved 62 ± 4 % of baseline methylation,
whereas 3′-CD treatment resulted in 85 ± 4 % methylation which was further reduced
to 75 ± 3 % upon illumination, which was statistically significant (p=0.0484). In
conclusion, HEK293T cells showed low sensitivity to dAC and caged-dAC treatments
and in addition the extent of light-sensitivity was milder compared to other cell lines.
Treatments were carried out in triplicates. Key for symbols of statistical significance:
ns: p > 0.05, *: p < 0.05, **: p < 0.01.
92 Bioactivity of Photocaged Azanucleosides
Our results also show that with 3′-CD light-dependent demethylation was successfully
achieved in Saos-2 and T24 cell lines, but only at low concentrations (<0.5µM).
Remarkably, demethylation could be induced upon illumination to achieve a biological
effect nearly equivalent to dAC’s.
Unfortunately, demethylating activity in response to non-illuminated 3′-CD was also
observed in all cell lines tested. The ’dark activities’ were more significant at higher
treatment concentrations (>0.5 µM) and notably in Saos-2 cells. This effect could
be due to chemical or enzymatic hydrolysis of the photocaged analogue (3′-CD) in
the dark that would lead to the release of active dAC. Since Saos-2 cells are highly
sensitive to the lowest treatment concentrations of dAC, the early onset of dark activity
(starting at 0.3 µM) could be explained by this characteristic.
Another possible explanation for the unexpected activity is an alternative mechanism
induced by the 3′-CD that does not proceed via the conventional replication-dependent
mechanism of dAC. Ghoshal and colleagues reported an alternative pathway whereby
dAC may interact with other enzymes such as δPKC in order to exert methylation
changes via DNMT1 degradation.117 The exact details of this mechanism are still
unknown. It was possible that 3′-CD could exert bioactivity through this pathway
in the absence of light activation. Intrigued by their findings, the next aim was to
investigate the DNMT1 levels in response to 3′-CD treatment.
3.5 Western blot analysis
The next objective was to determine whether the reduction in methylation was also
detectable in terms of lower DNMT1 levels. DNMT1 enzymes are endogenously ex-
pressed in most cell lines and are responsible for maintaining methylation patterns. The
changing levels of DNMT1 can be detected using Western blot analysis. Degradation
of DNMT1 can be induced by azanucleosides and this has been studied in a number of
cell lines including lymphoma, HeLa and HCT116 cells.114,117
We were particularly interested in the sensitivity of DNMT1 levels to different concen-
trations dAC and 3′-CD. Saos-2 and T24 cells were treated under the same conditions
as described in the methylation analysis studies. In addition to 3′-CD and dAC, 5′-CD
was also included as treatments for comparison. Whole cell extracts from treated
Saos-2 and T24 cells were subjected to Western blot analysis to assess DNMT1 levels.
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3.5.1 Western blot analysis of Saos-2 cell extracts
Western blot analyses (Figure 3.8) show the expression levels of DNMT1 and con-
trol glyceraldehyde 3-phosphate dehydrogenase (GAPDH) enzymes of Saos-2 cells in
response to dAC, 3′-CD and 5′-CD with and without illumination (’UV’ or ’CONT’).
Fig. 3.8 Western blot analysis of SaOS-2 cell extracts. In order to determine
the effect of 3′-CD and 5′-CD treatment on the cellular DNMT1 levels, western blot
analysis was carried out on treated SaOS-2 extracts. SaOS-2 cells were treated with
4 concentrations (0, 0.1, 0.5, 1.5 µM) of dAC and 3′-CD (with and without UV,
annotated as 3′-CD-CONT and 3′-CD-UV respectively) for 24 h, followed by extraction
of cell lysate (see Experimental Section). Western blot analysis was performed with
anti-DNMT1 and anti-GAPDH. Untreated (M) SaOS-2 cells have high level of baseline
DNMT1 represented by the thick bands. No treatment followed by UV irradiation also
did not have an effect on DNMT1 protein levels. On the other hand, dAC treatment
even at the lowest concentration. The effect was similar looking at 3′-CD-UV and
5′-CD-UV treatments. On the other hand, the 3′-CD-CONT treatments maintained a
significant level of DNMT1 at 0.1 µM, which can still be detected at 0.5 µM treatments,
but not at 1.5 µM. This effect can also be observed for 5′-CD-CONT but to a lower
extent.
Non-treated cell extracts (M) had high DNMT1 expression levels, represented by thick
bands on both western blots, which were not affected by UV illumination. However,
under all other treatment conditions the DNMT1 levels were significantly diminished
in both treatment sets, but to a slightly smaller extent for 3′-CD control at 0.1 µM.
The faint band observed at 0.1 µM indicates that the phototag partially blocked the
bioactivity of dAC, resulting in a limited degradation of DNMT1. This is in line with
expectations. At higher concentration treatments, this effect was not observed.
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3.5.2 Western blot analysis of T24 cell extracts
Western blots of T24 cell extracts show similar patterns to those of Saos-2 cells (Figure
3.9). Untreated T24 cells had high expression levels for DNMT1 that were not altered
by UV illumination. dAC and 3′-CD and 5′-CD treatments led to complete removal
of DNMT1 levels, with the exception of the lowest concentration of non-illuminated
0.1 µM 5′-CD (5′-CD-CONT). Similarly to Saos-2 cells, these observations are in line
with expectations. In non-illuminated photocages dAC treatments (3′-CD-CONT and
5′-CD-CONT), considerable levels of DNMT1 were detected.
Fig. 3.9 Western blot analysis of T24 cell extracts. The effect of caged-dAC
treatment on DNMT1 levels in T24 cells were also investigated via Western blot
analyses. T24 cells were treated with 4 concentrations of dAC, 3′-CD and 5′-CD and
were either kept in the dark (“CONT”) or were irradiated for 1 h (“UV”), followed by
24 h incubation and extraction of the cell lysate (see Experimental Section). Similarly
to the SaOS-2 cell extracts, untreated T24 cells had high level of DNMT1 indicated by
the thick bands (M). dAC and irradiated 3′-CD, 5′-CD treatments had a significant
effect on DNMT1 levels, resulting in the complete loss of DNMT1 band at all dAC
treatment concentrations and the higher 3′-CD and 5′-CD treatment concentrations
(0.5 and 1.5 µM). At the lowest irradiated treatment concentration, a weak band
can be observed for both 3′-CD and 5′-CD, suggesting that a very small amount of
DNMT1 is still present. DNMT1 levels were higher when cells were treated with either
3′-CD or 5′-CD and were not subjected to irradiation, especially at lower treatment
concentrations (0.1 µM).
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3.5.3 Summary of western blot results
In this section, the DNMT1 protein levels of Saos-2 and T24 cells were measured in
response to dAC and photocaged dACs using Western blot analyses. The primary aim
was to assess the sensitivity of DNMT1 enzyme levels to 3′- and 5′-CD. The secondary
aim was to further investigate the dark activity observed in non-illuminated caged
dAC treated cells.
The general observation was that illuminated 3′-CD had significant effect on DNMT1
levels. dAC and illuminated 3′-CD resulted in the disappearance of >90% of DNMT1.
Interestingly, 3′-CD control treatments also had remarkable effect on DNMT1 levels.
At the highest concentrations, DNMT1 levels were completely degraded, similarly
to the other treatment conditions. At lower concentrations, this effect was variable
between cell lines and compounds. T24 cells retained significantly higher amounts of
DNMT1 compared to Saos-2 cells. Although the western blots were run a single time
for each cell line and treatment condition, this conclusion is not as strong as if it was
run three times. However given the similar type of response from different types of
conditions (notable DNMT1 degradation) across the two cell lines, it was felt that it is
not essential to repeat the western blots.
Overall, there was a significant difference between changes in DNMT1 and DNA
methylation levels in response to azanucleoside treatments. The DNMT1 degrading
effects of dAC and illuminated 3′-CD can occur at very low doses (as low as 0.1 µM) of
the drug. However at these doses, there appears to be little or no effect on demethylation.
A study by Patel and coworkers suggested that even if most of the cellular DNMT1
are degraded, residual chromatin-bound DNMT1 could still support maintenance
methylation in the presence of low dose dAC.114 The trapping of chromatin-bound
DNMT1 is more likely to occur at higher dAC concentrations and this is reflected in
the corresponding greater demethylating effects.
DNMT1 levels were expected to stay unchanged in response to ’inactive’ photocaged
dAC in the dark. However, the Western blot analyses showed that at higher concentra-
tions, caged dAC led to the degradation of DNMT1 even in the absence of light. This
indicated that an unwanted activity took place in the dark at higher concentrations
that led to the degradation of DNMT1, suggesting that photocaged dAC was no longer
inactive possibly due to the release or leaking of active dAC.
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3.6 Cell viability assays
3.6.1 Aims
In the final set of biological studies we aimed to evaluate the effect of photocaged dAC
on cell viability. According to literature, dAC treatments at lower concentrations (<1
µM) do not affect cell viability, whereas at higher concentrations cell cytotoxicity is
induced.244 However, the effect of photocaged dAC has not been tested on any cell
lines to date. For the cell viability assays with photocaged dAC, low concentration
(0.1 to 1.5 µM) and high concentration (1.5 to 13.5 µM) were tested.
3.6.2 Effect under low photocaged dAC concentrations
Low concentration treatments were conducted to determine any effect on cell viability
of photocaged dAC analogues under biologically relevant, hypomethylating conditions
that were also applied for the methylation studies and Western blot analyses.
For the assays, Saos-2, T24 and HEK293T cells were seeded on 24 well-plates in varying
densities to reach around 80% confluency after 72 h. Cells were then treated with
photocaged dAC (3′-CD) at three different concentrations (0.1, 0.5 and 1.5 µM) and
were either illuminated for 1 h at λ = 365 nm or kept in the dark at room temperature.
dAC controls at the same concentrations and conditions were also included.
Saos-2 cell viability
Figure 3.10 depicts the cell viability curves of Saos-2 cells in response to 3′-CD and
dAC at 0.1, 0.5 and 1.5 µM with or without UV illumination. Samples containing
media only and media containing 1.5 µM DMSO were also included.
In general, no significant changes were observed upon treatment. A slight reduction
in growth at t = 72 h corresponded to addition of dAC or 3′-CD, followed by a 1 h
incubation with or without illumination at room temperature. Cells quickly recovered
and reached 100% confluency within 24 h.
The uninterrupted and continuous cell growth and small error bars show that Saos-2
tolerated well UV illumination and low concentration dAC and 3′-CD (containing small
volumes of DMSO) for a period of up to 24 h.
3.6 Cell viability assays 97
Fig. 3.10 Cell viability assays of Saos-2 cells in response to low concentration dAC and
3′-CD. (A) 3′-CD, (B) 3′-CD followed by illumination at λ = 365 nm for 1 h, (C) dAC,
(D) dAC followed by illumination at λ = 365 nm for 1 h. All treatments were carried
out in triplicate. The figures indicate that the growth of SaOS-2 cells were not affected
by treatments with lower concentrations of dAC and 3′-CD.
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T24 cell viability
The effect of dAC and 3′-CD on T24 cell viability was more noticeable (Figure 3.11).
The slight drop in viability of the non-illuminated cells (corresponding to the time of
the treatment at t = 70 h) quickly recovered in the following 24 h (Figures 3.11A and
C). For illuminated cells the drop in viability was more pronounced (10%), but also
recovered in the next 24 h, though with greater variability represented by the large
error bars (Figures 3.11B and D). The concentration or the types of treatments did
not have a significant effect on cell growth and recovery.
Fig. 3.11 Cell viability assays of T24 cells in response to low concentration
dAC and 3′-CD. (A) 3′-CD, (B) 3′-CD followed by illumination at λ = 365nm for 1
h, (C) dAC, (D) dAC followed by illumination at λ = 365 nm for 1 h. All treatments
were carried out in triplicate. The figures indicate that the growth of T24 cells were
not affected by treatments with lower concentrations of dAC and 3′-CD.
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HEK293T cell viability
Among the three cell lines, HEK293T cells had the most notable response to dAC and
3′-CD (Figure 3.12) treatments in terms of cell viability, but at the same time the least
response considering methylation changes.
Fig. 3.12 Cell viability assays of HEK293T cells in response to low concentra-
tion dAC and 3′-CD. (A) 3′-CD, (B) 3′-CD followed by illumination at λ = 365nm
for 1 h, (C) dAC, (D) dAC followed by illumination at λ = 365 nm for 1 h. All
treatments were carried out in triplicate. HEK293T Cells were highly sensitive to dAC
and 3′-CD treatments, demonstrated by the significant drop in viability after the time
of the treatment (t=70 h). The viability slowly recovered in the next 30 hours. In the
case of non-irradiated 3′-CD and dAC treatment, recovery was successful. However,
irradiated samples showed a greater degree of variability possibly due to the longer
term effects of treatments combined with UV radiation.
The first observation when looking at all four conditions is that treatment was followed
by a drastic drop in cell viability. For non-illuminated 3′-CD, the reduction in cell
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viability ranged from 7-33%, with the DMSO control having the greatest drop of all
the conditions in that plate (Figure 3.12A).
DMSO and 1.5 µM CD treated cells only recovered to 80% confluency after 24 h,
whereas cells treated with lower concentrations successfully recovered to nearly 100%
confluency.
Given the absence of illumination in these treatment conditions, the drop in viability
can be explained by the 1 h incubation of cells at room temperature, outside of the
37 ◦C incubator. The confluency of cells at the time of the administration may have
also affected the drop in viability. DMSO-treated cells had the lowest average viability
(74%) compared to cells that received 0.1 µM 3′-CD (82%) prior to administration.
The recovery rate was also likely affected by the treatment condition itself. Cells that
received media only recovered more rapidly compared to cells that were treated with
1.5 µM 3′-CD.
UV illumination resulted in even greater drops in cell viabilities (Figure 3.12B). The
notable drop in viability is the result of the UV illumination in combination with
keeping the cells outside of the 37 ◦C incubator for 1 h. Cells that received media
only and DMSO-containing media seemed to be the most affected. One explanation
could be the uneven UV distribution density among the wells as a result of the tilted
positioning of the UV lamp in the UV-illuminating cabinet. Media and DMSO treated
cells may have been positioned in regions in slightly higher UV density.
HEK293T cells are more sensitive to differences in UV density distribution compared
to Saos-2 and T24 cells. The 3′-CD treatments had a concentration-dependent effect
on cell viability, though it is difficult to conclude due to the large error bars.
dAC had similar effects on cell viability compared to 3′-CD (Figure 3.12C). However,
UV illumination resulted in a significantly greater drop in viability and slower recovery
rates at all concentrations (Figure 3.12D). The largest drops observed were for 0.5 and
1.5 µM dAC treated cells (53%). These cells, together with DMSO-treated cells could
only recover to 60% average confluency, whereas cells that received media only and 0.1
µM dAC grew to 75% confluency after 24 h.
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On the effect of DMSO on HEK293T cell growth
DMSO is an amphiphilic molecule and is is a widely used solvent to facilitate the
solubility of hydrophobic substances in physiological solutions. DMSO is usually well
tolerated with no observable toxic effect in cells at 0.1%. At 1% or higher, toxic effects
have been reported and the response will generally depend on the type of cell or cell line.
DMSO treatment at higher concentrations can substantially alter the morphology and
the attachment of the cells, substantially decreasing cell viability in a dose dependent
manner. For example, SW620 cells showed significant change in morphology in the
presence of DMSO (enlargement, elongation).245
The toxic effects may be in some cases due to reversible cell cycle arrest (CHO
cells at 1-2% DMSO for 96 h), and in other cases it can be associated with cell
differentiation to other lineages (HL-60 cells, 1-3% DMSO, 96 h) or even cell death
at higher concentrations (CaCO2 cells, >10 %, due to the release of LDH). Some
other reports were suggesting that DMSO at lower concentrations had stimulating
effect on cell growth. For example, at 100 uM (0.00078% m/V) DMSO increased the
proliferation of OVCAR-3, SK-OV-3 and Caov-3 ovarian cancer cell lines.246 Similarly,
0.05%-0.2% DMSO significantly increased the growth of RPMI-8226 myeloma cells
relative to mediom only control.247
There are no studies in literature describing any adverse effect of DMSO on HEK293T
cell growth. One study looked at the effect of DMSO on the hERG channels that are
expressed in HEK293 cells.248 The authors found that high concentration of DMSO
resulted in the increase in osmolality of the bath solution which then altered the cell
morphology and the biological property of the cell membrane. This would interfere
with whole-cell current recordings and the authors discovered that this effect can be
prevented by application of DMSO in pipette solutions. Despite that, there has been
no report of adverse viability of the HEK293 cells in the study.
In our experiments, the cells treated with DMSO experienced a drop in cell viability
that was even greater than the ones that contained DMSO and treatment (dAC,
caged-dAC). This was intriguing as the dAC and caged-dAC treatments had the same
concentration of DMSO or even lower. There could be two possible reasons for this
unusual effect. One is that the concentration of DMSO in the control is higher than in
the treatment solutions possibly due to uneven serial dilutions. This is highly unlikely.
The second one is that the DMSO/media solution was contaminated with an unknown
substance that had an effect on the cell viability resulting in a greater drop and slower
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recovery. Although the DMSO control has now questionable validity, the fact that the
cell growth in response to treatments in combination with DMSO and the media only
control is the same suggests, that DMSO on its own does not have an significant effect
on cell growth (unlike suggested by the graphs).
3.6.3 Effect under high photocaged dAC concentrations
High concentration of dAC are used less frequently due to its non-specific cytotoxic
effect on cells. Given the high tolerability of Saos-2 cells towards low concentration
dAC and 3′-CD, it was chosen to evaluate the effect of high concentration on cell
viability.
Saos-2 cells were seeded in 24 well-plates and were allowed to grow for 24 h. They
were then treated with high concentrations of dAC and 3′-CD (1.5, 4.5 and 13.5 µM)
every 24 h for 3 days. Figure 3.13 shows the results of the cell viability assays.
Saos-2 cells that received media only grew to 90% confluency by the end of the viability
studies. dAC had a notable effect on cell growth, however the effect did not have
significant concentration dependence. All treatment concentrations resulted in a final
average confluency of 40-45%. Similarly, 3′-CD also had a significant effect on cell
viability, with a slight concentration-dependence - the final average confluencies reached
58%, 50% and 44% at the end of 1.5, 4.5 and 13.5 µM, respectively. The reduction in
viabilities were not as large as expected from such big increases in concentration.
UV illumination did not affect the viability of cells that received media only (Media
UV), but it drastically reduced viability in all other conditions. The reductions were
in no particular order or concentration dependence, with final cell viabilities ranging
from 22% to 35%.
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Fig. 3.13 Cell viability assays for Saos-2 cells at high concentration dAC and
3′-CD. Cells were treated followed by (A) dark incubation at room temperature (B)
or light illumination at λ = 365 nm for 1 h at room temperature. All treatments were
carried out in triplicate. The data shows that higher intensity (after 24 h of seeding,
cells were treated every 24 h for 3 days) and higher concentration treatments (1.5, 4.5,
13.5 µM) have a significant effect on the growth of SaOS-2 cells, even in the absence of
UV irradiation. Treatment concentrations ranging from 1.5 µM to 13.5 µM resulted
in cell confluences between 40-60%. UV irradiation following treatment had an even
greater effect on the cell growth, achieving cell viability between 20 and 40% after 96 h.
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3.6.4 Summary of cell viability assays
In this section, the cell viabilities of various cell lines were tested in response to
photocaged dAC (3′-CD) and dAC. Low concentrations were explored to determine
the effect of photocaged dAC in biologically relevant hypomethylating conditions. By
contrast, high concentrations were tested to establish if the photocage can block the
cytotoxic effects of dAC.
At low concentration and low intensity (1 x 24 h), cell viability was not affected
significantly in Saos-2 and T24 cells. By contrast, HEK293T cells experienced a
considerable drop in viability due to sensitivity to temperature and UV illumination
conditions during treatment.
Higher concentration and light intensity (3 x 24 h) resulted in significantly reduced
viability in Saos-2 cells. The conclusion was that the photocage in caged dAC did not
block the biological activity of dAC sufficiently at higher treatment concentrations,
which suggested that there was a significant degree of unwanted activity in the absence
of light due to the release of active dAC. This phenomenon was indicated by the
methylation and western blot analyses and was then confirmed by the cell viability
assays.
3.7 Preliminary cell assays on previous analogues
3.7.1 Aim of preliminary experiments
The experiments described below were carried out prior to all biological experiments
discussed before. The aim of these preliminary cell experiments were to briefly assess
the light-dependent activity of the N-DEACMOC-dAC 78 analogue via cell viability
assays and the Infinium 450K Methylation Array. The 450K Array is a locus-specific
indication of methylation changes and the analysis was carried out by Dr Sabrina
Stewart.
At the beginning of the project (prior to any global methylation assay trials), a number
of initial cell biological experiments were conducted on the N-DEACMOC-dAC 78
analogue, which was considered the first promising analogue amongst photocaged
azanucleosides, due to its rapid uncaging rate. At the time of the cell assays, the
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compound’s aqueous instability was not known and fully characterised, and the 5′- and
3′-caged analogues had not been synthesised yet.
The findings from the initial cell experiments suggested the compound’s instability,
which then prompted further syntheses of alternative analogues. As the protocol for cell
experiments changed considerably throughout the course of the project, the description
of these experiments are only included for completeness.
3.7.2 Cell viability assays on N-DEACMOC-dAC
Cell viability in response to various treatment concentrations
Human osteosarcoma (SaOS2) cells were treated at 4 different concentrations of N-
DEACMOC-dAC, 78: 0.5, 1.5, 4.5 and 13.5 µM. The cells were treated every day for
24 hours followed by either a one hour illumination period at 365 nm or incubation in
the dark. After the illumination or incubation in the dark, the confluence of the cells
was determined every hour via an automated live cell imaging system.
Two key observations were made from the corresponding cell growth curves. First of
all, the N-DEACMOC-dAC analogue on its own did not have a pronounced effect on
cell growth (Figure 3.14A). However, its addition to the cells followed by illumination
resulted in a concentration dependent cell killing, illustrated by the dashed lines (Figure
3.14B). As the non-treated cells were also unaffected under illumination (blue dashed
line), it is confirmed that this effect was not due to UV illumination on its own.
At the time of the experiments, it was considered that N-DEACMOC-dAC treatment
without illumination did not have a pronounced effect on cell growth when comparing
the non-illuminated and the illuminated curves. However, after conducting further
stability studies and cell experiments, the results of these cell viability curves were
reconsidered. The graph on the left did suggest that a small amount of dAC was
being released which resulted in a slower growth of cells at 13.5 µM treatment (brown)
compared to the media control (blue).
Cell viability in response to various treatment conditions
In the same setup, the effect of media, N-DEACMOC-dAC and dAC was tested on cell
viability at a single concentration of 1.5 µM (Figure 3.15). In this treatment range, the
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Fig. 3.14 Cell viability of SaOS2 cells in response to N-DEACMOC-dAC (A)
with no illumination and (B) with a one-hour illumination after treatment. Caged-
dAC treatment in combination with illumination resulted in a notable concentration-
dependent cell killing. All treatments were carried out in triplicate
illuminated cells (red dashed line) treated by N-DEACMOC-dAC showed equivalent
growth to the cells exposed to 1.5 µM dAC (black) up to about 80 hours, after which
the cells have recovered.
This confirmed that the uncaging in the growth medium was successful, resulting in a
similar growth to control cells up to about 80 hours. After this point, the amount of
dAC released during the uncaging may not have been sufficient enough to maintain
the same level of cell viability as the dAC control. At the end of this experiment, the
cells were collected and their DNA was extracted in order to subject them to further
analysis via 450K Methylation Array.
3.7.3 450K Methylation Array
To prove that the illuminated N-DEACMOC-dAC indeed caused reduction in DNA
methylation, genomic DNA was isolated from treated (dAC, N-DEACMOC-dAC) and
control cells (Media), and subjected to 450k BeadChip analysis. This technique allows
the quantification of DNA methylation at over 450, 000 CpG sites following bisulfite
conversion. This experiment and analysis was carried out by Dr Sabrina Stewart.
The result of the microarray analysis showed that exposure to N-DEACMOC-dAC
in combination with light achieved demethylation to a median of 32% 5 mC groups
compared to 68% of the non-treated cells (Media) as shown by the boxplot in Figure
3.16. The value 32% is very close to reported methylation level for non-caged dAC,
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Fig. 3.15 Cell viability of SaOS2 cells in response to various treatments
conditions at 1.5 µM. It has been shown that N-DEACMOC-dAC treatment in
combination with light (red dashed line) could achieve equivalent growth to dAC
control (black line) up to 80 h. Non-illuminated N-DEACMOC-dAC treatment did
not have a notable effect on cell growth. All treatments were carried out in triplicate
suggesting restoration of full bioactivity after illumination and deprotection of N-
DEACMOC-dAC.159
Fig. 3.16 450K Array results. Exposure to N-DEACMOC-dAC in combination with
light resulted in demethylation to a median of 32% 5mC groups compared to 68% of
the non-treated cells. However, N-DEACMOC-dAC exposure in the absence of light
also resulted in notable demethylation to 52% 5 mC, suggesting that the photocage
may not have been able to block activity in the dark
The microarray analysis also showed that N-DEACMOC-dAC exposure on its own also
resulted in demethylation, to a median of 52%. This indicated that photocaged-dAC
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on its own was not “inactive” as expected and that active dAC is potentially is being
released in the dark which led to the reduction in percentage methylation.
3.8 Summary of cell biology experiments
The aim of the cell biological studies was to assess if the photocaged dAC analogues
were able to achieve light-dependent demethylation. By placing a photocage on dAC,
the demethylating effects of dAC were expected to be blocked. If successful, the
photocaged dAC analogue could maintain methylation levels in the absence of light.
Upon light illumination, the release of the active dAC should lower methylation levels
in a concentration dependent manner to a similar extent as control dAC treatments.
For the methylation studies, Saos-2 cells were chosen due to their high baseline
methylation level, but T24 and HEK293T cells were also included due to their known
concentration-dependent sensitivity to dAC. Global DNA methylation analysis of
treated cells via LC-MS/MS suggested that light-dependent demethylation was achieved
at low concentrations (<0.5 µM). However, at higher concentration (>0.5 µM) the
photocaged dAC could not maintain methylation levels, which suggested that significant
activity was occurring in the absence of light.
Western blot analyses of treated Saos-2 and T24 cell extracts confirmed that photocaged
dAC led to the degradation of DNMT1, the enzyme responsible for reduced methylation
levels when inhibited by dAC.
Although cell viability was not significantly affected at concentrations below 1.5 µM,
Saos-2 cell growth was significantly reduced when photocaged dAC was administered
more frequently and at higher concentrations (up to 13.5 µM).
All three biological studies suggested that at the highest concentration photocaged
dAC treatments, sufficient amounts of ’active’ dAC were leaked, resulting in marked
biological activity even in the absence of light. Under these conditions, decreased
methylation levels were detected by global methylation analysis, reduced DNMT1 levels
by western blot analyses and significant reduction in cell viability were observed in
Saos-2 cells.
This is unfortunate as photocaged dAC analogues should remain stable and not release
dAC in the absence of light. The source of instability could be the chemical or enzymatic
hydrolysis of the caged compounds in media and the cellular environment. In order to
3.8 Summary of cell biology experiments 109
reassess the stability of the photocaged compounds in such conditions, further studies
were carried out using HPLC and mass spectrometry analyses.
3.8.1 Limitations and suggestions for further improvements
The setup of the current cell experiments had a number of limitations that could be
addressed in the future cell experiments.
First of all, the UV-irradiation system used in these experiments was a benchtop UV
Cabinet that contained the UV lamp on top with a slanted position. This resulted in
an uneven distribution of light density that reached the wells. Since the wells were 20
cm from the lamp and the measured variation in density was around 5-10 µW/cm2, we
went ahead with this system as at the time a horizontal UV cabinet was not available.
It was confirmed that the variation in UV power density did not have an effect on cell
growth when the cells received no treatment.
For these set of experiments, the treatments of the wells were in a non-randomised
format (see Experimental section) ie. the similar treatment concentrations were adjacent
to each other in order to speed up the addition of treatment to the wells. However
this setup could potentially skew the results – the wells with higher power density
(closer to the lamp) could have a faster uncaging compared to wells that receive lower
power density from the lamp. In order to avoid this bias, future cell treatments should
include randomisation in the position of the treatment wells.

Chapter 4
Stability of Photocaged
Azanucleosides
4.1 Introduction
Photocaged azanucleosides are biologically inactive forms of azanucleosides. The
stability of a photocaged azanucleoside is crucial in maintaining its inactivity and light
tunable nature. The biological studies described in Chapter 3 suggested that when cells
were treated with photocaged dAC, active dAC was being released due to hydrolysis of
the carbonate linker resulting in unwanted biological effects.
On the contrary, our previous HPLC stability studies (Chapter 2) suggested that the 3′-
and 5′-caged analogues did not release active dAC. Incubation of these analogues did
not give rise to detectable dAC peaks, suggesting that the carbonate link between dAC
and the photocage remained intact. However, over 24 h of incubation at 37 ◦C, the
main caged dAC peak degraded into additional smaller peaks with similar retention
times, which was indicative of the triazine ring opening.155
The main aim of this chapter was to further investigate the stability profiles of
photocaged dAC analogues. The first objective was to detect the source and mechanism
of instability that was observed in the cell biological studies. The second objective was
to quantitatively characterise the degradation profiles to determine the exact amount
of any active dAC that was being released.
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4.2 Literature on carbonate link stability
Prior to describing experimental analysis, a literature survey on the stability of the
carbonate linkage is provided. The stabilities are variable in different literature reports.
For example, a 5′-coumarin-caged adenosine analogue 94 with a carbonate linker
synthesised by Suzuki et al. had a half-life of 467 h (over 19 days).191 On the contrary,
André et al. found that carbonate linkers have moderate stabilities that are poorer
than carbamate but stronger than ester bonds.220 When exploring various linkers
between 5-iodo-2′-deoxyuridine and a melanoma tracer, the authors observed that the
carbonate-linked analogue 95 had a half-life of 7 h 35 min in phosphate-buffered saline
(PBS) buffer at 37 ◦C. In cell culture medium and human serum the half-lives were
even lower with 6 h and 4 h, respectively. The hydrolysis of carbonate bonds in serum
could be accelerated by enzyme in the serum such as carboxyl esterases and plasmin
enzymes.249
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Scheme 4.1 Reported stabilities of carbonate linked nucleosides in literature191,220
The stability of carbonate linkers greatly depends on the structures of the linked
analogues and the incubation environment. To date, no study has been reported on
the stability of carbonate-linked dAC analogues. Despite the known instability of dAC
caused by the triazine ring opening, our aim was to determine the stability of the
carbonate linker in photocaged dAC analogues.
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4.3 Hypothesis on the sources of instability and
aims
Based on the literature studies, we hypothesised that two sources of instability could
account for the degradation of photocaged dAC analogues (Scheme 4.2). The first source
is the hydrolytic opening of the triazine ring (Route I) known in the literature.154,155 In
this proposed mechanism, water attacks at the electrophilic C6 position of the triazine
ring of compound 93, forming intermediate Ia. This intermediate is in equilibrium with
analogue Ib where the triazine ring is partially open. Irreversible ring opening occurs
upon attack of another water molecule, releasing formic acid and giving analogue Ic.
The second possible source of instability is the hydrolysis of the carbonate link (Route
II) that could be initiated chemically or enzymatically. The hydrolysis may release
the free DEACM-OH phototag first, leaving a 3′-carboxylated dAC analogue (IIa)
that eventually decarboxylates to give active dAC (IIb). The rate of this hydrolysis
depends on the chemical nature of the two linked components, the temperature and
pH of the buffer.220,250
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The aim was to test the hypothesis by quantifying the rates of triazine ring opening
and carbonate link hydrolysis. To determine rates for triazine ring opening, the non-
photocaged dAC was selected. By comparison, for the rate of carbonate link hydrolysis
a reference compound was chosen that is related in structure to 3′-DEACMOC-dAC
(3′-CD) but does not have triazine ring instability which would complicate analysis. The
reference compound is 3′-DEACMOC-dC (3′-CdC) which contains the hydrolytically
stable cytosine base instead of the triazine ring (Scheme 4.3)
3′-DEACMOC-dC (3′-CdC) was synthesised by Master’s student Gurpreet Virdi. As
additional reference, 5′-DEACMOC-dAC (5′-CD) was also selected (Scheme 4.3)
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Scheme 4.3 Structures of compounds used for stability studies
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4.4 Stability studies via HPLC
The stabilities of dAC and 3′-CD at 37 ◦C in water were measured and quantified via
HPLC (Chapter 2). Two additional concentrations of 3′-CD were also tested. The 24 h
stability profiles are shown in Figure 4.1. The incubation of 100 µM dAC at 37 ◦C led
to the degradation of 55% of the compound after 24 h (Figure 4.1A). The measured
half-life was 11 h, which is in close agreement with reported literature values (t1/2 = 10
h).155
Fig. 4.1 HPLC stability analysis of dAC (A) and photocaged dAC at different concen-
tration (B) at 37 ◦C
The analysis of 3′-CD stability was carried out at three different concentrations (10, 100
and 500 µM) to determine if the concentration affects degradation rates (Figure 4.1B).
The results showed that increasing the concentration of 3′-CD significantly increased
degradation rates. The corresponding half-lives of 10, 100 and 500 µM 3′-CD stability
profiles were t1/2 = 5.5, 3.5 and 1.5 h respectively. One possible explanation for these
surprising results is the aggregation or limited solubility of 3′-CD in aqueous solutions
at higher concentrations.
The concentrations used in HPLC stability studies were higher than those used in cell
experiments (0.1− 1.5 µM). As HPLC has a low detection limit of 10 µM with a likely
negative impact on accurate measurement of stability profiles, a decision was made to
switch to alternative analytical methods that allowed the detection of submicromolar
concentrations with high accuracy. LC-MS/MS was identified as the method of choice.
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4.5 Stability studies via mass spectrometry
4.5.1 Triple quadrupole mass spectrometer
LC-MS/MS is a highly sensitive and accurate method to detect and quantify small
molecules. The technique also provides additional information of molecular weight and
enables the separation of compounds based on their unique fragmentation profile.
For the stability studies, an LC system coupled to a triple quadrupole mass spectrometer
at UCL School of Pharmacy was used. Figure 4.2 shows a schematic diagram of a
triple quadrupole mass spectrometer.251
Fig. 4.2 Schematic diagram of a triple quadrupole mass spectrometer251
During LC-MS/MS analysis, a sample mixture is separated on an LC column followed
by ionisation of the individual analytes. Mass detection is carried out in three steps,
via sequential filtering through three chambers that contain the quadrupole mass
filters. Quadrupoles consist of four cylindrical rods set parallel to each other that
are responsible for the filtering of sample ions based on their mass to charge ratio
(m/z). The first quadrupole selects the ions of desired m/z and transmits them to the
second quadrupole. There, the ions are further fragmented, and the third quadrupole
scans the entire m/z range to determine the sizes of the fragmentation products that
subsequently reach the detector.
A triple quadrupole mass spectrometer features various scan modes. For the stability
studies, multiple reaction monitoring (MRM) was used (Experimental Section, page
214) to selectively detect and quantify dAC, photocaged dAC and phototag fragment
ions in the stability mixture at high sensitivity.
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4.5.2 MS stability studies in water
Stability studies at room temperature
In the first round of stability studies, the selected analogues (1.5 µM dAC, 3′-CD,
5′-CD and 3′-CdC) were incubated in water at room temperature and their stabilities
were monitored for 6 h (Figure 4.3). The degradation of dAC showed an unusual
pattern (Figure 4.3A). After 30 min of incubation at room temperature, only 58% of
the total dAC was detected. This was followed by a significantly slower decay, reaching
44% of the starting dAC concentration at the end of the 6 h incubation period. One
explanation could be the equilibrium between the dAC (MW = 228) and its partially
ring opened form (MW = 246) (Scheme 4.2). The exchange between the two species is
potentially slow enough to allow their separate detection via MS. The slow decay from
58% to 44% of dAC potentially corresponded to the irreversible opening of the triazine
ring.
Fig. 4.3 Stability profiles of dAC and caged analogues in water at RT measured by MS
The stabilities of 3′-CD, 5′-CD and 3′-CdC at room temperature are shown in Figure
4.3B. 3′-CdC was the most stable, with 80% present after 6 h of incubation (t1/2 = 16.5
h). The moderate disappearance of 3′-CdC was due to the carbonate bond hydrolysis.
By comparison, the rate of decay for 3′-CD was faster (t1/2 = 180 min), leaving 38% of
the intact compound at the end of the 6 h incubation period. The faster decay was
likely due to the combination of carbonate bond hydrolysis and triazine ring opening.
The stability of 5′-CD was surprisingly better than that of 3′-CD with 51% still intact
compared to 38% of 3′-CD.
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Stability studies at 37 ◦C
The next round of stability studies was carried out at 37 ◦C to better mimic cell
biological conditions. The measured stability of dAC at 37 ◦C was markedly different
from the profile obtained from the room temperature (Figure 4.4). After 6 h of
incubation, 60% of the intact dAC was detected. The degradation was fitted to an
exponential decay curve with a half-life of 11.5 h, which was in close agreement with
our previous HPLC stability studies and reported literature values.155 We postulated
that the exchange between dAC and its partially ring-opened form at 37 ◦C was more
rapid and that the two species were indistinguishable using MS analyses.
Fig. 4.4 MS Stability profiles of dAC, 3′-CD and 3′-CdC in water at 37 ◦C
3′-CdC was less stable at 37 ◦C than at room temperature. Considerable amounts of
the analogue disappeared over 6 h, leaving 37% of intact 3′-CdC (t1/2 = 180 min),
indicative of a faster rate of carbonate hydrolysis at higher temperature. The degree
of decay of 3′-CD was also higher than dAC and 3′-CdC at 37 ◦C and 3′-CD at room
temperature. Indeed, after 6 h, only 15% of the intact 3′-CD was detected (Figure 4.4),
with a measured half-life of 30 min. The fast dissociation of 3′-CD at 37 ◦C is likely
due to the combination triazine ring opening and the carbonate link hydrolysis, which
is accelerated by the increased kinetic energy resulting from the rise in incubation
temperature (from room temperature to 37 ◦C).
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Determination of dAC released during 3′-CD incubation at 37 ◦C
The degradation of 3′-CD at 37 ◦C was further investigated in order to determine
the amount of dAC released. Multiple reaction monitoring (MRM) enabled the
quantification of the three main analytes (dAC, 3′-CD and DEACM-OH phototag) at
each time points of the stability analysis as shown in Figure 4.5.
Fig. 4.5 Quantification of analytes during 3′-CD incubation in water at 37 ◦C
Strikingly, the rapid disappearance of 3′-CD did not correspond to an equally rapid
and matching appearance of dAC and the DEACM-OH phototag. The initial 3′-CD
concentration of 750 pg/µL (1.5 µM) decreased to 115 pg/µL after 6 h of incubation
(15% of the initial 3′-CD). On the contrary, the concentration of DEACM-OH phototag
gradually increased during the course of the stability study, reaching a final concentra-
tion of 171 pg/µL after 6 h. This suggests that only 171 pg/µL of the original 3′-CD
(23%) underwent the first steps of direct carbonate bond hydrolysis that released the
DEACM-OH phototag as shown in Scheme 4.4.
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Considerably less of the 3′-CD was directly converted to active dAC. The concentration
of dAC increased slower than DEACM-OH, reaching a maximum amount of 60 pg/µL
at t = 240 min followed by a gradual decrease, which could be due to the triazine ring
opening. These measurements suggest that approximately 8% of the photocaged dAC
is directly converted to active dAC as a result of chemical hydrolysis during incubation
at 37 ◦C. A mechanistic summary of this process is shown in scheme 4.4.
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Scheme 4.4 Mechanism of carbonate link hydrolysis
The rate of carbonate link hydrolysis greatly depends on the pH and components of
the buffer.220 The stability studies up to this point were carried out in HPLC grade
water for simplicity of detection. However, the pH of HPLC grade water (pH=8.4) was
higher than the pH of the physiological environment (pH=7.4) or the pH of the cell
culture media (pH=6.9-7.3) used in the cell biological studies.
4.5.3 MS stability studies in HEPES buffer pH 7.2
To mimic the pH conditions of the cell biological studies, the next stability experiments
were conducted in HEPES buffer at pH 7.2. HEPES is widely used in cell culture mainly
because it maintains physological pH well, despite changes in CO2 concentrations. The
reduced complexity of HEPES buffers compared to PBS and other cell culture media
also enables its direct use in mass spectrometry analyses.
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As a drawback, the presence of buffer made the detection of dAC using MS more
challenging. In particular, the buffer and dAC likely eluted at similar retention times,
leading to the interference of buffer molecules with the detection of dAC analytes.
Nevertheless, the presence of HEPES buffer did not interfere with the detection of
other photocaged dAC analogues and DEACM-OH phototag. Despite the limitation
in the detection of dAC analytes, the photocaged analogues were subjected to stability
studies in HEPES buffer. Figure 4.6 shows the stability profiles of the analogues at
room temperature (A) and at 37 ◦C (B).
Fig. 4.6 MS Stability profiles of photocaged analogues in HEPES pH 7.2 at (A) room
temperature and (B) 37 ◦C
In buffer, the stabilities of photocaged analogues (3′-CD and 5′-CD) at room temperature
were significantly improved (Figure 4.6A). 64% of 3’-CD and 78% of 5′-CD were intact
after 6 h of incubation. In the case of 3′-CdC, the compound also showed higher
stability in buffer. This suggests that HEPES buffer - which had a lower pH than water
- slowed down hydrolysis of the carbonate linkage, in line with literature observations.220
HEPES also increased the stability of compounds at 37 ◦C when compared to water
(Figure 4.6B). The disappearance rate of 3′-CD in HEPES was higher compared to
the room temperature studies, however they were slightly improved compared to the
rates observed in water at 37 ◦C. 3′-CdC was still considerably more stable than 3′-CD.
After 6 h of incubation, 50% of the initial 3′-CdC was still intact.
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4.6 Summary of stability studies
The aim of the stability studies was to characterise the mechanisms of instability
of photocaged dAC analogues and to quantify their degradation products. Mass
spectrometry analysis was chosen as the analytical method of choice due to its accuracy
and higher sensitivity of detection compared to HPLC.
The stabilities of photocaged dAC analogues were tested in water and HEPES buffer
pH 7.2 at room temperature and 37 ◦C. In addition, the stabilities of dAC and a
3′-caged dC analogue were also measured to separately determine the rate of triazine
ring opening and carbonate link hydrolysis, respectively. Table 4.1 summarises the
measured half-lives from the MS results.
Solvent Temperature dAC 3′-CdC 3′-CD 5′-CD
Water
pH 8.4
RT 30 min 12 h 50 min 3 h 6 h
37 ◦C 11 h 30 min 3 h 30 min N/A
HEPES
pH 7.2
RT N/A 38 h 30 min 11 h 30 min 16 h 30 min
37 ◦C N/A 5 h 50 min 1 h 40 m N/A
Table 4.1 Summary of half-lives from MS stability studies
The stability data provided valuable information on the two main mechanisms of
fragmentation that contributed to the degradation of 3’-CD.
Triazine ring-opening rates were extracted from the stability profiles of dAC. The
measured half-life of dAC degradation in water (t1/2 = 11.5h) was in agreement with
reported literature values.155 Incubation at 37 ◦C led to the degradation of 36% of the
initial amount of dAC. This suggests that in photocaged dAC, this portion of the
observed decay was due to triazine ring opening.
The rates of hydrolysis for the carbonate linkage were determined from the examination
of the 3′-CdC stability. The structure of 3′-CdC is identical to that of 3′-CD except for
the stable cytosine ring instead of a triazine ring that undergoes ring opening. The
measured half-life of 3′-CdC degradation was 5 h 50 min in buffer and 3 h in water,
which suggests that carbonate link hydrolysis rates were greater than triazine ring
opening rates. After 6 h of incubation at 37 ◦C, 48% of the carbonate-linked analogue
was degraded in buffer.
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The measured rates of decay for dAC and 3′-CdC confirmed our initial hypothesis that
the overall rate of instability in 3′-CD is the combination of the rates for triazine ring
opening and carbonate link hydrolysis, respectively. Indeed, the calculated sum of the
two degradation curves of dAC and 3′-CdC (’predicted’ 3′-CD stability) was close to
the experimentally measured 3′-CD degradation curve (Figure 4.7).
Fig. 4.7 Comparison of calculated and experimentally measured degradation curves of
3′-CD
Further analysis of the 3′-CD stability profiles provided additional insights on the
degradation mechanisms. Despite the rapid rate of disappearance of the photocaged
analogue 3′-CD (15% remaining after 6 h), only 8% of the active dAC was released
during a 6 h incubation period. This observation may be accounted for by the
degradation mechanism that also features relative rates of decays for the different
pathways (Scheme 4.5).
In the proposed scheme, 3′-CD (1a) can either undergo ’Ring Opening A’ (to give Ib
to an unknown extent - A%) or carbonate link hydrolysis (maximum of 48%) to give
the 3′-carboxylated dAC analogue (IIa). Decarboxylation of this analogue is thought
to proceed slowly and can directly release active dAC (IIIa). However, ’Ring Opening
B’ of the carboxylated analogue (to give IIb) can also compete with and prevent the
release of active dAC.
124 Stability of Photocaged Azanucleosides
O
O
HO
N
N
N
NH2
O
O
O
OH2
48%
O
O
HO
N
N
N
NH2
O
OH
O
O
OH
HO
N
N
N
NH2
O
O
O
HO
H2N
HN
N
NH2
O
OH
O
O
OH
HO
H2N
HN
N
NH2
O
ACTIVE dAC
8%
O
O
HO
H2N
HN
N
NH2
O
O
O
Ia
DEACM
DEACM
DEACM
OH
-CO2
Ring 
Opening
C
Ring 
Opening
B
Ring 
Opening
A
A% B% C%
A+B+C = 36%
Ib IIb
IIIaIIa
IIIb
?%
87
Scheme 4.5 Proposed mechanism of degradation of photocaged dAC
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In addition, after the release of the active dAC, it can also be further degraded by
’Ring Opening C’to give IIIb. The combined effects of the three ring opening steps
(A/B/C) contribute to the degradation of 36% photocaged dAC via ring opening. The
slow decarboxylation rates and the competing ring opening mechanisms at each step of
the carbonate link hydrolysis could be an explanation for the limited amount of active
dAC released.
In summary, a viable interpretation of the cell biological studies was proposed based
on the results obtained from the stability studies. The unwanted activity was due
to the release of >8% active dAC at higher caged dAC treatments that resulted in
comparable effects at equivalent dAC concentrations.

Chapter 5
Non-hydrolysable Azanucleosides
5.1 Introduction
The previous chapters were focused on the synthesis, photochemical characterisation
and stability assessment of photocaged analogues. The aim of this section was to
synthesise and evaluate the bioactivities of non-hydrolysable and non-photocaged forms
of azanucleosides.
It has been long established that dAC is a DNMT1, and in order to exert its bioactivity,
it first has to be incorporated into the replicating DNA.252 However, a study published
by Ghoshal and coworkers suggested that this might not be the case.117 In their
work, the authors demonstrated that dAC could target DNMT1 via a proteosomal
degradation pathway even in the absence of DNA replication, suggesting that dAC
may exert bioactivity even when it is not incorporated into the DNA.
Taking this finding into account, the following questions arose considering photocaged
azanucleosides: If the photocage (on the 5′- or 3′-position) blocks the incorporation of
dAC into DNA, but the „free flowing” dAC could still be active (ie. degrade DNMT1)
in the absence of DNA replication, does it mean that photocaged-dAC can also exert
bioactivity in its „free flowing” form?
The triazine ring of dAC is thought to contribute towards the DNMT1 blocking activity
of dAC. Since the photocage (that is conjugated either on the 3′- or 5′- position) is
not sterically blocking the triazine ring of dAC, the suggested theory above could be a
plausible mechanism.
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Due to the problematic aqueous stability profiles of the photocaged azanucleosides, it
is challenging to determine, whether the observed bioactivity (ie. demethylating effect)
in the absence of illumination was solely due to the release of dissociated dAC as a
result of carbonate bond hydrolysis, or also due to the activity of the „free flowing”,
intact photocaged analogue.
To further investigate, it was envisioned that a non-hydrolysable form of dAC would
provide further insights to the question above. A dAC analogue with a non-hydrolysable
linker would be able to distinguish between replication dependent (ie. bioactivity that
requires dAC incorporation into the DNA) and independent activities (ie. activity of
„free flowing” analogues) of dAC. Synthesis of Non-hydrolysable forms
5.2 Synthesis of non-hydrolysable Azanucleosides
Example structures of a non-hydrolysable forms of dAC include tritylated dAC (96
) and DMT-conjugated dAC (97) (Scheme 5.1). Ether linkers are known to be
significantly more resistant to aqueous hydrolysis compared to carbonate bonds..220
Trityl ethers also show good stability in mild acidic or basic media which make them
good candidates to be used in total syntheses of related targets.253 In this section, the
synthesis of both analogues was attempted.
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Scheme 5.1 Structures of non-hydrolysable Azanucleosides
The synthesis of tritylated dAC (96) was attempted in several rounds. First, a protocol
described by McGuigan and coworkers was followed (Scheme 5.2, (i)).,254 in which
dAC was treated with 2.2 equivalents of trityl chloride in the presence of DMAP and
pyridine at 80 ◦C. Unfortunately the reaction did not yield any products. The same
protocol was repeated at room temperature, but again no product spot was detected.
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Scheme 5.2 Synthesis of Trityl-dAC 96. Reagents and Conditions: (i) 2.2 eq TrCl,
DMAP, pyridine, 80 ◦C, 24 h; (ii) 1.1 eq TrCl, DMAP, imidazole, DMF, rt, 24 h
As a control, AC was used instead of dAC as a starting material (as described in the
original protocol), but this time a clear product spot appeared on the TLC, which was
then later confirmed by LC/MS to be the product spot. In summary, this method was
only suitable for AC tritylation, but not dAC tritylation.
An alternative method described by Andre and coworkers was trialled, in which TIPS
protection of 5′-OH of nucleosides was conducted (Scheme 5.2, (ii)).220 In this method,
dAC was treated with 1.1 equivalents of trityl chloride (instead of TIPS-Cl as described
in the original protocol) in the presence of DMAP, imidazole and DMF at room
temperature. Unfortunately this reaction did not yield any product either.
Given that the tritylation of dAC was unsuccessful, the conjugation of an alternative
group, DMT was attempted next (Scheme 5.3). A protocol described by Kim and
coworkers involved the treatment of dAC with 1.1 equivalents of DMT-chloride in
the presence of pyridine at room temperature, followed by 80 ◦C.255 The reaction
successfully gave DMT-dAC in 52% yield.
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Scheme 5.3 Synthesis of DMT-dAC 96. Reagents and Conditions: (i) 1.1 eq DMT Cl,
pyridine, 80 ◦C, 24 h
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5.3 Stability analysis of non-hydrolysable Azanu-
cleosides
The stability of the DMT-dAC at 37 ◦C in water was assesed using HPLC analysis and
is shown in Figure 5.1. In the HPLC trace, two main peaks can be detected, one of
them corresponds to DMT-dAC (Rt=17 min) and the other one to dAC (Rt=5 min),
which is likely an impurity from the synthetic mixture.
Fig. 5.1 HPLC Stability analysis of DMT-dAC, 97.
During the incubation, the dAC peak did not increase significantly after 4 and 22
hours, according to the peak integral values. This suggests that there was no rapid
dissociation from DMT-dAC. However, the DMT-dAC peak did decrease, which was
potentially due to triazine ring opening, the product of which could not be detected
via HPLC.
After further column purification, the DMT-dAC was successfully isolated (Figure 5.2).
Subsequent stability analysis on the twice purified analogue showed that after 24 hours,
a noticeable peak can be detected which could correspond to a very small amount of
dAC that may have dissociated during the incubation (Figure 5.3).
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Fig. 5.2 HPLC traces reflecting the purification steps of DMT-dAC
Fig. 5.3 HPLC Stability analysis of twice purified DMT-dAC, 97
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Given that it could not be confirmed whether the DMT-dAC analogue had superior
hydrolytic stability compared to the photocaged analogues, it was decided not to
test this analogue further in cell biological experiments. The hydrolysis of the DMT-
conjugated analogue could be explained due to the presence of methoxy groups on the
phenyl groups. The presence of the methoxy group may have increased the electron
density of the functional group, making the DMT group a better leaving group and
more prone to dissociation.
5.4 Suggested future work
Future work in this section could involve exploring alternative functional groups that
can be linked to 5′-OH of dAC. Potential linkers could include an ether or other
hydrolytically stable bonds. Once a non-hydrolysable analogue of dAC is synthesised
and characterised, stability analyses need to be conducted using LC/MS (as described
in Chapter 4), rather than HPLC. It is essential to identify an analogue that is not
prone to hydrolysis in aqueous media at 37 ◦C.
After a hydrolytically stable analogue is identified and established, cell experiments can
be conducted to determine whether the non-hydrolysable version of dAC is biologically
active or not (ie. degrade DNMT1). To determine that, western blot analyses can be
performed to measure the level of DNMT1 in response to the analogue.
If the non-hydrolysable analogue is able to reduce DNMT1 level, that would suggest
that any 3′- or 5′-modified version of dAC could induce demethylation even in the
absence of replication, since these modifications block the incorporation of dAC into
the DNA. This would also suggest that phototags on these positions would not have a
activity masking effect. However, if these non-hydrolysable analogues do not reduce
DNMT1 level, that suggests that 3′and 5′modifications (including photocaging) are
able to block dAC bioactivity.
Chapter 6
Conclusion
6.1 Summary and aim of the work
DNA methylation plays an essential part in maintaining and regulating key cellular
events. Aberrant changes in DNA methylation patterns such as hypermethylation
or increased methylation can lead to the development of cancer. DNA methylation
inhibitors such as azanucleosides (AC, dAC) can reverse hypermethylation by covalently
blocking DNMT1 enzyme. However the therapeutic use of these analogues can lead
to severe side effects (e.g. cytotoxicity) due to their non-specific nature. It would
be desirable to be able to target the activity of these agents to the cancerous site
of interest, in order to reduce potential side-effects. There is a significant need for
epigenetic tools that can be switched on and off “on demand”, both for therapeutic
and research applications. For research applications, these agents can serve as tools to
deepen our understanding of epigenetic modifications, which would be invaluable to
the scientific community.
The aim of this work was to develop optically controlled small molecule methylation
tools to target epigenetic modifications, more specifically DNA methylation. A series
of novel photocaged azanucleoside analogues were synthesised and characterised for
the purpose of light-dependent demethylation. It was established that caging position
strongly affected the photochemical and stability characteristics of the caged compounds.
Photocaged azanucleosides modified at the exocyclic –NH2 experienced significant dark
instability. This was due to the electronic properties of the triazine nucleobase that
led to the dissociation of the phototag. Placing the phototag on the 5′-OH greatly
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mitigated this effect, although the light-activation rate of this analogue suffered from
slower uncaging rates. The 3′-modified analogue (3′-DEACMOC-dAC) was the most
promising candidate due to its rapid deprotection rates and significantly improved
stability compared to the N-caged analogue.
Photocaged azanucleosides are biologically inert forms of azanucleosides that can be
activated upon light irradiation. Cell biological studies on SaOS2, T24 and HEK293T
cells showed that 3′-DEACMOC-dAC induced light-dependent demethylation, but the
effect was limited to lower concentration treatments (< 0.5 µM). At higher concen-
trations, significant demethylating activity was observed even in the absence of light,
suggesting that active dAC may have been released. These findings were corroborated
by Western blot analyses and cell viability assays.
Further investigation into the stability profile of 3′-DEACMOC-dAC using LC-MS/MS
analysis suggested that the mechanisms contributing to the degradation of this analogue
were the triazine ring opening (t1/2= 11.5 h) and carbonate link hydrolysis (t1/2 = 5 h
50 min) when the compound is incubated under physiological conditions. The latter
event also resulted in the release of 8% active dAC from photocaged dAC over a 6
hour incubation period, which likely caused the effects observed in the cell biological
experiments.
6.2 Impact and significance of the work
6.2.1 Significance of the work
This work describes the design and synthesis of chemical tools, more specifically
photocaged azanucleoside analogues that can achieve light-dependent demethylation
within the cellular environment. This is the first work in the field to describe the
photocaging strategy of azanucleoside analogues, which will be a valuable addition to
the limited amount of literature reports on the chemical modification of azanucleosides.
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6.2.2 Related work described in the field
Modified azanucleoside analogues
There were a number of efforts in the past 20 years to design safer and less cycotoxic
analogues and prodrugs of azanucleosides that can still achieve significant demethy-
lation, but with reduced or no side effects.87 The most successful clinical candidate
to date is SGI-110, a dinucleotide prodrug of dAC, in which the active dAC is linked
to deoxyguanosine (dG) via a phosphodiester bond. The analogue’s differentiated
pharmacokinetic and pharmacodynamic profiles offer improved clinical efficacy over
existing hypomethylating agents, not only in patients with haematological malignancies,
but the drug also demonstrated efficacy in the treatment of solid tumours.256 The
agent has been tested in bladder and colon cancer cells and is currently in phase III
trials. While there is clear evidence that the analogue offers improved safety profile,
its activity and efficacy relies on the presence of a phosphodiesterase enzyme that is
required for the release of active dAC.87
Another, similarly promising analogue was the N-modified 4-NPEOC-dAC, which was
originally developed by Byun et al to circumvent the metabolic instability of dAC
due to the inactivation by cytidine deaminase (CDA) enzyme.166 This analogue was
synthetically modified at the exocyclic amine by addition of a chloroformate version of
the functional group (4-NPEOC), which then rendered the dAC physiologically inactive.
The synthetic protocols applied in this work served as a basis and initial starting point
for this thesis. The demethylation activity of the prodrug was proven by cell biology
experiments.166 These experiments showed that NPEOC-dAC significantly decreased
global DNA methylation by reversing hypermethylation and reactivate the expression
of TSG and ID4 genes. However, the DNA methylation ability of the analogue was
found to be specific to liver cancer cell lines.
Similarly to SGI-110, the activation of this analogue relies on an enzyme, in this case
Carboxylesterase 1 enzyme (CES1), which is unevenly distributed in different tissues
and is more abundant in liver cells, but may be found in lower amounts in other tissues
such as ovarian cells. In addition, the analogue also had a 3 day delay in effect and
less toxicity was observed compared to dAC. The low potency and delayed effect was
due to the inefficient and slow conversion of NPEOC dAC to the active dAC. The fact
that NPEOC-dAC is dependent on the activity of CES1 enzyme for its metabolisation
to dAC has limited the clinical development of this prodrug, because the expression of
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CES1 is variable in different tissues and also the enzyme may not be 100% efficient in
converting NPEOC-dAC to dAC.
In summary, two promising prodrugs of dAC have been developed so far (one in clinical
development and one in pre-clinical stage). Both compounds rely on enzyme activation
to release active dAC. While it was demonstrated that these analogues have superior
safety and toxicity profiles compared to dAC, the activation is somewhat a limiting
factor as the presence of the enzymes in tissues cannot be controlled by external factors.
On the other hand, activation of photocaged azanucleosides is controlled by light, which
can be easily manipulated externally, for example by changing the location, timing
and intensity of the light source. Therefore photocaged azanucleosides are a valuable
addition to the current selection of azanucleoside prodrugs, as they can be activated
under precise spatiotemporal control, which could potentially allow the release the
exact amount of active compound in a given space at a given time.
Photocaged nucleoside analogues to study epigenetic processes
Photocaging of nucleoside analogues is a well-studied area and there are many instances,
where photocaging strategy was developed to understand the details of biological
processes, mechanisms that involve nucleoside analogues, which are comprehensively
discussed in a review by Tang et al. For example caged-ATP (for studying the energy-
dependent steps of metabolic reactions) and caged cyclic nucleotide monophosphates
(studying signal transduction pathways where secondary messengers play a key role).
To date, very few photocaged analogues have been synthesised to study epigenetic
processes, but this is likely to change in the near future due to the increasing interest
in understanding the mechanism of epigenetic modifications and its impact on the
development of cancer. The synthesis of one of the first analogues - photocaged
5 hydroxymethylcytosine was recently reported by a research group in the Czech
Republic.257
In their study, two types of photocaged derivatives of 2’-deoxy-5-hydroxymethylcytosine
dNTPs were synthesised. One was protected by 2-nitrobenzyl (one of the most simple
photocages) and the other one had a 6-nitropiperonyl group to mask its activity.
Both analogues were tested for enzymatic incorporation into DNA and photochemical
deprotections. While the nitropiperonyl group was efficiently deprotected by UV
irradiation, the nitropiperonyl group was more suitable with visible light at 400-425
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nm. The authors argued that the NB-caged analogue still has a good potential for
photocaging of DNA containing 5 hmC and some biological applications including
studies in order to better understand the role of 5 hmC in the regulation of transcription,
genomic stability and active demethylation.257
The photocaging of another base, 5 hmU was reported by the same group.258 5 hmU is
a less known epigenetic mark as it is usually found in certain bacterial species. Similarly
to the 5 hmC analogue, photocaged versions of this analogue were synthesised the
probe their ability to be incorporated into DNA and their photochemical deprotection
was checked. Apart from these two analogues, there are no other photocaged small
molecules that can selectively target DNA methylation processes.
Light sensitive biological tools to study epigenetic processes
On the other hand, biological tools that can finely manipulate epigenetic modifications
even with the control of light are rapidly emerging in the last few years with the recent
development of the CRISPR-CAS system. An example of such system was reported by
Polstein and coworkers in 2015.177
In their work, the authors engineered a light-activated CRISPR-Cas9 effector (“LACE”)
system that could induce transcription of endogenous genes in the presence of blue
light. They fused the light-inducible heterodimerizing proteins (CRY and CB1) to a
transactivation domain and the catalytically inactive dCas9 respectively. The resulting
LACE system can easily be directed to specific DNA sequences for the dynamic
regulation of endogenous genes.177 The light-inducible CRISPR-CAS system enabled
spatial and temporal control of endogenous gene activation and cell behaviour (e.g.
increase in mRNA levels upon illumination) as claimed by the authors.
While the CRISPR-Cas system offers a versatile platform that can be tailored to any
DNA sequence, the gene activation for the LACE system is reversible through removal
of illumination. In the case of the photocaged-dAC, the activation is non-reversible.
Azanucleosides are not targeting specific DNA sequences, but rather they are “global
demethylators”. Therefore photocaged-azanucleosides (although could be switched on
and off with the control of light) would therefore offer a less targeted approach compared
to the light inducible CRISPR-CAS system in terms of locus-specific modifications,
but its effect is non-reversible (at the time of the illumination).
138 Conclusion
6.3 Limitations of the work
The current work has three main limitations. The first limitation was the chemical
instability of the compound. The second limitation, which is partly related the
compound’s instability, is the setup of the cell biological experiments. And finally, the
stability assays conducted with mass spectrometry also had a number of drawbacks
that could potentially be addressed in future experiments. In this section, each of
these points will be discussed in detail and how these limitations could be improved in
future studies.
6.3.1 Limitation 1: Hydrolytic Instability
Unfortunately the hydrolytic instability of the carbonate bond linking the photocage
and the dAC limits its cell biological applications of photcaged azanucleosides as it
resulted in significant activity of the compound even in the dark.
Literature survey of related compounds and their reported instabilities
In light of this limitation, literature reports of analogues with similar structures
were investigated in order to determine if any stability issues were reported and
how the authors addressed these limitations. Similar structures included nucleoside
analogues containing a carbamate or carbonate linkers (they could be photocaged or not
photocaged). Alternatively, any other photocaged analogues, where the photocage is
connected via a carbamate or carbonate linker to the active compound were considered.
Five analogues were identified from the literature search, the structures of which are
shown in Scheme 6.1.
Of the five, three are nucleoside analogues (12, 94, 100), one is an azanucleoside
analogue (12) and three are photocaged compounds (94, 101, 102).
The first analogue (12), which is the most closely related to photocaged azanucleosides is
4-NPEOC-dAC, which was already introduced in the previous sections. This analogue
is not a photocaged azanucleoside as the 4-NPEOC group cannot be removed by
light. But rather, 4-NPEOC-dAC is a prodrug of dAC that relies on enzymatic
activation.166 The NPEOC group is linked to dAC via a carbamate bond. There was no
mention in the study regarding the stability or instability of the compound and the cell
experiments suggested that there was no dark instability observed. This is intriguing
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as in our experience, N-modified dAC analogues had poor hydrolytic stability, which
was confirmed by HPLC analysis at physiological conditions.
The second analogue (94) is a photocaged nucleoside analogue, coumarinyl adenosine
(5′-Bhmoc-adenosine).191 In this analogue, the coumarin photocage is linked to the
nucleoside via a carbonate linker at the 5′-position of the nucleoside. Apart from the
adenosine, other compounds such as galactose were also caged to coumarin photocages
via a carbonate linker in the study.191 According to the authors, these compounds show
“modest to good hydrolytic stabilities”. Their half-lives in the dark was reported to be
467 h for the photocaged nucleoside analogue. However, the temperature conditions
for the stability analysis were not reported, likely that they were conducted at room
temperature rather than 37 0 ◦C.
The third analogue (98) is a BHC-ceramide, a photocaged small molecule and not a
nucleoside analogue. In this analogue, the phototag is linked to the ceramide active
molecule via a carbonate linker. Similarly to the previous compound, the half-life was
reported to be very good (30 hours).217 However, it was stated that the temperature
at which stability was measured was room temperature, which cannot be considered
physiologically applicable.
The fourth analogue is “phototaxel” (99), a water-soluble photoresponsive prodrug
of the anticancer agent paclitaxel. In the study, the authors made a carbamate and
carbonate type versions of phototaxel and measured their stabilities at physiological
conditions.259 The carbamate version of phototaxel was stable in the dark prior to
activation, whereas the carbonate version showed poor aqueous stability in the dark.
More specifically, only 20% of paclitaxel was released in PBS (pH 7.4, 37 0 ◦C) after
8 hours of incubation and only 18% of the prodrug remained when the analogue was
stored at 4 0 ◦C for 13 days. In contrast, the carbamate analogue was stable under
physiological conditions as well as under alternative storage conditions. Therefore, for
latter studies the authors chose the carbamate analogue for further detailed study.259
This study is an example of where the instability of the carbonate-type analogue was
identified and addressed by the authors, by switching the carbonate to a more stable
carbamate linker.
In the final analogue (100), the antitumour agent 5-iodo-2′-deoxyuridine nucleoside
was conjugated to a melanoma carrier molecule via varying linker structures for
potential intratumoural specific drug release.220 The authors explored various linker
types including ester, acetal, carbonate and carbamate. The stabilities of each analogues
(with different linker types) were tested in various physiologically relevant conditions
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such as PBS (pH 7.4), cell culture medium (MEM) and human serum, as well as acidic
buffer (pH 5.0). As demonstrated by the Figure 6.1, the analogue with the carbonate
linker had a poor aqueous stability. After 6 hours of incubation in PBS, MEM and
human serum, only 60%, 50% and 40% of the carbonate analogue remained in the
solution respectively. In acidic conditions, the stability was just as poor as in human
serum. The authors reported an even poorer stability profile for the ester analogue,
but the carbamate conjugate on the other hand was reported to be stable over 3 days
in PBS and MEM (data was not shown in the article).220
Fig. 6.1 The reported stability profiles by Andre and coworkers on carbonate linked
5-iodo-2′-deoxyuridine 100 to a melanoma carrier molecule in (A) PBS buffer (B)
human serum (C) cell culture media and (D) acidic buffer. The profiles confirm that
carbonate linked analogues have poor aqueous stability under physiologically relevant
conditions.220
These results are in alignment with our findings. In our stability experiments, the
stability of the carbonate conjugated cytidine analogue was comparable to that of
analogue 100. After 6 hours of incubation in HEPES at pH 7.2, around 53% of the
photocaged compound remained in solution, which is slightly lower to what is reported
by the authors of this study (60%). Based on these findings, it is likely that the
aqueous stability of the photocaged azanucleosides would be even poorer in cell culture
media and human serum. Instead of modifying the structure of the carbonate linked
analogue, the authors confirmed that the carbamate linked analogue has a superior
stability profile and therefore should be used in further cell biological experiments.
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Based on the five literature studies reporting on the stability of carbonate and carbamate
linked analogues, it can be concluded that none of the carbonate linked analogues had
good aqueous stability under physiological conditions. In the two examples where the
authors claimed good stability and long half-life, the stability studies were conducted
under non-physiological conditions. In the studies, where the aqueous instability was
evaluated under physiologically relevant conditions, the half-lives obtained were very
similar to the ones obtained from our study. There was only one way the authors
addressed this instability issue and it was simply using the carbamate analogue of the
same compound instead of the carbonate analogue for further biological studies.
Alternative structures with improved hydrolytic stabilities
In the case of photocaged azanucleoside, replacement of the carbonate linkers with
carbamate bonds would require the modification of the photocage. The position of the
photocage is fixed to the 3′-position of dAC, due to the limitations in stability and
deprotection kinetics as observed for the N’- and 5′-caged dAC analogues previously.
This requires the Oxygen atom to be part of dAC (3′-position) and the Nitrogen atom
to be part of the photocage. Therefore, either the part of the photocage that links to
dAC must contain a Nitrogen atom or there should be an additional linker between
the photocage and the carbamate linker (e.g. a self-immolative linker) that enables
this connection (Scheme 6.2).
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Self-immolative linkers
Self immolative linkers are special types of linkers. They can undergo a controlled
cleavage mechanism upon a certain kind of trigger such as photouncaging, as well as
enzymatic, nucleophilic or redox processes.260
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Scheme 6.3 Self immolative linker strategy
In the case of photouncaging, this linker forms a scissile bond with the protecting
group and a stable bond to the target molecule (in this case dAC). The latter bond
becomes labile upon removal of the protecting group, resulting in a rapid disassembly
of the three components.
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Self-immolative linkers are becoming increasingly common in conjugate systems for drug
delivery.261 An example of a photocaged-dAC structure containing a self-immolating
linker and its proposed decomposition upon UV irradiation is shown in Scheme 6.3.
Self-immolative breakdown occurs through a cascade of electronic elimination processes
and it is driven by an increase in entropy and the irreversible formation of thermody-
namically stable products (in this case CO2, 5-membered ring and the photocage).
It is hypothesised that the insertion of a self-immolative linker between the DEACM
photocage and dAC would ensure rapid removal of the photocage and the linker upon
light irradiation. Furthermore, the self-immolative linker also allows DEACM phototag
to be attached to dAC via a carbamate linker, which is expected to significantly increase
its hydrolytic stability as suggested by literature.
6.3.2 Limitation 2: The setup of cell biological experiments
The aim of the cell biological experiments was to demonstrate how the DNA methylation
levels of the cells were altered upon various treatments (dAC, photocaged-dAC and
irradiated photocaged-dAC). One of the most challenging steps of the setup of the
cell biological assays was to identify a robust methylation assay that can determine
the change in DNA methylation levels of the treated cells at a relatively rapid rate.
Given the lack of sensitivity of the ELISA assays, LC-MS was identified to be the
most suitable technique to reflect even small changes in DNA methylation levels upon
treatment.
Unfortunately it was not possible to set up the LC-MS assay "in house", given the lack
of time for optimisation and access to specialised equipment. An alternative laboratory
in Cambridge was selected to conduct the LC-MS assays, where an already established
and validated protocol was used to measure DNA methylation levels using LC-MS.
For each measurement cycle, a limited number of samples could be submitted and due
to the limited access to the equipment, it often took between 2 weeks to 1 month to
receive the methylation results for the samples that have been submitted. Given these
limitations, it was not possible to send a large number of samples at once.
The cell line screening described in Section 3.4.1 was one of the examples where this
resource limitation had a potential impact. In the screening, four different cell lines
were tested for their sensitivity to dAC treatment, at 5 different concentrations. Ideally,
the treatments should have been carried out in triplicates, which would have resulted
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in 60 samples. But at the time, only one replicate was produced for each treatment
condition and cell line, which resulted in 20 samples. It is recognised that this is
a potential limitation of the work and having triplicates of the samples would have
provided higher level of confidence in the results obtained. However, because the
following readings with the selected cell lines (SaOS2, T24 and HEK293T) always
included triplicate measurements, it was not considered essential at the time to repeat
the measurements for the cell line screening.
Similarly for the treatment optimisation, potentially more concentrations could have
been explored (for example for SaOS2 cells, between 0 and 0.1 µM to determine a
concentration where SaOS2 cells still respond to dAC in a concentration dependent
manner). But given the limitations described above, these measurements were not
carried out.
Another limitation of the cell experimental setup was the treatment duration. Initially,
a four day treatment regimen was trialled, where the cells were treated with dAC every
24 hours. It was then decided to switch to a single treatment which only lasted 24
hours. The switch was performed, because a notable level of toxicity was observed at
the highest concentration dAC treatment (1.5 µM), which affected the amount of DNA
that could be extracted from the cells.
With the new treatment regimen, significantly greater amount of DNA could be
obtained, however it is also recognized in hindsight that 24 hours is not a long enough
time for dAC to be fully incorporated into the DNA. Therefore a lower concentration
(e.g. below 0.5 µM) treatment for longer duration (for 3 days and potentially even
longer) potentially would have better reflected the effect of dAC on DNA methylation.
In literature, dAC treatments are usually conducted for 72 hours in different cell
lines.262
6.3.3 Limitation 3: Stability Experiments
Another set of limitations of this thesis were concerning the stability assays. The aim
of the stability assays was to gain additional (qualitative and preferably quantitative)
insights on the potential mechanisms that contributed towards the hydrolytic instability
of the photocaged-dAC compound that resulted in unwanted biological activity of the
compound in the dark.
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The stability analysis using mass spectrometry enabled the detection of dAC, caged-
dAC and photocage in various conditions (water, HEPES buffer at room temperature
and 37 0 ◦C) over a period of 6 hours. The current setup enabled the collection
of limited amount of data points (in time) and it allowed the detection of limited
number of compounds (only dAC, caged-dAC and photocage, but none of the potential
intermediates inbetween).
Limited amount of data points
The sample collection interval of the stability analysis was limited to a minimum of
30 minutes as this amount time was required for the full separation and individual
detection of the caged-dAC compound and the DEACM photocage on the liquid
chromatography column.
For the stability measurements at 37 0 ◦C, an endpoint at 6 h was chosen due to the
limited availability of LC/MS machine and requirement to manually transfer samples
to the LC/MS vials. The reason for manual transfer was because the samples were
incubated in a separate container (a heating block) from the LC/MS sample holder.
Prior to each injection, 200 µL aliquot of each sample was placed in an LC/MS vial
and then sample holder. After the injection (of approximately 10 µL), the remaining
sample was returned to the heating block to maximise the available liquid volume for
subsequent stability analyses.
Detection of limited number of compounds
The current setup only enabled the detection and quantification of three compounds:
dAC, caged-dAC and the photocage. Only these compounds were available in a
pure and isolated form for initial calibration, which was preceded by MRM (multiple
reaction monitoring) optimisation using the triple quadrupole mass spectrometry.
Subsequently, LC/MS only allowed the quantification of compounds that underwent
MRM optimisation and calibration.
The ability to monitor the levels caged-dAC gave an exact indication of the extent of
hydrolytic instability of the compound, demonstrated by its rate of disappearance. The
concomitant release of dAC ( 8 % of starting caged-dAC concentration) measured also
reflected the amount of biological activity that was observed in the cell experiments
(ie. equivalent to dAC activity at approximately tenth of the concentration).
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Need for additional reference compounds for stability analyses
It was possible to confirm through the series of stability experiments (with photocaged-
dAC, dAC, but also photocaged-dC) that there were two main sources of the hydrolytic
instability: triazine ring opening and carbonate bond dissociation. However, it was
not possible to quantify the presence of any degradation intermediates and byproducts
(such as the triazine ring opened forms or the hydrolysed/dissociated carbonate dAC
intermediate) due to the lack of pure and isolated form of these compounds for MRM
optimisation and calibration.
It was particularly challenging to measure the rate of decarboxylation as there was
no indication of the level of carbonated dAC. The only available measure was the
appearance of the photocage (step prior the appearance of carbonated dAC) and
the appearance of pure dAC (step after the carbonated dAC). Similarly, the rate of
ring opening was also difficult to measure in the absence of a standard solution of
the ring opened form. Independent measurements of dAC triazine ring opening and
photocaged-dC stability did help stability measurements, however we had to assume
that the behaviour of these bonds are similar within photocaged-dAC.
A more comprehensive and quantitative stability study would require additional ref-
erence compounds (for calibration), such as the ring opened triazine form or the
carbonated dAC intermediate. The ring opened form is possible to isolate via prepara-
tive HPLC from a 24 h old aqueous solution as described by Beisler et al.154 However,
the carbonated dAC would not be possible to isolate as the compound itself is labile.
In summary, a number of assumptions were stated and tested during the stability
studies, but only qualitative and limited quantitative conclusions could be drawn
due to the small number of compounds that could be monitored (ie. no degradation
intermediates and by-products). Further improvements can be done by including more
reference compounds in order to gain further insights on the individual mechanistic
steps that lead to the triazine ring opening or the carbonate bond dissociation.
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6.4 Suggested future work
Based on our observations and the discussion of the current work’s limitations, we
suggest that the stability of the caged analogues could be improved by replacing the
carbonate bond with a carbamate linker. Given the instability of the exocyclic position
in azanucleosides and poorer uncaging rates observed at the 5′-position, the most ideal
position for the carbamate-linked phototag would be at the 3′-position (Scheme 6.4).
O
O
HO
N
N
N
NH2
O
H
N
O
PHOTOTAG
Self-immolative 
linker
O
O
HO
N
N
N
NH2
O
N
O
NO2
R1
R2
7-nitroindole
phototag87
Scheme 6.4 Suggested analogues with improved hydrolytic stabilities
This would require a phototag with an amine handle. Unfortunately, the DEACM
phototag does not have an amine handle. It is however possible to keep the DEACM
phototag by the introduction of a self-emmolative linker as described in the previous
section. Alternatively, a different phototag can be used. The 7-nitroindole phototag is
one of the rare phototags that has an amine handle, but its photochemical properties
are considerably poorer than coumarin phototags’ used in this work.181,263
Further work could either involve the improvement of the photochemical properties
of the 7-nitroindole phototag or the photochemical investigation of the combination
of DEACM phototag and self-immolative linker. All of the future photochemical
investigations should be conducted in physiological buffer instead of water.
Stability experiments should ideally be conducted prior to any cell biological exper-
iments to ensure that the compound has good aqueous stability even in the dark.
Similarly to the DEACM-dAC analogue, a dC analogue (that does not have triazine
ring instability) should also be synthesised so that the carbamate bond stability can
be probed individually.
In terms of the cell biological experiments, treatment duration should be extended to
72 hours from 24 hours and the treatment concentrations should be focused on the
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lower range (< 0.5 µM). LC/MS measurements should be kept for DNA methylation
analysis, but it should be ensured that measurements are conducted in triplicates.
Azanucleosides provided an important first step towards the development of light-
tunable small molecule methylation tools. In order to achieve greater therapeutic
impact, DNMT inhibitors other than azanucleosides should also be explored in the
future. Currently, azanucleoside are the most potent global hypomethylators. With the
rapid development in the field of epigenetics, the discovery of new small molecule DNMT
inhibitors with greater potencies will provide additional platforms for photocaging and
controlling methylation levels with the precision of light.

Appendix A
Experimental
A.1 General experimental
A.1.1 Chemicals and solvents
All chemicals and solvents were purchased from Sigma Aldrich, Fischer Scientific, Alfa
Aesar, Acros Organics and used as received unless otherwise stated. 5-azacytidine and
5-aza-2′-deoxycytidine were purchased from Carbosynth Ltd.
A.1.2 Chromatography
All reactions were monitored by thin layer chromatography using Merck 60 F254 silica
gel coated plates. Visualisation was achieved by UV irradiation at 254 nm or 365 nm.
Flash column chromatography was carried with silica gel (43 − 60 µm) supplied by
Merck.
A.1.3 Spectroscopy
Nuclear Magnetic Resonance (NMR)
1H NMR spectra were recorded at 500 MHz and 600 MHz and 13C NMR at 75 MHz, 100
MHz, 125 MHz and 150 MHz on Bruker AMX500 and AMX600 at 25 ◦C as described
below. All chemical shifts (δ) for 1H and 13C are quoted relative to residual signals
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of the solvent on the parts per million (ppm) scale. The multiplicity of the signal
is designated by the following abbreviations: m=multiplet, s=singlet, d=doublet,
t=triplet, q=quartet. The abbreviation br refers to a broad signal. Coupling constants
(J values) are reported in Hz and refer to JH-H couplings unless otherwise stated.
Infrared Spectroscopy (IR) and melting point analysis
Infrared spectra were obtained on a Perkin Elmer Spectrum 100 FTIR Spectrometer
operating in ATR mode. Melting points were measured with a Gallenkamp apparatus
and are uncorrected.
UV-Vis
UV analysis was performed using Varian Cary 300 Bio UV-Vis Spectrophotometer
and a quartz cuvette with a path length (l) of 1 cm. All solutions were prepared
at a concentration (c) of 50 µM in water unless otherwise stated. Molar absorption
coefficients values (ϵ) were calculated according to the Beer Lambert Law.
Absorption = log10
I0
I
= ϵlc (1)
LCMS, HRMS
ESI-MS analysis was performed using a Waters Aquity Ultra performance LC-MS
system equipped with an Acquity UPLC BEH C18 column (50 x 2.1 mm, 1.7 mm
beads). CI-MS analysis was performed on a Thermo Finnigan MAT900 XP equipment
by Dr Kersti Karu, UCL Chemistry.
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A.1.4 HPLC
HPLC analysis was performed using reverse phase Varian ProStar system with a
Model 210 solvent delivery mode and a Model 215 dual wavelength detector. The UV
absorbance was monitored at λ = 254 nm. Semi-preparative HPLC was carried out
using a Supelco C18 column (250 x 21 mm, 10µM) column with an elution system of
5-95% ACN in water over 45 min at 5 mL.min−1 flow rate. Analytical HPLC analysis
was performed using an Agilent Eclipse C18 column (250 x 4.6 mm, 5 µm), with an
elution system of 5-95% ACN in water over 20 min at 1 mL.min−1 flow rate.
A.1.5 Photouncaging experiments
Photouncaging was carried out inside a UV Viewing Cabinet (UVP, #95-0072-01)
equipped with a handheld UV lamp (Mineralight, #UVGL-58) at a measured power
density of 145 µM/cm2. The photouncaging solutions were prepared at 100 µM in
water from frozen 10 mM DMSO stocks of photocaged azanucleosides. 500 µL of the
freshly prepared photouncaging solutions were placed in a 24 well tissue culture plate
(BD Falcon, #353047) and positioned 20 cm from the UV lamp inside the UV Viewing
cabinet. Irradiations were carried out at λ = 365 nm, unless otherwise stated. 20 µL
aliquots were taken every 30 min and the concentration of the caged compounds and
the liberated azanucleosides were measured using HPLC.
A.1.6 Quantum yield measurements
Uncaging reactions are typically carried out using xenon or mercury lamps. Quantum
yield measurements for photouncaging reactions are conventionally determined using a
combination of potassium ferrioxalate actinometer (to measure the amount of photons
absorbed) and HPLC (to measure the ratio of molecules converted from caged to
uncaged state. The photochemical quantum yield is defined as the ratio of caged
molecules converted to the amount of photons absorbed that was measured by the
actinometer.
For our uncaging setup, two adjustments were made to the conventional methods
described in literature. The first adjustment was the light source used for the irradiation
experiments. Instead of conventional xenon and mercury lamps, a benchtop UV lamp
was used to irradiate the compounds. The benchtop UV lamp was found to be a
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convenient and compatible choice for the chemical photouncaging experiments as well
as the cell biological assays that required photoirradiation of cell cultures. The second
adjustment was the measurement tool for the photon influx. In the absence of an
actinometer equipment at the time, an alternative method was employed that was
already used to measure quantum efficiency of photocatalytic reactions.264,265 In this
method, the amount of photons absorbed was measured using a spectrophotoradiometer
(UVX Radiometer) that was positioned in the place of the uncaging solution. The ratio
of the molecules converted was determined via HPLC, following literature reported
protocols.
There are several limitations of this method and it is important to point out that
the “yield” calculated here is the formal quantum efficiency rather than the quantum
yield. The spectrophotometer measures that number of incident photons - that is
the number of photons that reach the solution. The limitation is that the actual
number of photons absorbed by the solution is not known using this measurement,
and it is tricky to determine as some photons may get lost via radical chain reactions
participating in the degradation process. The formal quantum efficiency / apparent
quantum efficiency gives an idea of the efficiency of the uncaging process, however
it relies on the measurement of incident photons rather than the photons absorbed.
Therefore, the values calculated are likely an underestimation of the actual quantum
yield values.
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A.1.7 Quantum yield calculations
The quantum yields, Φ, defined as the ratio of caged molecules converted to the amount
of photons absorbed were estimated based on the equations below.
Photon Flux (photons.cm−2s−1) = Irradiance (mW/cm
2)
Energy (J) (2)
Quantum Yield Φ (molecules.photon−1) = Molecules destroyed (molecules.cm
−2s−1)
Photon Flux (photons.cm−2s−1)
(3)
The calculated photon flux at λ = 365 nm at an irradiance of 145 µW/cm2 was 2.64 x
1014 photons.cm−2s−1. Table A.1 summarises the calculated quantum yield values of
the photocaged analogues.
Photocaged
analogue
Rate of
decay (s−1)
Molecules destroyed
(molecules cm−2 s−1)
Formal Quantum
Efficiency Φ365nm
mono-NPEOC-dAC, 60 8.33E-05 1.32E+12 4.93E-03
mono-DMNPEOC-dAC, 64 6.67E-05 1.05E+12 3.94E-03
N-DEACMOC-dAC, 78 1.03E-03 7.11E+12 6.11E-02
5′-DEACMOC-dAC, 84 4.83E-04 3.34E+12 2.88E-02
3′-DEACMOC-dAC, 93 1.50E-03 1.03E+13 8.84E-02
Table A.1 Quantum yield calculations of photocaged analogues
A.1.8 Rate calculations
Photouncaging rates were estimated from linear regression of the 30-40% steps of the
area curves extracted from zero order kinetics (as shown in the Figure A.1). Log of
measured concentration and initial concentration ratio was plotted against time and
the measured slope of the linear function was taken as the corresponding rate of the
decay.
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(A) mono-NPEOC-dAC, 60 (B) mono-DMNPEOC-dAC, 64
(C) N-DEACMOC-dAC, 78 (D) 5′-NPEOC-dAC, 84
(E) 3′-NPEOC-dAC, 93
Fig. A.1 Linear Regression plots of Photouncaging Decays
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A.2 Characterisations
2-nitrophenethyl carbonochloridate (NPEOC-Cl) 58187
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To a solution of 2-nitrophenethyl alcohol 57 (1.0 mL, 7.1 mmol) in dry tetrahydrofuran
(THF) (20 mL) was added a solution of 20% w/w phosgene in dry toluene (7.5 mL,
14.18 mmol) dropwise at 0 ◦C under inert atmosphere. The reaction mixture was
stirred at 0 ◦C for 1 h, followed by room temperature overnight. TLC analysis (5%
MeOH/CH2Cl2) confirmed the complete conversion of the alcohol (Rf = 0.48) to the
chloroformate (Rf = 0.80). Excess phosgene was removed under reduced pressure and
was quenched with 0.1 M NaOH. 2-nitrophenethyl carbonochloridate 58 was isolated
(1.53 g, 94%) as a viscous yellow oil. The crude product was used in the next step
without further purification. 1H NMR (600 MHz, CDCl3) δ 7.96 (dd, 1 H, J=7.6, 1.0
Hz, H -3), 7.58 (td, 1 H, J=7.6, 1.0 Hz, H -5), 7.43 (td, 1 H, J=7.6, 1.2 Hz, H -4), 7.39
(dd, 1 H, J=7.6, 1.2 Hz, H -6), 4.61 (t, 2 H, J=6.5 Hz, H -8), 3.31 (t, 2 H, J=6.5 Hz,
H -7); 13C NMR (150 MHz, CDCl3) δ 150.55 (C-9), 149.33 (C-2), 133.63 (C-5), 133.08
(C-6), 131.67 (C-1), 128.60 (C-4), 125.32 (C-3), 71.19 (C-8), 32.40 (C-7); HRMS (CI)
calcd for C9H8ClNO4 [M]+ 229.01419, found 229.00250.
2-(4,5-dimethoxy-2-nitrophenyl)ethan-1-ol (DMNPE-OH) 62266
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To a solution of 2-(4,5-dimethoxy-2-nitrophenyl)acetic acid 61 (519 mg, 2.15 mmol) in
dry THF (13 mL) was added 1 M BH3·THF (5 mL, 5 mmol) under inert atmosphere.
The solution was allowed to stir at room temperature for 2 h, then H2O (2 mL) was
slowly added to quench the reaction. The crude mixture was concentrated in vacuo
and the resultant residue was diluted in ethyl acetate (100 mL) and washed with
saturated NaHCO3 (2 x 60 mL) and brine (60 mL), dried over MgSO4 and concentrated
in vacuo to afford 2-(4,5-dimethoxy-2-nitrophenyl)ethan-1-ol 62 (476 mg, 98%) as a
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yellow precipitate: Rf 0.62 (5% MeOH/CH2Cl2); m.p.: 97 ◦C; 1H NMR (600 MHz,
DMSO-d6) δ 7.54 (s, 1 H, H -3), 7.03 (s, 1 H, H -6), 4.74 (t, 1 H, J=5.3 Hz, -OH ),
3.87 (s, 3 H, -OMe), 3.82 (s, 3 H, -OMe), 3.62 (q, 2 H, J=6.8 Hz, H -8), 3.02 (t, 2
H, J=6.8 Hz, H -7); 13C NMR (150 MHz, DMSO-d6) δ 152.49 (C-4), 146.89 (C-5),
141.32 (C-2), 128.86 (C-1), 114.52 (C-6), 107.88 (C-3), 61.11 (C-8), 56.13 (MeO), 55.95
(MeO), 36.01 (C-7); IR vmax(solid): 3507 (O-H), 3322 (C-H), 2945 (C-H Ar), 1581
(C=C Ar), 1581-1325 (N-O) cm−1; HRMS (CI) calcd for C10H13NO5 [M]+ 227.07882,
found 227.07888.
4,5-dimethoxy-2-nitrophenethyl carbonochloridate (DMNPEOC-Cl) 63
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To a solution of 2-(4,5-dimethoxy-2-nitrophenyl)ethan-1-ol 62 (450 mg, 1.98 mmol)
in dry THF (10 mL) was added a solution of 20% w/w phosgene in dry toluene (2.5
mL, 4.73 mmol) dropwise at 0 ◦C under inert atmosphere. The reaction mixture was
stirred at 0 ◦C for 1 h, followed by room temperature overnight. Excess phosgene was
removed under reduced pressure and was quenched with 0.1 M NaOH. 4,5-dimethoxy-
2-nitrophenethyl carbonochloridate 63 was isolated (550 mg, 96%) as dark yellow
precipitate: Rf0.94 (5% MeOH/CH2Cl2); m.p.: 64 ◦C. 1H NMR (600 MHz, CDCl3)
δ 7.66 (s, 1 H, H -3), 6.73 (s, 1 H, H -6), 4.65 (t, 2 H, J=6.3 Hz, H -8), 3.98 (s, 3 H,
-OMe), 3.95 (s, 3 H, -OMe), 3.35 (t, 2 H, J=6.3 Hz, H -7); 13C NMR (150 MHz, CDCl3)
δ 153.25 (C-4), 150.60 (C-9), 148.20 (C-5), 141.34 (C-2), 126.74 (C-1), 114.32 (C-6),
108.52 (C-3), 71.36 (C-8), 56.62 (MeO), 56.49 (MeO), 33.22 (C-7); HRMS (CI) calcd
for C11H13ClNO6 [M]+ 290.04259, found 290.04190.
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6-Bromo-4-(chloromethyl)-7-hydroxymethylcoumarin (BHC-Cl) 70217
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A solution of 4-bromoresorcinol 69 (1.00 g, 5.29 mmol) in methanesulfonic acid (8 mL)
was treated with methyl 4-chloroacetoacetate (0.92 mL, 7.94 mmol) and was stirred
for 2 h at room temperature. The resulting mixture was slowly poured into ice-water
(24 mL) and then stirred for 30 min to give a white precipitate. The precipitate was
collected by filtration and washed with cold water (3 x 5 mL). The resulting off-white
precipitate was recrystallised with hexane/ethyl acetate (15 mL) to give compound 70
(0.96 g, 63%): Rf0.17 (hexane/ethyl acetate 3:1); 1H NMR (600 MHz, DMSO-d6) δ
11.56 (s, 1 H, 7-OH ), 7.99 (s, 1 H, H -5), 6.91 (s, 1 H, H -8), 6.47 (s, 1 H, H -3), 5.00 (d,
2 H, J=0.9 Hz, H -9); 13C NMR (150 MHz, DMSO-d6) δ 159.70 (C-2), 157.53 (C-7),
154.08 (C-6), 150.18 (C-4’), 129.09 (C-5), 112.14 (C-3), 110.70 (C-4), 106.19 (C-8’),
103.28 (C-8), 41.24 (C-9); HRMS (CI) calcd for C10H6BrClO3 [M+H]+ 288.92671,
found 288.92624.
6-Bromo-7-hydroxy-4-hydroxymethylcoumarin (BHC-OH) 71217
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A suspension of 6-bromo-4-(chloromethyl)-7-hydroxymethylcoumarin 70 (0.92 g, 3.18
mmol) in water (230 mL) was heated at reflux for 5 days. The resulting mixture was
cooled to room temperature concentrated in vacuo. The residue was triturated with hex-
ane/diethyl ether (2:1, 6 mL) to afford 6-bromo-7-hydroxy-4-hydroxymethylcoumarin
71 (0.73 g, 85%). Rf0.80 (ethyl acetate); 1H NMR (600 MHz, DMSO-d6) δ 11.42 (br,
1 H, 7-OH ), 7.83 (s, 1 H, H -5), 6.89 (s, 1 H, H -8), 6.26 (d, 1 H, J=1.6 Hz, H -3), 5.63
(br, 1 H, 9′-OH ), 4.69 (s, 2 H, H -9); 13C NMR (150 MHz, DMSO-d6) δ 160.17 (C-2),
157.09 (C-7), 156.06 (C-6), 153.68 (C-4′), 128.20 (C-5), 110.98 (C-3), 107.63 (C-4),
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106.00 (C-8′), 103.07 (C-8), 59.07 (C-9); HRMS (CI) calcd for C10H7BrO4 [M+H]+
270.96060, found 270.96005.
6-bromo-7-O-(hydroxy)-4-((trimethylsilyl)ethoxymethyl)coumarin
(BHC-OSEM) 73
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To a solution of 6-bromo-7-hydroxy-4-hydroxymethylcoumarin 71 (150 mg, 0.55 mmol)
in dry CH2Cl2 (12 mL) was added DIPEA (94 µL, 0.54 mmol) slowly and the solution
was cooled to 0 ◦C. 2-(trimethylsilyl)ethoxymethyl chloride (96 µL, 0.54 mmol) was
added dropwise. After being stirred at 0 ◦C for 2 h, the reaction mixture was diluted
with CH2Cl2 and poured into 0.5 M citric acid (30 mL). The layers were separated
and the organic layer was washed with citric acid (30 mL) followed by brine (30 mL).
The residue was dried and concentrated in vacuo to afford a brown oil. Trituration
with hexane afforded compound 73 (118 mg, 54%) as a light brown powder. Rf0.69
(hexane/EtOAc 1:1); m.p.: 75 ◦C; 1H NMR (600 MHz, DMSO-d6) δ 11.45 (br, 1 H,
7-OH ), 7.86 (s, 1 H, H -5), 6.90 (s, 1 H, H -8), 6.27 (s, 1H, H -3), 4.80 (s, 2 H, H -10), 3.36
(s, 2 H, H -9), 2.50 (s, 2 H, H -11), 0.84 (s, 2 H, H -12), 0.03 (s, 9 H, H -13); 13C NMR
(150 MHz, DMSO-d6) δ 160.08 (C-2), 153.91 (C-7), 153.71 (C-8′), 147.22 (C-4), 131.71
(C-5), 115.81 (C-4′), 111.71 (C-3), 111.41 (C-8), 110.54 (C-6), 95.51 (C-10), 69.12 (C-9),
66.65 (C-11), 24.01 (C-23), 2.12 (C-13); HRMS (CI) calcd for C16H21BrO5Si [M+H]+
401.33542, found 401.32444.
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6-bromo-7-O-(methoxymethyl)-4-hydroxymethylcoumarin
(BHC-OMOM) 74217
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A mixture of 6-bromo-7-hydroxy-4-hydroxymethylcoumarin 71 (200 mg, 0.74 mmol)
and DIPEA (141 µmL, 0.81 mmol) in dry CH2Cl2 (10 mL) was cooled to 0 ◦C, and
chloromethyl methyl ether (62 µL, 0.81 mmol) was added dropwise. After being stirred
for 2 h at 0 ◦C, the reaction mixture was poured into 0.5 M citric acid (20 mL) and
extracted with CHCl3 (2 × 20 mL). The combined organic layer was washed with brine
(2 x 30 mL) and dried over MgSO4. After the solvent was removed in vacuo, the residue
was triturated with hexane (2 × 5 mL) to afford 6-bromo-7-O-(methoxymethyl)-4-
hydroxymethylcoumarin 74 (132 mg, 57%): Rf0.34 (hexane/EtOAc 1:1); 1H NMR
(600 MHz, DMSO-d6) δ 7.94 (s, 1 H, H -5), 7.26 (s, 1 H, H -8), 6.36 (s, 1 H, H -3), 5.68
(t, 1 H, J=5.5 Hz, -OH ), 5.42 (s, 2 H, H -10), 4.72 (dd, 2 H, J=5.5, 1.7 Hz, H -9),
3.42 (s, 3 H, H -11); 13C NMR (150 MHz, DMSO-d6) δ 159.98 (C-2), 157.32 (C-7),
155.15 (C-8′), 155.22 (C-4), 128.25 (C-5), 112.79 (C-4′), 108.96 (C-3), 106.14 (C-8),
103.54 (C-6), 94.81 (C-10), 59.09 (C-9), 56.28 (C-11); HRMS (CI) calcd for C12H12BrO5
[M+H]+ 315.98633, found 315.98263.
7-(diethylamino)-4-(hydroxymethyl)chroman-2-one (DEACM-OH) 76218
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To a solution of 4-diethylaminocoumarin 75 (4.63 g, 20 mmol) in hot p-xylene (120
mL) was added SeO2 (3.33 g, 30 mmol) and the mixture was heated under reflux
with vigorous stirring overnight. The mixture was then filtered and concentrated
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under reduced pressure. The dark brown residual oil was dissolved in a mixture of
ethanol and THF (1:1, 120 mL) and sodium borohydride (380 mg, 10 mmol) was
added and the solution was stirred overnight at room temperature. The suspension
was carefully hydrolysed with 1 M HCl (20 mL), diluted with water (30 mL) and
extracted with CH2Cl2 (3 x 50 mL). The organic phase was washed with water (2
x 100 mL), brine (100 mL) and dried over MgSO4 and concentrated in vacuo. The
crude material was purified by flash chromatography (CH2Cl2/Acetone 5:1) to yield
7-(diethylamino)-4-(hydroxymethyl)chroman-2-one 76 as a yellow solid (2.71 g, 55%);
1H NMR (600 MHz, DMSO-d6) δ 7.39 (d, 1 H, J=9.0 Hz H -6), 6.62 (dd, 1 H, J=9.0,
2.7 Hz, H -7), 6.48 (d, 1 H, J=2.7 Hz, H -9), 6.03 (s, 1 H, H -3), 5.51 (t, 1 H, J=5.6 Hz,
-OH ), 4.63 (d, 2 H, J=5.6 Hz, H -13), 3.38 (q, 4 H, J=7.2 Hz, H -11), 1.0 (t, 6 H, J=7
Hz, H -12); 13C NMR (150 MHz, DMSO-d6) δ 161.21(C-2), 156.97 (C-10), 155.64 (C-8),
150.16 (C-4), 125.11 (C-6), 108.53 (C-3), 105.64 (C-5), 103.80 (C-7), 96.73 (C-9), 59.05
(C-13), 43.99 (C-11), 12.17 (C-12); HRMS (CI) calcd for C14H17NO3 [M]+ 247.12084,
found 247.120289.
(7-(diethylamino)-2-oxochroman-4-yl)methyl carbonochloridate
(DEACMOC-Cl) 77219
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A solution of 7-(diethylamino)-4-(hydroxymethyl)chroman-2-one 76 (550 mg, 2.23
mmol) in dry THF (18 mL) was treated with DIPEA (522 µL, 3.34 mmol) and stirred
for 5 min at 0 ◦C. After the dropwise addition of 15% w/w phosgene (2.94 mL, 5.58
mmol), stirring was continued under the exclusion of light at 0 ◦C for 3 h. The reaction
mixture was transferred onto a mixture of ethyl acetate and water (1:1, 250 mL) and
the layers were separated and the organic layer was dried over MgSO4 and concentrated
in vacuo. The crude chloroformate 77 was was isolated as a yellow solid (656 mg,
95%) and was used in the next step without further purification. 1H NMR (600 MHz,
DMSO-d6) δ 7.41 (d, 1 H, J=9.0 Hz H -6), 6.62 (dd, 1 H, J=9.0, 2.7 Hz, H -7), 6.52
(d, 1 H, J=2.7 Hz, H -9), 6.01 (s, 1 H, H -3), 4.65 (d, 2 H, J=5.6 Hz, H -13), 3.41 (q,
4 H, J=7.2 Hz, H -11), 1.0 (t, 6 H, J=7 Hz, H -12); 13C NMR (150 MHz, DMSO-d6)
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δ 161.21(C-2), 156.97 (C-10), 155.64 (C-8), 150.16 (C-4), 148.23 (C-14) 125.11 (C-6),
108.53 (C-3), 105.64 (C-5), 103.80 (C-7), 96.73 (C-9), 59.05 (C-13), 43.99 (C-11), 12.17
(C-12); HRMS (CI) calcd for C15H16ClNO4 [M]+ 310.52084, found 310.520289.
4-N -[di-(2-nitrophenyl)ethoxycarbonyl]-5-azacytidine (Bis-NPEOC-AC) 59
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5-azacytidine 5 (150 mg, 0.61 mmol) was coevaporated with anhydrous pyridine (3
x 5 mL) and subsequently suspended into anhydrous DMF (10 mL) before adding
hexamethyldisilazane (650 µL, 3.11 mmol). After being stirred for 2 h at room tem-
perature, the solution was concentrated, and the residue was dried by three cycles of
evaporation from toluene (5 mL), followed by anhydrous pyridine (3 x 5 mL). The
resultant residue was subsequently suspended into anhydrous pyridine (30 mL) to
which chloroformate 58 (1.53 g, 6.69 mmol) in anhydrous CH2Cl2 (8 mL) was added
and the resultant mixture was stirred at room temperature overnight. The solvent
was removed under reduced pressure and the resultant residue was coevaporated with
toluene (3 x 10 mL) and suspended in anhydrous DMF (10 mL). Silyl deprotection was
achieved with the addition of tris(dimethylamino) sulfonium difluorotrimethylsilicate
(TAS-F)(600 mg, 2.17 mmol). After 2 h, the mixture was concentrated in vacuo and
the resultant residue was coevaporated with anhydrous toluene (3 x 5 mL). The crude
material was purified by flash chromatography (0-10% EtOH/DCM, 10% EtOH/DCM
Rf 0.58) to yield bis-NPEOC-AC 59 as a colourless film (56.9 mg, 15%). 1H NMR (600
MHz, DMSO-d6) δ 9.10 (s, 1 H, H -6), 7.93 (d, 2 H, J=8.2 Hz, H -3′′), 7.64 (td, 2 H,
J=7.6, 1.2 Hz, H -5′′), 7.51-7.48 (m, 4 H, H -4′′,H -6′′), 5.74 (d, 1 H, J=4.8 Hz, 3′-OH ),
5.68 (d, 1 H, J=1.4 Hz, H -1′), 5.34 (t, 1 H, J=4.6 Hz, 5′-OH ), 5.11 (d, 1 H, J=6.8
Hz, 2′-OH ), 4.46 (tt, 4 H, J=6.0, 2.9, Hz, H -8′′), 4.14 (dt, 1 H, J=4.7, 2.4 Hz, H -2′),
4.09 (dt, 1 H, J=7.0, 3.5, Hz, H -3′), 3.97 (dt, 1 H, J=7.8, 2.2 Hz, H -4′), 3.85 (ddd, 1
H, J=12.0, 4.5, 2.6 Hz, H -5′a), 3.64 (ddd, J=12.1, 4.4, 2.1 Hz, H -5′b), 3.18 (t, 4 H,
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J=6.2 Hz, H -7′′); 13C NMR (150 MHz, DMSO-d6) δ 163.59 (C-4), 159.03 (C-6), 152.66
(C-9′′), 150.16 (C-2), 149.31 (C-2′′), 133.36 (C-5′′), 132.67 (C-6′′), 131.78 (C-1′′), 128.134
(C-3′′), 118.14 (C-1′′), 91.24 (C-1′), 83.97 (C-4′), 74.02 (C-2′), 67.66 (C-8′′), 67.50
(C-3′), 58.86 (C-5′), 30.62 (C-7′′); IR vmax(oil): 3292 (O-H), 1755 (C=O NPEOC), 1520
(N-O) cm−1; HRMS (ESI) calcd for C26H26N6O13Na [M+Na]+ 653.1456, found 653.1456.
General synthesis of mono-N-tagged dAC and dC derivatives
5-aza-2′-deoxycytidine 6 (0.66 mmol) or 2′-deoxycytidine 7 (1 mmol) was dried after
three successive evaporations of a solution in anhydrous pyridine (5 mL). The residue
was dissolved in anhydrous DMF (10 mL) and treated with hexamethyldisilazane (2.5
eq). After 2 h of stirring at room temperature, the solution was concentrated and
the residue was dried by three cycles of evaporation from toluene (5 mL) followed by
anhydrous pyridine (3 x 5 mL) before finally being dissolved in anhydrous pyridine
(20 mL). To this, a solution of the relevant chloroformate (2 eq) in dry CH2Cl2 (8 mL)
was added and the mixture was left stirring overnight. The solution was concentrated
to dryness and traces of pyridine were removed by coevaporation with toluene (3 x
10 mL). The resultant residue was suspended in dry DMF (10 mL) and TAS-F (1.5
eq) was added to achieve silyl deprotection. After 2 h, the mixture was concentrated
in vacuo and the resultant residue was coevaporated with anhydrous toluene (3 x 5
mL). The crude material was purified by flash chromatography (0-10% MeOH/DCM)
to yield the title compounds.
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2′-Deoxy-4-N -[mono-(2-nitrophenyl)ethoxycarbonyl]-5-azacytidine
(mono-NPEOC-dAC) 60
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Isolated as a white foam (231 mg, 53%); 5% MeOH/DCM Rf 0.16; m.p. 46 ◦C to 48 ◦C;
1H NMR (600 MHz, DMSO-d6) δ 10.71 (br, 1 H, NH ), 8.81 (s, 1 H, H -6), 7.97 (dd, 1
H, J=8.1, 1.1 Hz, H -3′′), 7.67 (td, 1 H, J=7.6, 1.2 Hz, H -5′′), 7.60 (dd, 1 H, J=7.7,
1.1 Hz, H -6′′), 7.54-7.50 (m, 1 H, H -4′′), 5.98 (t, 1 H, J=5.1 Hz, H -1′), 5.36 (d, 1 H,
J=4.4 Hz, 3′-OH ), 5.19 (t, 1 H, J=5.1 Hz, 5′-OH ), 4.36 (t, 2 H, J=6.5 Hz, H -8′′),
4.25-4.22 (m, 1 H, H -3′), 3.87 (q, 1 H, J=3.7 Hz, H -4′), 3.64 (ddd, 1 H, J=12.0, 5.0,
3.5Hz, H -5′a), 3.57 (ddd, 1 H, J=12.0, 5.0, 3.5 Hz, H -5′b), 3.19-3.15 (m, 2 H, H -7′′),
2.30 (ddd, 1 H, J=13.3, 6.3, 4.8Hz, H -2′a), 2.20 (dt, 1 H, J=13.4, 5.9 Hz, H -2′b); 13C
NMR (150 MHz, DMSO-d6) δ 162.46 (C-4), 157.33 (C-6), 153.07 (C-9′′), 150.73 (C-2),
149.32 (C-2′′), 133.42 (C-5′′), 132.95 (C-6′′), 132.13 (C-1′′), 128.25 (C-4′′), 124.53 (C-3′′),
88.02 (C-4′), 86.36 (C-1′), 69.31 (C-3′), 64.38 (C-8′′), 60.42 (C-5′), 40.63 (C-2′), 31.41
(C-7′′); IR vmax(solid): 3291 (O-H), 2929 (N-H), 1756 (C=O NPEOC), 1681 (C=O
Aza), 1520 (N-O), 1435 (N-O), 1180 (C-O), 1050 (C-O) cm−1; HRMS (ESI) calcd for
C17H19N5O8 [M]− 420.1155, found 420.1135.
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2′-Deoxy-4-N -[mono-[2-(4,5-dimethoxy-2-nitrophenyl)]ethoxycarbonyl]-
5-azacytidine (mono-DMNPEOC-dAC) 64
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Isolated as a yellow foam (140 mg, 28%); 5% MeOH/DCM Rf 0.39; m.p. 106 ◦C to
108 ◦C. 1H NMR (600 MHz, DMSO-d6) δ 10.73 (br, 1 H, NH ), 8.82 (s, 1 H, H -6),
7.61 (s, 1 H, H -3′′), 7.05 (s, 1 H, H -6′′), 5.99 (t, 1 H, J=6.0 Hz, H -1′), 5.28 (d, 1 H,
J=4.4 Hz, 3′-OH ), 5.13 (t, 1 H, J=5.1 Hz, 5′-OH ), 4.37 (t, 2 H, J=6.5 Hz, H -8′′),
4.25-4.22 (m, 1 H, H -3′), 3.89 (s, 3 H, OCH 3), 3.88-3.87 (m, 1 H, H -4′), 3.84 (s,
3 H, OCH 3), 3.67-3.63 (m, 1 H, H -5′a), 3.59-3.53 (m, 1 H, H -5′b), 3.20 (t, 2 H,
J=6.5 Hz, H -7′′), 2.30 (ddd, 1 H, J=13.3, 6.3, 4.8 Hz, H -2′a), 2.21 (dt, 1 H, J=13.4,
5.9, Hz, H -2′b); 13C NMR (150 MHz, DMSO-d6) δ 163.46 (C-4), 157.35 (C-6), 152.74
(C-5′′), 150.69 (C-9′′), 147.28 (C-4′′), 141.00 (C-2′′), 127.37 (C-1′′), 114.75 (C-6′′), 108.06
(C-3′′), 88.07 (C-5′), 86.33 (C-1′), 69.32 (C-3′), 64.38 (C-8′′), 60.44 (C-5′), 56.25 (-OMe),
55.97 (-OMe), 40.64 (C-2′), 32.20 (C-7′′); IR vmax(solid): 3351 (O-H), 2944 (N-H), 1743
(C=O DMNPEOC), 1680 (C=O Aza), 1518 (N-O), 1461 (N-O), 1182 (C-O), 1060
(C-O) cm−1; HRMS (ESI) calcd for C19H22N5O10Na [M+Na]+ 480.1367, found 480.1369.
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2′-Deoxy-4-N -[mono-7-(diethylamino)-2-oxochroman-4-yl)methoxycarbonyl]-
5-azacytidine (N-DEACMOC-dAC) 78
N5
6
2
N 3
4
HN
ON
3' 2'
1'
O
4'
OH
5'HO
14'' O
13''
O
4''
3'' 2'' O1''
10''
5''
9''
8''
7''
6''
O
N
11''
12''
87
Isolated as a yellow solid (52 mg, 16%); 5% MeOH/DCM Rf 0.45); m.p. 148 ◦C to
150 ◦C. 1H NMR (600 MHz, DMSO-d6) δ 11.04 (br, 1 H, NH ), 8.86 (s, 1 H, H -6),
7.47 (d, 1 H, J=9.0 Hz, H -6′′), 6.70 (dd, 1 H, J=9.2, 2.4 Hz, H -7′′), 6.55 (d, 1 H,
J=2.4 Hz, H -9′′), 6.17 (s, 1 H, H -3′′), 6.00 (t, 1 H, J=6.3 Hz, H -1′), 5.37 (s, 2 H,
H -13′′), 5.29 (d, 1 H, J=4.4 Hz, 3′-OH ), 5.14 (t, 1 H, J=5.2 Hz, 5′-OH ), 4.25 (m, 1
H, H -3′), 3.87 (q, 1 H, J=3.8 Hz, H -4′), 3.65 (ddd, 1 H, J=11.7, 5.2, 3.6Hz, H -5′a),
3.57 (ddd, 1 H, J=11.7, 5.2, 3.6 Hz H -5′b), 3.43 (q, 4 H, J=7.2 Hz, H -11′′), 2.31 (ddd,
1 H, J=13.6, 6.5, 4.7 Hz, H -2′a), 2.22 (dt, 1 H, J=13.4, 5.9 Hz, H -2′b), 1.12 (t, 6
H, J=7.0 Hz, H -12′′); 13C NMR (150 MHz, DMSO-d6) δ 160.78 (C-2), 160.73 (C-2′′),
157.56 (C-10′′), 155.76 (C-8′′), 153.04 (C-4), 150.76 (C-14′′), 150.48 (C-6), 125.45 (C-6′′),
108.77 (C-3′′), 105.07 (C-5′′), 104.88 (C-7′′), 96.86 (C-9′′), 88.13 (C-4′), 86.43 (C-1′),
69.32 (C-3′), 61.99 (C-13′′), 60.45 (C-5′), 44.05 (C-11′′), 40.68 (C-2′), 12.32 (C-12′′); IR
vmax(solid): 3239 (O-H), 2942 (N-H), 1680 (C=O), 1072 (C-O) cm−1; HRMS (ESI)
calcd for C23H27N5O8Na [M+Na]+ 524.1757, found 524.1755.
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2′-Deoxy-4-N -[mono-7-(diethylamino)-2-oxochroman-4yl)methoxycarbonyl]
cytidine (N-DEACMOC-dC) 81
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Isolated as a yellow solid (400.1 mg, 80%); 5% MeOH/DCM Rf 0.48); m.p. 155 ◦C to
156 ◦C. 1H NMR (600 MHz, DMSO-d6) δ 11.07 (br, 1 H, NH ), 8.35 (d, 1 H, J=7.5
Hz, H -5), 7.47 (d, 1 H, J=9.0 Hz, H -6′′), 7.04 (d, 1 H, J=7.4 Hz, H -6), 6.70 (dd, 1 H,
J=9.1, 2.3 Hz, H -7′′), 6.55 (d, 1 H, J=1.7 Hz, H -9′′), 6.15 (s, 1 H, H -3′′), 6.11 (dd, 1
H, J=6.5, 6.2 Hz, H -1′), 5.39 (s, 2 H, H -13′′), 5.28 (d, 1 H, J=4.2 Hz, 3′-OH ), 5.06
(dd, 1 H, J=5.5, 5.0 Hz, 5′-OH ), 4.22-4.20 (m, 1 H, H -3′), 3.85 (ddd, 1 H, J=3.9,
3.6, 3.3 Hz, H -4′), 3.63-3.60 (m, 1 H, H -5′a), 3.56 (ddd, 1 H, J=11.8, 4.7, 4.5 Hz
H -5′b), 3.43 (q, 4 H, J=6.8 Hz, H -11′′), 2.28 (ddd, 1 H, J=13.2, 6.0, 3.8 Hz, H -2′a),
2.02 (dt, 1 H, J=13.4, 6.3 Hz, H -2′b), 1.12 (t, 6 H, J=7.1 Hz, H -12′′); 13C NMR (150
MHz, DMSO-d6) δ 160.76 (C-2), 160.76 (C-2′′), 155.77 (C-8′′), 154.32 (C-4), 153.21
(C-14′′), 152.58 (C-10′′), 150.49 (C-6), 145.00 (C-5), 125.41 (C-6′′), 108.77 (C-7′′), 105.07
(C-3′′), 104.88 (C-8′′), 96.87 (C-9′′), 94.11 (C-6) 87.91 (C-4′), 86.16 (C-1′), 69.95 (C-3′),
62.19 (C-13′′), 60.95 (C-5′), 44.05 (C-11′′), 40.16 (C-2′), 12.37 (C-12′′); IR vmax(solid):
3191 (O-H), 2926 (N-H), 1740 (C=O), 1642 (C=O Aza), 1604 (C=C), 1272 (C-N),
1063 (C-O) cm−1; HRMS (ESI) calcd for C24H29N4O8 [M+H]+ 501.1985, found 501.1986.
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2′-Deoxy-4-N -[mono-(2-nitrophenyl)ethoxycarbonyl]-cytidine
(N-NPEOC-dC) 80
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Isolated as a white foam (208 mg, 50%); 5% MeOH/DCM Rf 0.19; m.p. 57 ◦C to 58 ◦C.
1H NMR (600 MHz, DMSO-d6) δ 10.72 (br, 1 H, NH ), 8.29 (d, 1 H, J=7.5 Hz, H -5),
7.98 (d, 1 H, J=8.2 Hz, H -3′′), 7.68 (t, 1 H, J=7.4 Hz, H -5′′), 7.60 (dd, 1 H, J=7.7
Hz, H -6′′), 7.52 (t, 1 H, J=7.8 Hz, H -4′′), 6.98 (d, 1 H, J=7.5 Hz, H -6), 6.09 (dd, 1 H,
J=6.8, 6.1 Hz, H -1′), 5.27 (d, 1 H, J=4.2 Hz, 3′-OH ), 5.06 (t, 1 H, J=5.2 Hz, 5′-OH ),
4.39 (t, 2 H, J=6.5 Hz, H -8′′), 4.21-4.19 (m, 1 H, H -3′), 3.84 (q, 1 H, J=3.6 Hz, H -4′),
3.61-3.59 (m, 1 H, H -5′a), 3.57-3.54 (m, 1 H, H -5′b), 3.18 (t, 2 H, J=6.6 Hz, H -7′′b),
2.28-2.24 (m, 2 H, H -2′′a), 2.00 (ddd, 1 H, J=13.5, 6.8, 5.7 Hz, H -2′b); 13C NMR (150
MHz, DMSO-d6) δ 162.70 (C-4), 155.28 (C-2), 153.03 (C-9′′), 149.37 (C-4), 144.69
(C-5), 133.41 (C-5′′), 133.02 (C-6′′), 132.13 (C-2′′), 128.26 (C-4′′), 124.56 (C-3′′), 94.17
(C-6), 87.87 (C-4′), 86.05 (C-1′), 69.95 (C-3′), 64.54 (C-8′′), 60.97 (C-5′), 40.85 (C-2′),
18.61 (C-7′′), 157.33 (C-6), 153.07 (C-9′′), 149.32 (C-2′′), 133.42 (C-5′′), 132.95 (C-6′′),
132.13 (C-1′′), 128.25 (C-4′′), 124.53 (C-3′′), 88.02 (C-4′), 86.36 (C-1′), 69.31 (C-3′),
64.38 (C-8′′), 60.42 (C-5′), 40.63 (C-2′), 31.41 (C-7′′); IR vmax(solid): 3273 (O-H), 2931
(N-H), 1742 (C=O NPEOC), 1642 (C=O Aza), 1494 (N-O), 1342 (N-O), 1187 (C-O),
1054 (C-O) cm−1; HRMS (ESI) calcd for C18H20N4O8 [M+H]+ 421.1359, found 421.1349
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2′-Deoxy-4-N -[mono-carboxybenzoyl] cytidine (N-Cbz-dC) 85267
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Isolated as a pink solid (287 mg, 79%); 1H NMR (600 MHz, DMSO-d6) δ 10.83 (br, 1
H, NH ), 8.31 (d, 1 H, J=7.4 Hz, H -5), 7.42-7.38 (m, 4 H, H -1′′, H -2′′, H -5′′, H -7′′),
7.36-7.33 (m, 1 H, H -3′′), 7.04 (d, 1 H, J=7.3 Hz, H-5), 6.11 (t, 1 H, J=6.3 Hz, H -1′),
5.27 (d, 1 H, J=4.2 Hz, 3′-OH ), 5.18 (s, 2 H, H -7′′), 5.05 (t, 1 H, J=5.3 Hz, 5′-OH ),
4.22-4.20 (m, 1 H, H -3′), 3.85 (q, 1 H, J=3.7 Hz, H -4′), 3.61(ddd, 1 H, J=11.9, 5.5,
3.8 Hz, H -5′a), 3.56 (ddd, 1 H, J=11.9, 5.3, 4.0 Hz H -5′b), 2.27 (ddd, 1 H, J=13.4,
6.2, 3.9 Hz, H -2′a), 2.01 (ddd, 1 H, J=13.4, 6.7, 5.9 Hz, H -2′) b; 13C NMR (150 MHz,
DMSO-d6) δ 162.76 (C-2), 154.30 (C-4), 153.15 (C-8′′), 144.76 (C-6), 135.97 (C-6′′),
128.52 (C-1′′, C-5′′), 128.19 (C-2′′, C-5′′), 127.97 (C-3′′), 94.18 (C-5), 87.88 (C-4′), 86.08
(C-1′), 69.95 (C-3′), 66.52 (C-7′′), 60.97 (C-5′′), 40.87 (C-2′); HRMS (ESI) calcd for
C17H20N3O6 [M+H]+ 362.1352, found 362.1339.
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2′-Deoxy-5′-(2-nitrophenyl)ethoxycarbonyl-4-N -[mono-carboxybenzoyl] cy-
tidine (N-Cbz-5′-NPEOC-dC) 86
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Analogue 85 (100 mg, 0.28 mmol) was dried after three successive evaporations of a
solution in anhydrous pyridine (3 mL). The residue was dissolved in anhydrous pyridine
(3 mL) and was treated with chloroformate 58 (120 mg, 0.52 mmol) in anhydrous
CH2Cl2 (3 mL). After 5 h of stirring at room temperature, the solution was concentrated
and the residue was coevaporated with anhydrous toluene (3 x 3 mL). The residue was
diluted with water (15 mL) and the aqueous layer was back-extracted with CH2Cl2
(3x 50 mL). The organic layers were combined, dried and concentrated. The crude
was purified via flash column chromatography (0-10% MeOH/DCM) to yield the title
compound 86 (84 mg, 55%) as a white solid; m.p. 51 ◦C to 53 ◦C 1H NMR (600 MHz,
DMSO-d6) δ 10.86 (br, 1 H, NH ), 8.01 (d, 1 H, J=7.6 Hz, H -6), 7.95 (dd, 1 H, J=7.9,
1.4 Hz, H -18′′), 7.66 (td, 1 H, J=7.6, 1.4 Hz, H -16′′), 7.54 (dd, 1 H, J=7.7, 1.5 Hz,
H -15′′), 7.49 (td, 1 H, J=7.7, 1.5 Hz, H -17′′), 7.42-7.38 (m, 4 H, H -1′′, H -2′′, H -5′′,
H -7′′), 7.36-7.33 (m, 1 H, H -3′′), 7.04 (d, 1 H, J=7.5 Hz, H -5), 6.12 (t, 1 H, J=6.4
Hz, H -1′), 5.74 (d, 1 H, J=4.4 Hz, 3′-OH ), 5.20 (s, 2 H, H -7′′), 4.37 (t, 2 H, J=6.4
Hz, H -12′′), 4.29 (dd, 1 H, J=11.8, 3.6 Hz, H -5′a), 4.24 (dd, 1 H, J=11.8, 5.9 Hz,
H -5′b), 4.18 (dq, 1 H, J=6.3, 4.2 Hz, H -3′), 4.0 (dt, 1 H, J=5.9, 3.8 Hz, H -4′), 3.20
(t, 2 H, J=6.4 Hz, H -13′′), 2.29 (ddd, 1 H, J=13.6, 6.3, 4.2 Hz, H -2′a), 2.07 (dt, 1
H, J=13.6, 6.6 Hz, H -2′b); 13C NMR (150 MHz, DMSO-d6) δ 162.86 (C-2), 154.19
(C-4), 153.15 (C-8′′), 149.46 (C-9′′), 144.54 (C-6), 135.96 (C-6′′), 133.41 (C-15′′), 132.66
(C-19′′), 128.51 (C-1′′, C-5′′), 128.31 (C-16′′), 128.20 (C-2′′, C-5′′), 127.98 (C-3′′), 124.59
(C-18′′), 94.49 (C-5), 86.23 (C-4′), 84.08 (C-1′), 70.04 (C-3′), 67.33.97 (C-5′′), 67.18
(C-12′′), 66.56 (C-7′′), 48.63 (C-2′), 31.17 (C-13′′); IR vmax(solid): 3297 (O-H), 2922
(N-H), 1738 (C=O), 1644 (C=O), 1494 (N-O), 1192 (C-O), 1091 (C-O) cm−1; HRMS
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(ESI) calcd for C26H27N4O10 [M+H]+ 555.1727, found 555.1718.
2′-Deoxy-5′-[(2-aminophenyl)ethoxycarbonyl]-cytidine (5-APEOC-dC) 87
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Palladium on activated carbon (10 wt%, 10 mg, 0.009 mmol) was added to a stirred
solution of compound 86 (50 mg, 0.09 mmol) in anhydrous methanol (5 mL) under
inert atmosphere. The reaction flask was evacuated and flushed with H2. The resulting
mixture was stirred at room temperature for 1 h. After completion of the reaction, the
catalyst was filtered through a pad of celite and the filter was washed with methanol
(10 mL). The filtrate was concentrated under reduced pressure to obtain 87 as a white
film (33 mg, 94%). 1H NMR (600 MHz, DMSO-d6) δ 7.79 (d, 1 H, J=7.4 Hz, H -5), 7.13
(d, 1 H, J=35.2 Hz, dC–NH2), 6.93-6.86 (m, 2 H, H -4′′, H-5′′), 6.60 (dd, 1 H, J=12.1,
7.7 Hz, H -3′′), 6.47 (q, 1 H, J=7.1 Hz, H -6′′), 6.15 (t, 1 H, J=6.5 Hz, H -1′), 5.71 (d, 1
H, J=7.4 Hz, H -5), 4.95 (b, 1 H, -NH 2), 4.82 (s, 1 H, 3′-OH ), 4.20 (t, 1 H, J=7.1 Hz,
H -3′), 4.2-4.05 (m, 2 H, H -5′), 3.56- 3.52 (m, 1 H, H -4′), 2.78 (t, 2 H, J=7.1 Hz, H -8′′),
2.58 (t, 2 H, J=7.0 Hz, H -7′′), 2.11-2.08 (m, 1 H, H2′a), 1.96-1.90 (m, 1 H, H2′b); 13C
NMR (150 MHz, DMSO-d6) δ 165.56 (C-4), 155.27 (C-2), 146.50 (C-2′′), 141.00 (C-6),
130.06 (C-1′′), 127.34 (C-4′′), 126.65 (C-5′′), 123.15 (C-9′′), 116.17 (C-6′′), 114.77 (C-3′′),
93.94 (C-5), 87.21 (C-4′), 84.86 (C-1′), 70.43 (C-5′), 66.15 (C-3′), 40.38 (C-2′), 34.63 (C-
8′′), 30.06 (C-7′′); HRMS (ESI) calcd for C18H22N4O6 [M+H]+ 391.3960, found 391.3553.
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2′-Deoxy-5′-[7-(diethylamino)-2-oxochroman-4-yl)methoxycarbonyl]-4-N -[mono-
carboxybenzoyl] cytidine (N-Cbz-5′-DEACMOC-dC) 88
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Analogue 85 (237 mg, 0.66 mmol) was dried after three successive evaporations of a
solution in anhydrous pyridine (3 mL). The residue was dissolved in anhydrous pyridine
(3 mL) and was treated with chloroformate 77 (600 mg, 1.94 mmol) in anhydrous
CH2Cl2 (3 mL). After overnight stirring at room temperature, the solution was con-
centrated and the residue was coevaporated with anhydrous toluene (3 x 3 mL). The
residue was diluted with water (15 mL) and the aqueous layer was back-extracted with
CH2Cl2 (3x 50 mL). The organic layers were combined, dried and concentrated. The
crude was purified via flash column chromatography (0-10% MeOH/DCM) to yield
compound 88 (15 mg, 3.5%) as a yellow film. Identity of the product was confirmed
via LC-MS. The analogue was not submitted for full NMR characterization in order to
have enough material for the next hydrogenation step.
Hyrogenation of (N-Cbz-5′-DEACMOC-dC) 88
Palladium on activated carbon (10 wt%, 2.1 mg, 0.002 mmol) was added to a stirred
solution of compound 88 (14.7 mg, 0.02 mmol) in anhydrous methanol (3 mL) under
inert atmosphere. The reaction flask was evacuated and flushed with H2. The resulting
mixture was stirred at room temperature for 1 h. No product was detected using this
method even after 24 h.
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2′-Deoxy-5′-[7-(diethylamino)-2-oxochroman-4yl)methoxycarbonyl]-thymidine
(5-DEACMOC-dT) 83
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Thymidine 82 (74 mg, 0.3 mmol) was dried after three successive evaporations of a
solution in anhydrous pyridine (3 mL). The residue was dissolved in anhydrous pyridine
(3 mL) and was treated with chloroformate 77 (124 mg, 0.4 mmol) in anhydrous CH2Cl2
(3 mL). After overnight stirring at room temperature, the solution was concentrated
and the residue was coevaporated with anhydrous toluene (3 x 3 mL). The residue was
diluted with water (15 mL) and the aqueous layer was back-extracted with CH2Cl2
(3x 50 mL). The organic layers were combined, dried and concentrated. The crude
was purified via flash column chromatography (0-10% MeOH/DCM) to yield the title
compound 83 (48 mg, 31%) as an orange solid; m.p. 105 ◦C to 108 ◦C. 1H NMR (600
MHz, DMSO-d6) δ 11.32 (br, 1 H, NH ), 7.46 (d, 1 H, J=7.4 Hz, H -6), 7.45 (s, 1 H,
H -6′′), 6.69 (dd, 1 H, J=9.1, 2.6 Hz, H -9′′), 6.55 (d, 1 H, J=2.5 Hz, H -7′′), 6.20 (t,
1 H, J=6.9 Hz, H -1’), 5.97 (s, 1 H, H -3′′), 5.47 (d, 1 H, J=4.4 Hz, 3′-OH ), 5.37 (d,
1 H, J=4.4 Hz, H -13′′), 4.39-4.33 (m, 2 H, H -5′), 4.26 (ddt, 1 H, J=6.5, 4.4, 3.8 Hz,
H -4′), 3.95 (dt, 1 H, J=5.8, 3.8 Hz, H -4′), 3.43 (q, 4 H, J=7.1 Hz, H -11′′), 2.18 (dt,
1 H, J=13.7, 6.9 Hz, H -2′a), 2.10 (ddd, 1 H, J=13.6, 6.6, 3.9 Hz, H -2′b), 1.71 (d, 1
H, J=1.1 Hz, H -7), 1.11 (t, 6 H, J=7.0 Hz, H -12′′); 13C NMR (150 MHz, DMSO-d6)
δ 163.67 (C-4), 160.53 (C-2′′), 155.88 (C-10′′), 154.02 (C-14′′), 150.54 (C-2), 150.41
(C-8′′), 149.79 (C-4′′), 135.85 (C-6), 125.60 (C-6′′), 109.81 (C-5), 108.80 (C-7′′), 105.42
(C-3′′), 105.11 (C-5′′), 96.88 (C-9′′), 83.87 (C-1′), 83.37 (C-4′), 70.06 (C-3′), 67.91 (C-5′),
64.85 (C-13′′), 44.04 (C-11′′), 36.59 (C-2′), 12.34 (C-7), 12.11 (C-12′′);IR vmax(solid):
3412 (O-H), 2961 (N-H), 1752 (C=O DEACMOC), 1681 (C=O Aza), 1257 (C-O), 1076
(C-O) cm−1; HRMS (ESI) calcd for C25H30N3O9 [M+H]+ 516.1982, found 516.1986.
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[(7-(diethylamino)-2-oxochroman-4-yl)methyl(perfluorophenyl)] carbonate
(DEACMOC-PFP) 90
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A solution of 7-(diethylamino)-4-(hydroxymethyl)chroman-2-one 76 (300 mg, 1.2 mmol)
in dry THF (10 mL) was treated with DIPEA (261 µL, 1.5 mmol) and stirred for
5 min at 0 ◦C. Bis(pentafluorophenyl)carbonate (956 mg, 2.4 mmol) was added and
stirring was continued at room temperature under the exclusion of light overnight. The
reaction mixture was transferred onto a mixture of ethyl acetate and water (1:1, 200
mL) and the layers were separated and the organic layer was dried over MgSO4 and
concentrated in vacuo. The crude was purified via flash column chromatography (neat
CH2Cl2) to obtain DEACMOC-PFP 90 as a yellow oil (518 mg, 94%); m.p. 113 ◦C
to 114 ◦C; 1H NMR (600 MHz, CDCl3) δ 7.29 (d, 1 H, J=9.0 Hz H -6), 6.61 (dd, 1 H,
J=9.0, 2.6 Hz, H -7), 6.53(d, 1 H, J=2.7 Hz, H -9), 6.22 (t, 1 H, J=1.1 Hz, H -3), 5.44
(d, 1 H, J=1.1 Hz, H -13), 3.43 (q, 4 H, J=7.2 Hz, H -11), 1.22 (t, 6 H, J=7.1 Hz, H -12);
13C NMR (150 MHz, CDCl3) δ 161.97(C-2), 156.45 (C-10), 151.18 (C-14), 151.05 (C-8),
147.41 (C-4), 124.35 (C-6), 109.02 (C-7), 106.95 (C-3), 105.53 (C-5), 98.00 (C-9), 66.97
(C-13), 44.93 (C-11), 12.52 (C-12); IR vmax(solid): 1782 (C=O), 1722 (C=O), 1513
(C=C), 1234 (C-F) cm−1 LRMS (ESI) calcd for C21H16F5NO5 [M+H]+ 457.3530, found
457.3511.
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2′-Deoxy-5′-[7-(diethylamino)-2-oxochromn-4-yl)methoxycarbonyl]-
5-azacytidine (5′-DEACMOC-dAC) 84
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5-aza-2′-deoxycytidine 6 (157 mg, 0.69 mmol), DEACMOC-PFP 90 (518 mg, 1.13
mmol) and DMAP (4 mg, 0.03 mmol, 0.04 eq) were dissolved in anhydrous DMF (6
mL) and stirred at room temperature for 24 h under inert atmosphere. After 24 h,
the reaction mixture was concentrated and coevaporated with anhydrous toluene (3
x 3 mL). The residue was dissolved in CH2Cl2 (50 mL) and washed with water. The
organic layer was dried and concentrated in vacuo. The crude onto was dry-loaded
onto and purified via flash column chromatography (0-10% MeOH/CH2Cl2) to yield
the title compound 84 (76 mg, 22%) as a yellow solid. m.p. 145 ◦C to 147 ◦C 1H NMR
(600 MHz, DMSO-d6) δ 8.30 (s, 1 H, H -6), 7.59 (d, 2 H, J=11.0 Hz, aza-NH 2), 7.47
(dd, 1 H, J=14.2, 9.1 Hz, H -6′′), 6.71 (ddd, J=10.5, 9.1, 2.6 Hz, H -7′′), 6.55 (t, 1 H,
J=2.8 Hz, H -9′′), 6.04 (t, 1 H, J=6.7 Hz, H -1′), 6.01 (d, 1 H, J=2.5 Hz, H -3′′), 5.46 (d,
1 H, J=4.5 Hz, 3′-OH ), 5.36 (d, 2 H, J=3.2 Hz, H -13′′), 4.39 (dd, 1 H, J=11.6, 3.7 Hz,
H -5′a), 4.34 (dd, 1 H, J=11.6, 6.4 Hz, H -5′b), 4.37 (dq, 1 H, J=6.6 Hz, H -3′), 4.00 (dt,
1 H, J=6.3, 4.1 Hz, H -4′), 3.43 (qd, 4 H, J=7.1, 2.6 Hz, H -11′′), 2.30 (dt, 1 H, J=13.6,
6.6 Hz, H -2′a), 2.21 (ddd, 1 H, J=13.6, 6.7, 4.6 Hz, H -2′b), 1.12 (td, 6 H, J=7.1, 2.5 Hz,
H -12′′); 13C NMR (150 MHz, DMSO-d6) δ 165.85 (C-2), 160.66 (C-2′′), 156.13 (C-10′′),
155.86 (C-6), 153.97 (C-4), 153.44 (C-14′′), 152.94 (C-4′′), 150.56 (C-8′′), 125.60 (C-6′′),
108.85 (C-7′′), 105.33 (C-5′′), 105.10 (C-3′′), 96.88 (C-9′′), 84.94 (C-1′), 83.90 (C-4′),
70.06 (C-3′), 67.93 (C-5′), 64.83 (C-13′′), 44.04 (C-11′′), 40.07 (C-2′), 12.34 (C-12′′);
IR vmax(solid): 3392 (O-H), 3211 (N-H), 3085 (N-H), 1758 (C=O DEACMOC), 1711
(C=O Ar DEACMOC), 1682 (C=O Ar), 1599 (C=C), 1255 (C-O Ar), 1197 (C-O), 1048
(C-O) cm−1; HRMS (ESI) calcd for C23H28N5O8 [M+H]+ 502.1938, found 502.1917.
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2′-Deoxy-5′-(triisopropylsilyl)-5-azacytidine (5′-TIPS-dAC) 91
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To a stirred, cooled solution of 5-aza-2′-deoxycytidine 6 (150 mg, 0.66 mmol), imidazole
(98 mg, 1.45 mmol) and DMAP (8 mg, 0.07 mmol) in anhydrous DMF (4 mL) was
added a solution of triisopropyl silyl chloride (154 µL, 0.72 mmol) in anhydrous DMF
(2 mL). The mixture was stirred for 1 h at 0 ◦C and overnight at room temperature.
The crude was concentrated and purified via flash column chromatography (0-5%
MeOH/CH2Cl2) to obtain the title compound 91 as a white solid (133 mg, 52%); m.p.
179 ◦C to 180 ◦C; 1H NMR (600 MHz, DMSO-d6) δ 8.38 (s, 1 H, H -6), 7.51 (d, 2 H,
, J=14.0 Hz, -NH 2), 6.04 (t, 1 H, J=6.4 Hz, H -1′), 5.28 (d, 1 H, J=4.4 Hz, 3′-OH ),
4.27 (m, 1 H, H -3′′), 3.91-3.87 (m, 1 H, H -5′a), 3.88-3.86 (m, 1 H, H -4′), 3.83-3.80 (m,
1 H, H -5′b), 2.26 (ddd, 1 H, J=13.5, 6.6, 4.1 Hz, H -2′a), 2.21 (ddd, 1 H, J=13.6, 6.4,
6.4 Hz, H -2′b), 1.14-1.08 (m, 3 H, H -6′), 1.04 (d, 18 H, J=7.0 Hz, H -7′); 13C NMR
(150 MHz, DMSO-d6) δ 165.96 (C-2), 155.38 (C-6), 153.03 (C-4), 84.30 (C-1′), 85.14
(C-4′), 69.78 (C-3′), 63.10 (C-5′), 40.63 (C-2′), 17.67 (C-7′), 11.34 (C-6′); IR vmax(solid):
3343 (O-H), 2942 (N-H), 2865 (N-H), 1638 (C=O Aza), 1289 (Si-C), 1090 (Si-O), 1062
(C-O), 1008 (C-O) cm−1; HRMS (ESI) calcd for C17H32N4O4Si [M+H]+ 384.21928,
found 384.55200.
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2′-Deoxy-3′-(7-(diethylamino)-2-oxochromn-4-yl)methoxycarbonyl)-5′-
(triisopropylsilyl)-5-azacytidine (3′-DEACMOC-5′-TIPS-dAC) 92
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To a stirred solution of compound 91 (364 mg, 0.94 mmol) and DMAP (11 mg, 0.09
mmol) in anhydrous DMF (4 mL) was added a solution of 7 (340 mg, 0.74 mmol) in
anhydrous DMF (4 mL) at 0 ◦C. The mixture was stirred for 6 h and was concentrated
in vacuo. Traces of DMF were removed via coevaporation with toluene (3 x 3 mL).
The crude was purified via flash column chromatography (0-5% MeOH/CH2Cl2) to
obtain compound 92 as a yellow solid (191 mg, 31%); m.p. 82 ◦C to 84 ◦C; 1H NMR
(600 MHz, DMSO-d6) δ 8.35 (s, 1 H, H -6), 7.62 (d, 2 H, J=20.1 Hz, aza-NH 2), 7.48
(d, 1 H, J=9.1 Hz, H -6′′), 6.71 (dd, J=9.2, 2.6 Hz, H -7′′), 6.56 (d, 1 H, J=2.5 Hz,
H -9′′), 6.05 (dd, 1 H, J=7.8, 6.2 Hz, H -1′), 6.02 (s, 1 H, H -3′′), 5.36 (s, 2 H, H -13′′),
5.24 (dt, 1 H, J=6.5, 2.3 Hz, H -3′), 4.25 (q, 1 H, J=3.0 Hz, H -4′), 3.92 (dd, 1 H,
J=11.1, 3.75 Hz, H -5′a), 3.87 (dd, 1 H, J=11.2, 3.9 Hz, H -5′b), 3.43 (dt, 4 H, J=7.6,
6.8 Hz, H -11′′), 2.58 (ddd, 1 H, J=14.3, 5.9, 2.4 Hz, H -2′a), 2.40 (ddd, 1 H, J=14.5,
7.6, 6.5 Hz, H -2′b), 1.12 (t, 6 H, J=7.0 Hz, H -12′′), 1.12-1.05 (m, 3 H, H-6′), 1.01
(d, 18 H, J=6.9 Hz, H -7′).; 13C NMR (150 MHz, DMSO-d6) δ 165.90 (C-2), 160.56
(C-2′′), 155.93 (C-10′′), 155.43 (C-6), 153.36 (C-4), 153.36 (C-14′′), 152.86 (C-4′′), 150.55
(C-8′′), 125.72 (C-6′′), 108.82 (C-7′′), 105.84 (C-5′′), 105.21 (C-3′′), 96.87 (C-9′′), 85.48
(C-1′), 84.60 (C-4′), 65.06 (C-3′), 63.83 (C-5′), 63.39 (C-13′′), 44.04 (C-11′′), 39.38 (C-2′),
17.61 (C-6′), 12.34 (C-12′′), 11.26 (C-7′); IR vmax(solid): 2941 (N-H), 2865 (N-H), 1711
(C=O), 1600 (C=O), 1246 (Si-C), 1196 (C-O), 1126 (C-O), 1065 (Si-O) cm−1; HRMS
(ESI) calcd for C32H47N5O8Si [M+H]+ 658.3267, found 658.3268.
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2′-Deoxy-3′-(7-(diethylamino)-2-oxochromn-4-yl)methoxycarbonyl)-
5-azacytidine (3′-DEACMOC-dAC) 93
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To a stirred solution of compound 92 (87 mg, 0.13 mmol) in dry methanol (3 mL),
acetyl chloride (20 µL, 0.28 mmol) was added under inert atmosphere. The mixture was
stirred at room temperature for 3 h in the dark. It was then partially concentrated and
diluted with CH2Cl2 (20 mL) and neutralised with 10% sodium bicarbonate solution.
The organic layer was washed with water (10 mL), dried and concentrated. The
crude was purified via flash column chromatography (0-8% MeOH/CH2Cl2) to obtain
compound 93 (36.4 mg, 56%) as a yellow solid; m.p. 167 ◦C to 170 ◦C 1H NMR (600
MHz, DMSO-d6) δ 8.47 (s, 1 H, H -6), 7.59 (dd, 2 H, J=13.7, 2.3 Hz, aza-NH 2), 6.72
(dd, 1 H, J=9.1, 2.6 Hz, H -6′′), 6.56 (dd, J=9.2, 2.6 Hz, H -7′′), 6.56 (d, 1 H, J=2.5 Hz,
H -9′′), 6.05 (dd, 1 H, J=8.1, 6.0 Hz, H -1′), 6.02 (s, 1 H, H -3′′), 5.36 (s, 2 H, H -13′′),
5.22 (t, 1 H, J=5.3 Hz, H -3′), 4.17 (q, 1 H, J=3.8, 2.0 Hz, H -4′), 3.64 (m, 2 H, H -5′),
3.43 (q, 4 H, J=7.1 Hz, H -11′′), 2.43 (ddd, 1 H, J=14.3, 8.3, 6.1 Hz, H -2′b), 1.12
(t, 6 H, J=7.1 Hz, H -12′′); 13C NMR (150 MHz, DMSO-d6) δ 165.66 (C-2), 160.59
(C-2′′), 156.02 (C-10′′), 155.90 (C-6), 153.44 (C-4), 153.03 (C-14′′), 150.56 (C-4′′), 149.68
(C-8′′), 125.66 (C-6′′), 106.66 (C-7′′), 105.66 (C-5′′), 105.18 (C-3′′), 96.88 (C-9′′), 85.40
(C-1′), 84.94 (C-4′), 79.26 (C-3′), 64.95 (C-5′), 61.25 (C-13′′), 44.05 (C-11′′), 37.53 (C-2′),
12.34 (C-12′′); IR vmax(solid): 3433 (O-H), 3081 (N-H), 2969 (N-H), 1711 (C=O), 1666
(C=O), 1600 (C=C), 1252 (C-N), 1196 (C-O), 1098 (C-O) cm−1; HRMS (ESI) calcd
for C23H27N5O8 [M+H]+ 502.1932, found 502.1929.
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To a stirred solution of dAC 6 (100 mg, 0.44 mmol) in dry pyridine (3 mL), dimethoxytrityl
chloride (153 mg, 0.45 mmol) was added under inert atmosphere. The mixture was
stirred at room temperature overnight in the dark. The solution was then concentrated
and the crude was purified via flash chromatography (0-7% MeOH/CH2Cl2) to obtain
compound 97 (122 mg, 52%) as a white solid. 1H NMR (600 MHz, DMSO-d6) δ 8.56
(s, 1 H, H -6), 7.39-7.21 (m, 9H, H -8′, H -9′, H -10′), 6.88 (d, 2 H, J=8.9 Hz, -NH 2),
6.04 (t, 1 H, J=6.4 Hz, H -1′), 5.33 (d, 1H, J=4.4 Hz, H -5), 4.25-4.22 (m, 1H, H -4′),
3.94-3.92 (m, 1H, H -3′), 3.73 (s, 6H, H -15′), 3.22-3.14 (m, 2H, H -5′), 2.25-2.23 (m, 2H,
H -2′); 13C NMR (150 MHz, DMSO-d6) δ 165.52 (C-4), 157.36 (C-14′), 155.24 (C-2),
143.64 (C-6), 143.53 (C-7′), 136.25 (C-11′), 129.2-128.3 (C-8′, C-9′, C-10′, C-12′), 113.53
(C-13′), 94.32 (C-5), 93.25 (C-6′), 87.94 (C-4′), 70.34 (C-3′), 63.24 (C-5′), 54.25 (C-15′),
40.43 (C-2′); Measurements are in line with literature reported values.255
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A.3 Cell biology experiments
A.3.1 Cell lines and reagents
The Saos-2 human osteosarcoma cell line was obtained from the laboratory of Dr
Sandra Strauss (UCL Cancer Institute). The T24 human bladder, A549 human lung
cell carcinoma and HEK293T human embryonic kidney cell lines were received from
Dr Andrew Feber and Dr Anna Köferle (UCL Cancer Institute). All cell lines were
grown as adherent monolayers in respected cell culture media, supplemented with
10% foetal bovine serum (Gibco, #10500-064) on uncoated tissue culture plasticware.
Saos-2, T24 and A549 cells were grown in RPMI-1640 medium (Lonza, #12-702F) and
HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco,
#12491-015). All cells were maintained at 37 ◦C with 5% CO2.
A.3.2 Cell culture
Cell passaging
30 min prior to passaging, aliquots of Trypsin-EDTA (Sigma, #T4049) and the relevant
growth media were prewarmed in a 37 ◦C water bath and Dubbleco’s Phosphate-buffered
Saline (DBPS, Gibco, #14190136) solution was allowed to reach room temperature. A
small volume of old media was aliquoted into a 15 mL falcon tube (2 mL from T25
flasks, 7 mL from T75 and 10 mL from T125 flasks). After aspiration of the leftover
growth media, the plate containing the cells was gently washed with DBPS, avoiding
to disrupt the cell layer. The remining DBPS was aspirated and pre-warmed trypsin
(1 mL for T25 flask, 4 mL for T75 flask and 10 mL for T125 flask) was added. The
trypsin was evenly distributed by gently tilting the flask and the flask was placed into
an incubator (37 ◦C, 5% CO2) for a maximum of 5 min.
The detached cells were then resuspended in the old media (that was aliquoted
previously) and the suspension was transferred to a new 15 mL falcon tube (50 mL
in case the volume exceeded 12 mL). The tubes were spun down for 3 min at 1200
rpm to pellet the cells. The remaining supernatant was discarded and the pellet
was resuspended in fresh growth media. The suspension of cells was then split 1:5
(depending on their confluency and growth rate) in new flasks (T25, T75 or T125) and
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pre-warmed growth media were added for the appropriate flasks size (5 mL for T25, 15
mL for T75 and 25 mL for T125 flasks).
Cell freezing
Cells were detached and pelleted as described in the previous section. Instead of adding
fresh growth medium, the pellets were resuspended in freezing medium (10% DMSO to
growth medium). 0.8 mL of the resulting cell suspension was transferred to a cryovial
and was immediately placed on dry ice for 10 min before being transferred to the
−80 ◦C freezer overnight and to liquid nitrogen for long-term storage.
Cell counting
In order to calculate accurate seeding densities, cell numbers were determined using a
Vi-Cell XR (Beckman Coulter) automated cell viability analyser. This method uses
the tryptan blue exclusion method to count cells within a 500 µL volume.
A.3.3 Photocaged azanucleoside treatments
Preparation of treatment stocks
Photocaged azanucleosides (3′-DEACMOC dAC 93 or 5′-DEACMOC-dAC 84) were
dried under high vaccuum for 2 x 8 h to remove any residual solvent. Stocks of
photocaged analogues and commercially available dAC were prepared at 10 mm in
DMSO (between 500 and 1000 µL, in MS vials). The concentration of each stock
was confirmed by HPLC. The stocks were stored at 4 ◦C until further dilution for cell
studies.
Preparation of cells, treatment and irradiation
Cells were seeded into 10 cm TC-treated plates (Corning, #430167) at an initial
density of 1 x 105 cells/plate. For each treatment set per cell line, at least 36 cell plates
were prepared to account for the different concentrations (0.1 - 1.5 µM), analogues
(dAC, photocaged dAC), conditions (irradation or control) and triplicates (Table A.2).
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The cells were allowed to grow to about 70-80% confluency before the treatment
administration 72 h after seeding.
Table A.2 outlines the overall treatmant plan for one set of cell experiments for one cell
line. Groups A/B/C corresponded to triplicates. Due to the limited space in the UV
irradiating cabinet (4 plates), groups A/B/C were treated and irradiated 1 h apart.
Plateno.
Group
A
Group
B
Group
C
1 Media UV Media UV Media UV
2 0.1 µM CD UV 0.1 µM CD UV 0.1 µM CD UV
3 0.5 µM CD UV 0.5 µM CD UV 0.5 µM CD UV
4 1.5 µM CD UV 1.5 µM CD UV 1.5 µM CD UV
5 Media/DMSO Media/DMSO Media/DMSO
6 0.1 µM CD 0.1 µM CD 0.1 µM CD
7 0.5 µM CD 0.5 µM CD 0.5 µM CD
8 1.5 µM CD 1.5 µM CD 1.5 µM CD
9 Media Media Media
10 0.1 µM dAC 0.1 µM dAC 0.1 µM dAC
11 0.5 µM dAC 0.5 µM dAC 0.5 µM dAC
12 1.5 µM dAC 1.5 µM dAC 1.5 µM dAC
Table A.2 Plate setup for dAC and photocaged dAC cell treatments
The following process was repeated three times for each treatment group: 30 min prior
to treatment, the relevant cell culture media (RPMI-1640 or DMEM) was warmed to
37 ◦C in a water bath. Treatment dilutions were prepared in 50 mL falcon tubes as
described in Table A.3.
Tubeno.
Treatment
condition
Stock/solution
added
Fresh Media
(mL)
Final Volume
(mL)
1 DMSO/Media 4.5 µL DMSO 30 30
2 1.5 µM dAC 4.5 µL of 10 mM dAC stock 30 21
3 0.5 µM dAC 9 mL of 1.5 µM dAC (2) 18 22
4 0.1 µM dAC 5 mL of 0.5 µM dAC (3) 20 25
5 1.5 µM CD 4.5 µL of 10 mM CD stock 30 21
6 0.5 µM CD 9 mL of 1.5 µM CD (5) 18 22
7 0.1 µM CD 5 mL of 0.5 µM CD (6) 20 25
Table A.3 Preparation of treatment dilutions for cell experiments
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After the dilutions were prepared, the plates were taken out of of the 37 ◦C incubator
and the old media was aspirated away. The prepared treatment solutions were placed
into each plate (10 mL per plate) and plates 1-4 (refer to table A.3) were placed in the
UV cabinet and irradiated for 1 h at λ = 365 nm. The remaining plates (5-12) were
placed back into the incubator. After 1 h, the irradiated plates (1-4) were also placed
back into the incubator.
The cells were harvested 24 h after treatment. Aliquots of the old media (7 mL) were
withdrawn from each plate. The remaining old media was aspirated away and the cells
were washed with DPBS (7 mL). After removal of the DBPS, pre-warmed trypsin was
added (3 mL) and the plates were incubated for 1-3 min at 37 ◦C. The trypsinised
cells were transferred to 15 mL falcon tubes together with the 7 mL old media aliquots
taken previously and were spun down for 4 min at 1200 rpm. The supernatant was
discarded and the cell pellets were used immediately or were stored at −20 ◦C until
further analysis.
Preparation of samples for global DNA Methylation analysis
Cell pellets from photocaged azanucleoside treatments were either used immediately
or were defrosted to room temperature from −20 ◦C. Genomic DNA from cell pellets
were purified using DNeasy Blood & Tissue Kit (Qiagen; #69504), according to
manufacturer’s instructions.
The cells were resuspended in PBS (200 µL) and proteinase K (20 µL) and RNAse
A (4 µL, 100 mg/mL, Qiagen, #19101) were added and the samples were vortexed
and incubated for 2 min at room temperature. Buffer AL (200 µL) was added and the
samples were thoroughly mixed incubated at 56 ◦C for 10 min with continuous rotation.
Absolute ethanol (200 µL) was added to each sample and after vortexing, the solutions
were transferred into a DNeasy Mini spin column equipped with a collection tube. The
samples were centrifuged at 8000 rpm for 1 min and the collection tube was discarded.
The samples were subsequently washed with Buffer AW1 (500 µL) and Buffer AW2
(500 µL). After each buffer wash, the samples were centrifuged either at 8000 rpm for
1 min or 16000 rpm for 3 min. In order to maximise the amount of DNA extracted,
we modified the centrifugation times to 3 min and 5 min respectively. As a final step,
genomic DNA was eluted in RNAse free water (100 µL) and were collected in clean,
labelled eppendorf tubes.
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The DNA concentration was determined using the Qubit dsDNA HS Assay Kit following
the manufacturer’s protocol. The samples were then sent to Cambridge for LC-MS/MS
analysis to determine the %5mC content of purified genomic DNA samples.
Preparation of samples for Western blot analysis
Cells were washed with cold PBS, counted, resuspended and lysed in an appropriate
volume of lysis buffer (CelLytic M, #C2978 containing 50x Pierce Protease inhibitor,
#88666) with continuous rotation for 15 min at 4 ◦C. Samples were spun down for 15
min at 16 000 g, 4 ◦C. The supernatant was transferred to a fresh Eppendorf tube and
the protein concentration was determined by the Bradford Assay.
A.3.4 Global methylation analysis via LC-MS/MS
LC-MS/MS analysis was performed by Dr Shiqing Mao (Department of Chemistry,
University of Cambridge) as follows: 500 ng of genomic DNA was incubated with
5 U of DNA Degradase Plus (Zymo Research; # E2020) at 37 ◦C for 3 h. The
resulting mixture of 2′-deoxynucleosides was analysed on a Triple Quad 6500 mass
spectrometer (AB Sciex) fitted with an Infinity 1290 LC system (Agilent) and an
Acquity UPLC HSS T3 column (Waters), using a gradient of water and acetonitrile
with 0.1% formic acid. External calibration was performed using synthetic standards,
and for accurate quantification, all samples and standards were spiked with isotopically
labelled nucleosides.
A.3.5 Statistical analysis of methylation values
Cellular DNA methylation values (% 5mC) were expressed as mean ± SD. To verify a
between treatment difference, a two-tailed Student’s t-test was performed.
A.3.6 Methylation analysis via the Infinium 450K BeadChip
For DNA methylation analysis, 500 ng of each genomic DNA (gDNA) sample was
bisulfite converted using an EZ DNA Methylation kit (Zymo Research, #D5001) and
eluted in 12 µL of M-Elution buffer. 4 µL were used as input per array of the Infinium
450K BeadChip and processed by the UCL Genomics microarray facility according to
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the manufacturer’s protocol. Raw data files were uploaded to R and analysed using the
Chip Analysis Methylation Pipeline (ChAMP), available from Bioconductor. Probes
were filtered for a detection p-value < 0.01, leaving 483,824 probes in the final dataset.
Finally, the data was normalized using the SWAN method.
A.3.7 Reagents for western blot analysis
SDS PAGE Gel (8%) Running gel: 4.6 mL double-distilled (dd) H2O, 2.7 mL 30%
Bis-acrylamide solution, 37.5:1 (BioRad, #EC-890), 2.5 mL 1.5M Tris pH 8.8, 100
µL 10% SDS solution, 100 µL mL 10% Ammonium persulphate (APS) solution, 6 µL
TEMED (Scientific Laboratory, # EC-503)
Stacking gel: 2.1 mL ddH2O, 0.5 mL Bis-acrylamide, 0.38 mL 0.5 M Tris-HCl pH 6.8,
30 µL 10% SDS solution, 3 µL 10% APS solution
5x Laemmli buffer (100 mL): 12.5 mL 1M Tris-HCl pH 6.8, 25 mL 20% SDS
solution, 57.5 mL ddH2O, 5 mL β-mercaptoethanol, bromophenol blue
10 x SDS Running buffer (2 L): 288.2 g Glycine (1.92 M), 60.6 g Tris-base (250
mM), 100 mL of 20% SDS solution, fill up to 2 L with ddH2O
10 x Western blot transfer buffer (2 L): 288.2 g Glycine (1.92 M), 60.6 g Tris-base
(250 mM), 100 mL of 20% SDS solution, add 20%(v/v) methanol (400 mL), fill up to 2
L with ddH2O
10 x TBS pH 7.4 (2 L): 175.32 g NaCl (3 M), 121.14 g Tris-base (1 M), 75 mL of
37% HCl, fill up to 2 L with ddH2O and adjust pH to 7.4
A.3.8 Western blot analysis
Samples were mixed with 5x Laemmli Buffer and incubated at 95 ◦C for 5 min. 30 µg
whole cell lysate of each sample was loaded on a 8% SDS PAGE gel. As a standard,
6µL of Precision Plus Protein Standard, 10-250 kD (BioRad, #1610373) was included.
The gels were run in 1x SDS-PAGE running buffer at 35V for 30 min then 100V for 2
h.
Separated proteins were transferred from an SDS PAGE gel to a 0.45 µm pore polyvinyli-
dene (PVDF) membrane via wet transfer. PVDF membrane (Sigma, #Z671010) was
cut to the correct size of the gel and was prepared for the transfer by soaking in
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methanol for 30 seconds. Sponges and blotting paper were soaked in cold transfer
buffer. Gels were removed from the electrophoresis tank and removed from the glass
plates. They were sandwiched in a transfer cassette as shown in FIG A.2. The transfer
cassettes were loaded into the gel tank with an ice pack and cold transfer buffer
supplemented with 0.1% SDS (0.5 mL). Electrophoresis was performed at 60V for 2h
at 4 ◦C.
Fig. A.2 Electrophoretic transfer setup
The membrane was blocked with 5% Milk/TBST for 1 h at 4 ◦C. Membranes were
incubated with primary antibodies (1:200 anti-DNMT1, #sc-271729 and 1:300 anti-
GAPDH, #MAB374) overnight at 4 ◦C on a rocker, followed by 3 x 10 min rinse in
TBST. Membranes were then incubated with the relevant secondary antibodies (1:4000,
HRP-linked Mouse IgG, #NAV931V) for 1 h at room temperature on a rocker, followed
by a 5 x 10 min TBST wash.
Visualisation was achieved by the addition of 1:1 luminol and hydrogen peroxide
mixture (2 mL) (SuperSignalTM West Femto, 34095, Thermo). The blot was incubated
in the dark for 10 min. Chemoluminescence was detected using the ODYSSEY CLx
Imaging system (LI-COR Biosciences, UK)
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Densitometric analysis of western blot bands
In order to semi-quantify the amount of DNMT1 in the western blot analyses, the blots
were subjected to densitometric quantification. The data are expressed as arbitrary
units obtained by analysing the bands by using the software Image J. The intensities
of the DNMT1 and GAPDH bands were measured and the DNMT1 bands were
normalised to GAPDH bands. Tables A.4 - A.7 summarise the normalised DNMT1
band intensities and calculated relative baseline intensities in 3′- and 5′-CD treated
Saos-2 and T24 cells. Figures A.3 - A.6 visually summarise the change in relative band
intensities against different treatment conditions.
Laneno.
Treatment
condition
Normalised
DNMT1
% Baseline
intensity
1 Media (M) 9755 100
2 M/DMSO 9666 99
3 0.1 µM dAC 1696 17
4 0.5 µM dAC 516 5
5 1.5 µM dAC 1391 14
6 M-UV 12001 100
7 M/DMSO-UV 11814 98
8 0.1 µM 3′-CD UV 2865 24
9 0.5 µM 3′-CD UV 419 3
10 1.5 µM 3′-CD UV 1449 12
11 M/DMSO 6232 100
12 0.1 µM 3′-CD 1576 25
13 0.5 µM 3′-CD 665 11
14 1.5 µM 3′-CD 445 7
Table A.4 Normalised DNMT1 band intensities in 3′-CD treated Saos-2 cells
A.3 Cell biology experiments 189
Laneno.
Treatment
condition
Normalised
DNMT1
% Baseline
intensity
1 M/DMSO 9856 100
2 0.1 µM dAC 3383 34
3 0.5 µM dAC 2834 29
4 1.5 µM dAC 3772 38
5 M-UV 13052 100
6 M/DMSO-UV 12613 97
7 0.1 µM 5′-CD UV 5151 39
8 0.5 µM 5′-CD UV 3438 26
9 1.5 µM 5′-CD UV 3117 24
10 M/DMSO 14113 100
11 0.1 µM 5′-CD 5702 40
12 0.5 µM 5′-CD 3927 28
13 1.5 µM 5′-CD 2327 16
Table A.5 Normalised DNMT1 band intensities in 5′-CD treated Saos-2 cells
Laneno.
Treatment
condition
Normalised
DNMT1
% Baseline
intensity
1 Media (M) 14569 100
2 M/DMSO 12102 83
3 0.1 µM dAC 1245 9
4 0.5 µM dAC 787 5
5 1.5 µM dAC 804 6
6 M-UV 12237 100
7 M/DMSO-UV 12120 99
8 0.1 µM 3′-CD UV 2251 18
9 0.5 µM 3′-CD UV 718 6
10 1.5 µM 3′-CD UV 1046 9
11 M/DMSO 9495 100
12 0.1 µM 3′-CD 6374 67
13 0.5 µM 3′-CD 1815 19
14 1.5 µM 3′-CD 789 8
Table A.6 Normalised DNMT1 band intensities in 3′-CD treated T24 cells
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Laneno.
Treatment
condition
Normalised
DNMT1
% Baseline
intensity
1 M/DMSO 13326 100
2 0.1 µM dAC 1773 13
3 0.5 µM dAC 1045 8
4 1.5 µM dAC 1282 10
5 M-UV 13917 100
6 M/DMSO-UV 15564 112
7 0.1 µM 5′-CD UV 4118 30
8 0.5 µM 5′-CD UV 1696 12
9 1.5 µM 5′-CD UV 1898 14
10 M/DMSO 11706 100
11 0.1 µM 5′-CD 5259 45
12 0.5 µM 5′-CD 1674 14
13 1.5 µM 5′-CD 1112 10
Table A.7 Normalised DNMT1 band intensities in 5′-CD treated T24 cells
Fig. A.3 Relative DNMT1 band intensities in 3′-CD treated Saos-2 cells
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Fig. A.4 Relative DNMT1 band intensities in 5′-CD treated Saos-2 cells
Fig. A.5 Relative DNMT1 band intensities in 3′-CD treated T24 cells
Fig. A.6 Relative DNMT1 band intensities in 5′-CD treated T24 cells
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A.3.9 Cell viability assays
Low concentration treatments
Cells were seeded in 24-well tissue culture plates (BD Falcon #353047 or Cornig
Primaria #10288830) as described in Table A.8. For each cell type, two plates were
prepared, one for illumination and one for dark control. Accurate cell counts were
determined using a Vi-CELL™ XR cell viability analyzer (Beckman Coulter).
Cell type Seeding density (cells/well) Culture plate type
Saos-2 9.3 x 104 BD Falcon
T24 1.0 x 104 BD Falcon
HEK293T 2.5 x 104 Cornig Primaria
Table A.8 Cell seeding densities for low concentration treatments
After seeding, the plates were transferred to an IncuCyteTM (Essen Bioscience) for
automated monitoring of cell growth, allowing confluence measurements to be made at
1 or 2-h intervals over the entire course of the assay. 72 h after seeding, the cells were
treated with dAC and 3′-caged dAC (3′-CD). dAC and photocaged dAC treatment
dilutions were prepared in 15 mL falcon tubes 30 min prior to treatment (Table A.9).
Tubeno.
Treatment
solution
Stock/solution
added
Fresh
Media
(mL)
Final
Volume
(mL)
1 DMSO/Media 1.8 µL DMSO 12 12
2 1.5 µM dAC 1.8 µL of 10 mM dAC stock 12 8
3 0.5 µM dAC 4 mL of 1.5 µM dAC (2) 8 6
4 0.1 µM dAC 2 mL of 0.5 µM dAC (3) 8 10
5 1.5 µM CD 1.8 µL of 10 mM CD stock 12 8
6 0.5 µM CD 4 mL of 1.5 µM CD (5) 8 6
7 0.1 µM CD 2 mL of 0.5 µM CD (6) 8 10
Table A.9 Preparation of dAC and photocaged dAC dilutions for low concentration
treatments
The old media was aspirated away and 500 µL of the appropriate treatment solutions
were added to each well. The treatment setup for the 24-well plates is shown in Table
A.10. Each solution was administered in triplicates. One plate was placed in the UV
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cabinet and was irradiated at λ = 365 nm for 1 h. The other plate was kept in the
cell culture hood at room temperature and was covered with aluminium foil. After
the completion of the irradiation, the plates were returned to the IncuCyte. 24 h after
treatment, the plates were removed from the incucyte and the cell viability data was
analysed.
1 2 3 4 5 6
A 0.1 µM 3′-CD (3x) 0.1 µM dAC (3x)
B 0.5 µM 3′-CD (3x) 0.5 µM dAC (3x)
C 1.5 µM 3′-CD (3x) 1.5 µM dAC (3x)
D 1.5 µM DMSO (3x) Media (3x)
Table A.10 Cell viability treatment setup I.
High concentration treatments
Saos-2 cells were seeded in two 24-well tissue culture plates at a density of 2 x 104
cells/well. The plates were transferred to the IncuCyte for automated monitoring of
cell growth. Three treatments were administered at 24-h intervals, starting 24 h after
seeding of the cells. 30 min prior to each treatment, dilutions of 3′-CD and dAC at 1.5,
4.5 and 13.5 µM were prepared in 15 mL falcon tubes using pre-warmed fresh media
(Table A.11).
Tubeno.
Treatment
solution
Stock/solution
added
Fresh
Media
(mL)
Final
Volume
(mL)
1 162 µM dAC stock 48.6 µL of 10 mM dAC stock 3 3
2 13.5 µM dAC 1 mL of 162 µM dAC stock (1) 11 8
3 4.5 µM dAC 4 mL of 13.5 µM dAC (2) 8 8
4 1.5 µM dAC 4 mL of 4.5 µM dAC (3) 8 12
5 162 µM CD stock 48.6 µL of 10 mM CD stock 3 3
6 13.5 µM CD 1 mL of 162 µM CD stock (5) 11 8
7 4.5 µM CD 4 mL of 13.5 µM CD (6) 8 8
8 1.5 µM CD 4 mL of 4.5 µM CD (7) 8 12
Table A.11 Preparation of dAC and photocaged dAC dilutions for for high concentration
treatments
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The plates were removed from the IncuCyte and the old media was aspirated away.
500 µL of treatment solution was added to each well following the setup in Table A.12.
One plate was placed into the UV cabinet for 1 h irradiation at λ = 365 nm and the
other plate was covered in aluminium foil and was kept in the tissue culture hood at
room tempterature. After the irradiation was complete, the plates were returned to the
IncuCyte for imaging. The treatment process was carried out for three times in total.
1 2 3 4 5 6
A 1.5 µM 3′-CD (3x) 1.5 µM dAC (3x)
B 4.5 µM 3′-CD (3x) 4.5 µM dAC (3x)
C 13.5 µM 3′-CD (3x) 13.5 µM dAC (3x)
D Media (6x)
Table A.12 Cell viability treatment setup II.
A.3.10 ELISA assays
ELISA assays were performed according to the manufacturer’s instructions (MethylFlash,
Epigentek, #P-1034). The positive DNA controls were prepared via serial dilutions
(Table A.13).
Tubeno.
Stock added
(µL)
TE buffer added
(µL)
Total volume
(µL)
Final concentration
(ng. µl−1)
1 5 µL of 10 ng/muL 20 25 2
2 12.5 µL of 1 12.5 25 1
3 10 µL of 2 15 25 0.4
4 12.5 µL of 3 12.5 25 0.2
5 12.5 µL of 4 12.5 25 0.1
Table A.13 Preparation of positive control dilutions for ELISA assay
All samples were added to the 48-well plate and the plate was sealed and incubated for
1 h at 37 ◦C (Table A.13). After incubation, the wells were washed with buffer (3 x
150 µL) and a solution of capture antibody (1:1000, 50 µL) was added to each well.
The plate was covered and incubated at room temperature for 1 h. The wells were
subsequently washed (3 x 150 µL) and incubated with detection antibody (1:2000, 50
µL) at room temperature for 30 min. After removal of the detection antibody and
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subsequent washes (4 x 150 µL), enhancer solution (1:5000, 50 µL) was added and the
plate was incubated for room temperature for 30 min. After the final washes (5 x 150
µL), developer solution (100 µL) was added to each well and the plate was incubated
for 5-10 min away from light. The solutions turned blue in the presence of sufficient
methylated DNA. The final step was the addition of stop solution (100 µL). Final
absorbance readings were measured at λ = 450 nm on a VarioSkan Flash Multimode
Platereader (Thermo Scientific).
1 2 3 4
A ME3 (-) ME3 (-) 1.5 µM dAC 1.5 µM dAC
B 10 ng 10 ng 4.5 µM dAC 4.5 µM dAC
C 5 ng 5 ng 13.5 µM dAC 13.5 µM dAC
D 2 ng 2 ng 40.5 µM dAC 40.5 µM dAC
E 1 ng 1 ng 121.5 µM dAC 121.5 µM dAC
F 0.5 ng 0.5 ng 363.5 µM dAC 363.5 µM dAC
G Media Media Media Media
H Media Media Media Media
Table A.14 Assay setup for ELISA
1 2 3 4
A 0.051 0.055 0.077 0.077
B 0.289 0.724 0.052 0.051
C 0.179 0.495 0.058 0.051
D 0.149 0.332 0.048 0.047
E 0.160 0.220 0.052 0.053
F 0.098 0.118 0.061 0.047
G 0.050 0.058 0.057 0.048
H 0.092 0.086 0.100 0.054
Table A.15 Absorbance readings from first ELISA trial
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1 2 3 4
A 0.037 0.036 0.044 0.044
B 0.125 0.250 0.048 0.058
C 0.081 0.096 0.038 0.039
D 0.053 0.067 0.035 0.035
E 0.048 0.054 0.036 0.038
F 0.047 0.049 0.035 0.038
G 0.042 0.038 0.039 0.039
H 0.060 0.091 0.037 0.045
Table A.16 Absorbance readings from second ELISA trial
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A.4 Mass spectrometry analysis
A.4.1 Triple quadrupole mass spectrometer
The mass spectrometry analysis for the stability studies were performed on a Triple
Quadrupole 6460 Mass Spectrometer (Agilent Technologies) fitted with an Infinity
1260 LC system (Agilent) and a Hypersil Gold C18 column, 100 x 2.1 mm, 1.9 µm
(Thermo Scientific, UK), using a gradient of water and acetonitrile with 0.1% formic
acid (Table A.17). External calibration was performed and 2′-deoxycytidine (dC) was
used as an internal standard.
Time
(min)
Solvent
A (%)
Solvent
B (%)
Flow rate
(µL.min−1)
0 98 2 200
20 2 98 200
25 98 2 200
27 98 2 200
Table A.17 LC-MS method conditions
A.4.2 MRM optimisation
MRM optimisation was carried out using the MassHunter Optimizer Software (Agi-
lent) to determine the most suitable data acquisition parameters for each individual
compound analysed. The software automated the selection of the best precursor ions,
fragmentor voltages for each precursor ions, the best product ions and the collision
energy values for each transition.
1 ng/µL solutions of dAC, photocaged analogue (3′-CD, 5′-CD or 3′-CdC) and DEACM-
OH were prepared in HPLC grade water and the samples were introduced to the system
via an automatic injector. The fragmentor voltage range was set to 50-300 V with
5 step increments, the collision energy range was between 20 and 50 V and the cell
accelerator voltage was 4V. Precursor ions were monitored with a 50 m/z low mass
cutoff, in positive and negative ion mode. The optimisation duration for each analyte
was around 3 h.
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After the completion of the optimisation, the parameters with the highest product
and precursor ion intensity were selected from Table A.18. The optimised conditions
were incorporated into the LC method and were included in all subsequent LC-MRM
methods.
Compound
name
Precursor
ion
Fragmentor
voltage (V)
Product
ion
Collision
energy (V)
Measured
abundance
3′-CD 502 105 292 20 40083
3′-CD 502 105 248 40 19867
3′-CD 502 105 112.9 32 4852
3′-CD 502 105 98.9 28 3812
5′-CD 502 110 80.9 50 35140
5′-CD 502 110 372 20 65214
5′-CD 502 110 230 28 19175
5′-CD 502 110 215 40 9476
3′-CdC 501 115 112 20 159129
3′-CdC 501 115 292.1 20 18152
3′-CdC 501 115 248.1 40 12193
3′-CdC 501 115 147.1 50 87
DEACM-OH 248 125 203.9 28 375175
DEACM-OH 248 125 176 40 257117
DEACM-OH 248 125 219 20 327139
DEACM-OH 248 125 162 36 60083
dAC 229 80 112.9 20 23515
dAC 229 80 112.2 20 13810
dAC 229 80 80.9 24 5538
dAC 229 80 69 44 4108
dC 228 55 111.9 20 248685
dC 228 55 94.9 44 54257
dC 228 55 69 40 21516
dC 228 55 137.1 20 50
Table A.18 MRM optimisation results
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A.4.3 MRM LC-MS calibration of analytes
Calibration curves were constructed for each analyte in order to accurately quantify
them in stability mixtures. Known concentrations (25 - 1000 pg/µL) of dAC, DEACM-
OH and 3′-CD) were prepared and analysed using the optimised MRM LC methods
and the integrals of the corresponding peaks were measured. The fitted calibration
curves for dAC, DEACM-OH and 3′-CD are shown in Figure A.7.
Fig. A.7 MRM LC-MS calibration of dAC, DEACM and 3′-CD
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A.4.4 Sample preparation and stability experiments
All calibration solutions and stability mixtures were prepared from 10 mM stocks
of the corresponding analytes (dAC, DEACM-OH or 3′-CD) in DMSO. A 5 ng/µL
solution was made initially that was further diluted into the desired concentrations.
The solutions were prepared using HPLC grade water or 100 mM HEPES buffer pH
7.2. All solutions were spiked with 500 pg/µL dC internal standard.
For all stability experiments, 750 pg/µL of the photocaged analogue or dAC was
prepared (1 mL) and the solution was analysed at t=0, 30, 60, 120, 180, 240, 300
and 360 min via LC-MS/MS. The stability mixtures were either incubated at room
temperature or 37 ◦C. For room temperature measurements, the solutions were left in
the LC sample tray and an automatic sequence was set up to withdraw aliquots at the
desired time points. Inbetween hourly injections, an additional blank containing water
was also run to eliminate sample carry-over.
For stability studies at 37 ◦C, the mixtures were incubated in a ThermoMixer heating
block (Eppendorf). At each time point, the entire solution was transferred to a MS
vial for injection into the LCMS. After the injection, the solution was returned to the
eppendorf tube and the incubation continued. Similar to room temperature studies,
additional blanks containing water were included to eliminate sample carry-over. Each
stability run was carried out in triplicates.
A.4.5 Quantification
Stability data was quantified using the MassHunter Workstation Software. After each
time-point analysis (LC run), the peaks corresponding to the individual analytes (dAC,
DEACM-OH, photocaged analogue and dC internal standard) were extracted from
the main chromatogram and their areas were integrated. The integrals of the main
analytes were then normalised against the integrals of the internal standard.
A.4.6 Summary of measured stability profiles
The measured stabilities and standard errors (SE) are summarised in Tables A.19
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Time
(min)
%
dAC SE 3′-CD SE 5′-CD SE 3′-CdC SE
0 100 0.000 100 0.000 100 0.000 100 0.000
30 58 1.180 85 7.583 89 1.638 96 0.702
60 56 1.044 73 0.574 82 2.022 93 0.682
120 53 0.902 59 4.298 75 1.211 86 2.714
180 49 1.730 51 3.264 67 0.398 87 0.554
240 48 3.149 47 1.274 60 0.258 82 1.230
300 46 2.290 42 0.789 56 0.327 83 0.738
360 44 1.783 38 1.819 51 0.317 80 1.505
(a) Water, RT
Time
(min) dAC SE 3′-CD SE 3′-CdC SE
0 100 0.000 100 0.000 100 0.000
30 87 2.964 49 7.534 68 1.274
60 83 2.501 39 5.037 62 2.022
120 80 4.948 33 0.478 55 4.037
180 75 3.867 27 3.670 49 1.505
240 71 5.309 25 1.277 44 1.277
300 67 3.294 20 0.216 40 3.264
360 64 3.524 15 0.252 37 0.789
(b) Water, 37 ◦C
Time
(min) 3′-CD SE 3′-CdC SE 5′-CD SE
0 100 0.000 100 0.000 100 0.000
30 94 0.895 99 0.895 95 1.577
60 90 0.838 98 0.838 92 2.019
120 83 0.978 98 0.978 89 1.723
180 78 0.355 95 0.355 85 0.704
240 73 1.299 92 0.706 83 2.034
300 67 2.358 89 0.834 82 1.481
360 64 0.969 88 0.969 79 1.842
(c) HEPES, RT
Time
(min) 3′-CD SE 3′-CdC SE
0 100 0.000 100 0.000
30 67 1.667 88 1.577
60 58 0.706 80 2.019
120 48 2.470 76 1.723
180 40 2.240 70 0.704
240 34 1.392 61 2.034
300 27 0.815 55 1.481
360 22 1.199 53 1.842
(d) HEPES, 37 ◦C
Table A.19 Summary of LC-MS/MS measurements of stability studies
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